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1. INTRODUCTION 
Tamil medicine, being the ancient system in the world has a stringer attraction 
towards it because of its detoxification, Anti – oxidation, Immune modulation and 
metabolic balance. Since it has given away many incredible and rapid results in various 
unremitting ailments, the system has been carefully guarded. Without the aid of 
microscope, our ancient saints – Siddhars were able to identify innumerable herbs, their 
properties, purification process, also administered plant based and mineral based 
medicine with suitable adjuvant and they documented all these things in the form of 
manuscripts and handed over to their disciples over generation. The therapeutic effect of 
the system has been proved for thousands of years that were never changed for even day 
to day practice.  
Since, Siddha medicine is an individualistic medicine, on patients constitution and 
syndrome differentiation we cannot make use of modern medical system as a standard to 
explain in all levels. Our Siddha medicine not only pays attention to the preventive and 
curative methods, but also focussed on the physical, mental, spiritual and psychological 
well-being thus giving a total perfection in life. 
Recently people diverted their attention towards eco – friendly & bio – 
degradable organic plant based products for the prevention of many threatening 
diseases. It is documented by WHO that 80% of the world’s population has faith in 
traditional medicine, particularly plant drugs for their primary healthcare. (Dubey, et al 
2004) 
Anaemia is a global public health problem affecting both developing and 
developed countries with major consequences for human health as well as social and 
economic development. It occurs at all stages of the life cycle, but is more prevalent in 
pregnant women and young children. In 2012, iron deficiency anaemia (IDA) was 
considered to be a curse and deadlock for the development of the nation. Although the 
primary cause is iron deficiency, it is seldom present in isolation. More frequently it 
coexists with a number of other causes, such as malaria, parasitic infection, nutritional 
deficiencies, and Haemoglobinopathies. Several plants are used in treating anaemia and 
many are used effectively for their Haematinic properties in Siddha medicine. 
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I selected “PANDU NOI” which can be correlated with the clinical condition 
called iron deficiency Anaemia for my dissertation work. Pandu Noi is a very common 
disease in humans due to malnutrition, ignorance, poverty and poor socio –economic 
condition and also among the affluent and well fed due to unbalanced diet. In spite of the 
sophisticated advancement, the modern system of medicine does not provide a permanent 
solution to many chronic aliments. This work is done with an aim to come out with 
satisfactory results for one such chronic ailment named PANDU NOI (Anaemia). 
Basically I am interested in the well being of all human being irrespective of their 
economic status. I have witnessed many patients in the outpatient department during my 
graduation, who are the victims of Anaemia and most of them are below the poverty line. 
This kindled a spirit in me to carry out a work in Anaemia and come out with a most 
effective medicine at low cost effect. Healthy India reflects a developed India. So in order 
to achieve the goal of healthy India this work seems to be a limelight to some extent. This 
is the main motivation for the work done. 
Pandu noi is one of the conditions which has to be treated promptly with utmost 
care and requires a pragmatic approach. Any failure to treat Pandu noi can lead to 
dangerous end often fatal consequences. So I selected Puli ilai Chooranam to study its 
Haematinic Activity. 
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2. AIM AND OBJECTIVES 
 
AIM 
Anaemia is a major killer in India. Statistics reveal that every second Indian 
woman is anaemic and one in every five maternal deaths is directly due to anaemia. 
Anaemia spares none; it affects both adults and children of both sexes, although pregnant 
women and adolescent girls are most susceptible and most affected by this disease. 
Through the ages, man had learnt to utilize the natural resources placed at his 
dispoal, to satisfy his essential needs in all field. As important reserves and sources of 
abundance, natural resources are indispensable for socio – economic development. 
According to the literature of siddha the Puli ilai (Tamarindus indica) helps to cure 
Pandu noi (Anaemia). The principle aim of this study is to evaluate the efficacy of the 
Puli ilai chooranam in the management of Pandu noi (Anaemia) in Pre – clinical and 
Clinical aspect. 
OBJECTIVE           
The following machinery was carried out in this dissertation. 
 To study the Pharmacognostic features of the plant Puli ilai (Tamarindus indica) 
this includes the taxonomic identification of the plant with Macro, Microscopical 
information.  
 To collect the relevant literature from classical Siddha literature as well as Modern 
sciences that supports this study. 
 To prepare the drug according to Siddha literature. 
 Physio – Chemical and Phyto – Chemical analysis for the trial drug to identify the 
active components. 
 To study the acute toxicity of Puli ilai chooranam according to OECD guidelines 
425. 
 To establish the pharmacological activity of Puli ilai chooranam. 
 To review the therapeutic potential of the drug through clinical trail for the 
management of Pandu noi (Anaemia). 
 To scrutinize all the above study results to evaluate the efficacy of Puli ilai 
Chooranam in patients with anemia. 
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3. REVIEW OF LITERATURE 
 
3.1. Botanical aspects 
 
Botanical name  : Tamarindus indica (L) 
Family name      : Caesalpinaceae 
 
Scientific classification: 
 
Kingdom  : Plantae - Plants  
Subkingdom  :  Tracheobionta -Vascular plants  
Superdivision  :  Spermatophyta - Seed plants  
Division  :  Magnoliophyta - Flowering plants  
Class   :           Magnoliopsida - Dicotyledons  
Subclass  :  Rosidae  
Order   : Fabales 
Family   :  Caesalpinaceae  
Genus   : Tamarindus L. - Tamarind  
Species  :  Tamarindus indica L. - Tamarind  
 
 
Vernacular names: 
 
Sanskrit : Tintiri, Tintrani, Amlika, Tintidr, Tintili, Ambia 
English : Tamarind tree 
French  : Tamarinier 
Germany : Tamarindi 
Punjab  : Imli 
Telugu             : Chinta – Pandu, Asek 
Tamil  : Puliyan, Puli. 
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PLANT DESCRIPTION: 
 
Figure.1. Showing the leaves of Tamarindus indica (L.). 
Tamarind is a slow-growing enormous tree that can reach a height of 80 or even 
100 feet (24-30 m), spread a crown of 40 feet (12 m) and develop a very large trunk of 25 
feet (7.5 m) in circumference. It is a long-lived tree with high resistance to wind dark-
gray and rough bark and strong, supple branches that are gracefully drooping at the ends. 
The mass of bright-green, fine, feathery foliage is composed of pinnate leaves, each 
having 10 to 20 pairs of oblong leaflets, which fold at night. The leaves are normally 
evergreen but may shed briefly in very dry areas during the hot season. Inconspicuous, 
inch-wide flowers, born in small racemes, are 5-petalled (2 reduced to bristles), yellow 
with orange or red streaks. The flower buds are distinctly pink due to the outer colour of 
the 4 sepals, which are shed when the flower opens. The fruits are curved and bulged 
pods, borne in great abundance along the new branches. The pods are cinnamon-brown or 
greyish-brown and tender-skinned with green, highly acid flesh and soft, whitish and 
under-developed seeds. As they mature, the pods fill out and the juicy, acidulous pulp 
turns brown or reddish-brown. Then, the skin becomes a brittle, easily cracked shell and 
the pulp dehydrates naturally to a sticky paste enclosed by a few coarse strands of fibre.                                                                                
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Habitat:   
This evergreen tree which is indigenous to South India and it is cultivated 
throughout India and Burma. 
 
Part used:  
 Pulp of the fruit: Seeds, Leaves, Flowers and Bark 
 
Chemical Constituents: 
 
Leaves:  Moisture, Protein, Fat, Fibre, Carbohydrates ,Minerals. 
     
The mineral and vitamin constituents were as follows; 
Calcium, Magnesium, Phosphorus, Iron, Copper, Chloride, Sulphur, Thiamine, 
Riboflavin, Niacin, vitamin C. 
Pulp contains Tartaric Acid. Citric acid, Malic acid and Acetic acids, Tartaric of 
Potassium. Invertsugar, Gum and Pectin, Seeds testa contains a Fixed oil and insoluble 
matter. Seeds contain Albuminoids, Fat, and Carbohydrates. Fibre and Ash containing 
Phosphorus and Fibrinogen Fruit contains trace of oxalic acid. 
 
Action: 
 Unripe fruit is highly acid, pulp of ripe fruit, which is sweet or acid, is cooling 
(Refrigerant), Carminative, digestive and laxative: a valuable Antibilious. Leaves and 
flowers are cooling and Antibilious. Red outer covering of seeds is a mild astringent. 
Bark is astringent and tonic.  
Uses: 
 
Leaves crushed with water and expressed yield an acid fluid useful in bilious fever 
and in the scalding of the urine. Leaves crushed with water and made into a poultice are 
applied in inflammation of ankle joints, etc. to reduce swelling to relieve pain. Thick 
syrup of pulp and leaves boiled will heal up swellings with great heat and burnings.  
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3.2. GUNAPADAM ASPECT 
Gspapiy:  
nghJFzk;: 
    mOGz;iz ePf;Fk; mly;Nrhig khw;Wk; 
    vOghz;L itg;Nghf;Fk; ,g;ghy; - KOJk; 
    mspar; rpte;jfz;Nzh ahw;Wq; fdyhk; 
    Gspapiyia ed;wha;g; Gfy;;.    - mfj;jpau; Fzthflk; 
,J mOfpaGz;> Nrhif> ghz;L> rpte;j> fz;Nzha;> ,itfis ePf;Fk;.    
 gad;fs;: 
  ,iy xU gq;F> Ntg;gpiy xU gq;F ,t;tpuz;ilAk; Nru;j;jpbj;J 8 
gq;F ePu;tpl;L fha;r;rp Gz;fis fOtp tu MwhjGz;fs; Mwpg;NghFk;. 
  ,iyr;rhw;wpy; gOf;ff;fha;e;j ,Ug;G ryhifiaj; Njha;j;J 
mr;rhw;wpy; xd;wpuz;L rq;FtPjnkLj;Jr; rPjfopr;rYf;Ff; nfhLf;fyhk;. 
Gspapiy NrUk; kUe;Jfs;: 
1. ghz;L KjyhditfSf;F  - rpQ;rhjp ,Nyfpak;. 
 Gspapiy 3500fpuhk;> JUg;gpbj;j ,Uk;G 1050fpuhk;; vLj;J. jz;zPu;26 ypl;lu;  
tpl;L mLg;gpd; NkNyw;wp 2ypl;lu; FbePu; MFk;tiu Rz;lf;fha;r;rTk.;  
 gioa nty;yk; 1750fpuhk;; FbePUlNdfiuj;J Nkw;Gwzp ePf;fpa ,Q;rp 560 
fpuhk; $lg;Nghl;L kWgbAk; mLg;gpd; NkNyw;wpg; ghfhf;fpf; nfhs;sTk;. 
 rPufk; 
 fUQ;rPufk; 
 Rf;F  
 kpsF 
 jpg;gpyp 
 ,itfis tiff;F 70fpuhk;; vLj;J ,bj;J tj;jpufhak; nra;Jnfhz;L  
 Rj;jpj;j ,Uk;Gj;J}s; -  35fpuhk; 
 Rj;jpj;j kz;^uj;J}s; -  35fpuhk;; fye;J 
ghfpy; Nghl;Lf;fpswTk;. ,Nyfpa gjj;jpypwf;fp Mwpagpd; Rj;jkhd Njd;500kp.yp 
tpl;L Fog;gpf;nfhs;sTk;. 
 ,e;j ,Nyfpaj;ij jpdk; ,UNtis nfhLf;fg; ghz;L. fhkhiy> Kjypa 
,Nuhfq;fs; jPUk;;.  
gj;jpak;. 
Gsp> cg;G> fLF> ey;nyz;nza;> thAgjhu;j;jq;fs;> ,iwr;rp> Kjypaitfis 
ePf;fTk;. 
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Fwpg;G. 
 ,Uk;igr;Rj;jp nra;Ak;Kiw Kjy;ehs; ey;;nyz;nzapy; Cwitj;J 
kWehs; tWf;fTk;. 
 kz;^uk; gR%j;jpuj;jpy; Cwitj;J fOtptplTk; 
2. ghz;L KjyhditfSf;F magw;gk;.  
 ,Uk;Gj;J}is xUehs; KOtJk; ey;nyz;nzapY}w itj;J kWehsij 
mLg;gpy; NkNyw;wp tWj;Jf;nfhs;sTk;. ,ijnahU fy;tj;jpypl;L 
 ney;ypg;gUg;Gf; frhak; 
 Gsp ,iyr;rhW 
 ehfg;gl;ilr;rhW 
 ,itfs; tpl;Lj;jdpNa ed;whf miuj;J tpy;iyfs; jl;b mfypy; 
itj;Jr;rPiykz; nra;J. frGlk; (1000 twl;b) ,lTk;. ,t;thW 5 Glq;fs; 
NghlTk;. Rj;jkhd gw;gk; fpilf;Fk;. 
 jf;f mDghdq;fspy; rhg;gplr; ghz;L> Nrhif> fhkhiy> Kjyhd Neha;fs; 
jPUk;. 
 
Njd; (mDghd kUe;J): 
nra;iffs ;: (Fzghlk;- jhJ>rPt tFg;G) 
 cs;soyhw;wp     kykpsf;fp 
 Jtu;g;gp         mOfyfw;wp 
 Nfhioafw;wp     Ngh\zfhup 
 grpj;jPj;J}z;b     J}f;fKz;lhf;fp 
Rj;jp: 
 ePu; ve;jpuj;jpypl;Lf; fha;r;rp #lhapUf;Fk;NghNj> <uf;fk;gspapypl;L 
tbfl;bf; nfhs;sNtz;Lk.; 
 Xl;ilr; Rl;Lj; Njdpy; Nghl;L cgNahfpg;gJ ehl;L tof;fk;. 
Fzk;: 
 “ IaapUk yPistpf;f yf;fpg;Gz; ntg;Gly;Neha; 
  iga nthopAk; grpAKWk ;- itafj;jp 
  nyz;Zkpir ahkUe;jpw; Nfw;w tDghd 
  ez;Zkiyj; Njndhd;wp dhy;”. 
cgNahfq;fs;:   Njd; xU rpwe;j Jiz kUe;jhFk; 
mDghdg; nghUshtjd;wp mtpo;jg; nghUshfTk; ,Ue;J Njfj;ij 
ed;dpiyapy; itj;J> thj Kjypa Kf;Fw;wq;fisAk; Nghf;Ffpd;wJ. 
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“mDghd kha;g;gpd; mtpo;jKkha;j; Njhd;wp 
fdkhd Njfepiy fhl;bg;- gpDNk 
aurd; Kjy;Nth iuAkhl;L tpj;jhNy 
gpurj; jpdhw;Nghk; gpzp”.      
– Njud; nghUl;gz;G E}y;. 
mtpo;jk; gypf;f Ntz;Lkhapd; mDghdg;nghUs; Njit vd;gijAk;> mt;tDghdg; 
nghUl;fspy; NjDk; xd;W vd;gjidAk;> 
 Foe;ijfspd; ,UkYf;Fj; Njd; 60 kp.yp;> vYkpr;ir gourk; rkmsT $l;b 
nfhLf;f jzpAk;. 
 Njidg; ghdfk; nra;J te;jhy; fgg;gpzpfs; jPUk;> 
“,wTsu; mKijia ,wTsjhf;Fk;” vd;w Njud; fupry; mbahy; 
mwpayhk;. 
 Njid #Ls;s ghu;yp muprp fQ;rpAld; nfhLf;f kyge;jk;> nrupahik>         
 ePu;f;Nfhit> ,Uky;> njhz;il tpuzk;> EiuaPuy; rk;ke;jkhd gpzpfs; 
jPUk;. 
 
3.3. SIDDHA ASPECT OF THE DISEASE 
 
Synonyms:    Vemmai noi, Pandu noi.   
 
Nature of the disease:  
The natural colour of the body will be found changed, the body will appear pale. 
On examination of conjunctiva and nails, they appear pale due to loss of blood. 
 
Genesis of the disease:  
It is considered that the disease may be caused by the following factors: 
By eating diets of too much salty and sour which will impair the potency of blood, 
as a sequelae to fever, diarrhoea, vomiting and arthritis, as a sequelae to diseases such as 
polymenorrhoea, blood heat disease (kuruthiazhal),bloody diarrhea, haematemesis and 
haemorroids which cause loss of blood from the body, by taking drugs which are too 
toxic in excessive doses, worm infestation, fatigue, diarrhea with mucus, liver diseases 
which will impair haemopoiesis, frequent ingestion of tobacco, betel leaves and arecanut, 
sand, ashes, sacred ashes, and camphor. 
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Prodromal symptoms: 
The Pitha dosha becomes excessive in activity due to factors such as diet and 
impairs the colour and volume of the blood. In addition, it also makes the body pale 
without affecting the nutritional requirement of the body. Later patient may develop 
fatigue of legs even walking for a short distance, dyspnoea, anorexia, nausea, giddiness, 
diminution of vision, frequent fainting, palpitation and emaciation of the body.   
Types of disease: 
The disease has been classified into five types. Of these, four types are developed 
due to dosha and one type due to toxicity. They are: 
1. Vali Pandu (Anaemia due to derangement of Vatha humour) 
 2. Pitha Pandu (Anaemia due to derangement of Pitha humour) 
 3. Kapha Pandu (Anaemia due to derangement of Kapam humour) 
 4. Mukutra Pandu (Anaemia due to derangement of Mukktra humour) 
 5. Nanju Pandu. ( Due to toxicity) 
Besides, some ancient siddhars classified into one more type, viz. Anaemia due to 
sand eating. In addition, due to deficiency of blood the body will be emaciated and 
odematous: the colour of the body will be changed and appear as yellow or blue; the 
patient will develop excessive thirst, frequent giddiness and mental depression and 
impairment of learning. Further, in men diminished sexual potency may also occur. Some 
ancient physicians have classified this type of the disease into three sub – types as Neela 
paandu, Alasa paandu and Alimuga paandu; however, all these sub types have the 
clinical features of anaemia (veluppu noi), it is considered that there is no need to mention 
them separately. 
Signs and Symptoms 
Vali Pandu; 
In this disease, there will be abdominal pain. Patient will have anorexia and thirst. 
In addition, the blood vessels will appear black and tortuous. There will be also shivering 
of the body with congestion of the eyes; the body will also appear pale and oedematous; 
there may be pain at the oedematous sites. The bowels will be constipated and the stool 
will be hard. Ageusia, flatulence and colic pain are other features of the disease. 
Pitha Pandu: 
In this disease, body will become yellow in colour. The tongue, the upper and 
lower limbs will become pale: there will be diminution of vision. In addition, patient will 
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have excessive thirst and bitter taste in the mouth; patient may also develop giddiness; 
sometimes patient may also develop bitter taste. The other features of the diseases are; 
breathlessness as if the chest is constricted and giddiness; these features are called as 
Pitha pandu. 
In addition to the above mentioned clinical features, the following signs and 
symptoms may also appear; desire to eat cold diet, flatulence bad odour in the mouth, 
paleness of the body with yellow discolouration, ulcers in the mouth and frequent 
diarrhoea with stool appearing yellow in colour. 
Kapha Pandu: 
The skin will appear pale and the veins will become prominent, salty taste in the 
tongue, rising of the hairs of the body, vomiting and hoarseness of voice, frequent 
sneezing, expectoration of sputum, fainting attacks, pain in the hip, diminished sexual 
potency in male, getting angry frequently, fatigue and tiredness. 
Mukktra Pandu: 
Wheezing, dyspnoea, fatigue, loss of body strength with palpitation in the chest, 
body becoming hot and frequent micturation, body becoming hot with fainting, sneezing, 
frequent occurrence of oedema of the whole body. 
Nanju Pandu: 
In this disease, the body will become pale due to toxicity of the foods taken which 
are allergic. Excessive thirst, ageusia, vomiting, hiccup, cough, breathlessness and 
generalized anasarca are other features of the disease. In addition, there may be venous 
engorgement with body becoming hot. 
Pandu due to sand eating; 
The disease usually occurs in infant and young children and also in pregnant 
women who develop desire to eat sand, ash, brick, sacred ashes and camphor. The 
anaemia develops due to excessive intake of these substances. 
In this disease, depending upon the nature of the substances taken. Abdominal 
distension, indigestion, vomiting, diarrhoea will develop. In addition, worm infestation 
may also occur and the body will become lean. The blood volume also will decrease and 
body will become pale and oedematous. Patient may also develop palpitation. 
Curable and incurable disease; 
Above type of anaemia’s where uncontrolled vomiting or diarrhoea, excessive 
oedema of the body, excessive thirst, hiccup and cough develop are considered as disease 
which cannot be easily cured: in addition toxic anaemia is also not easily curable disease. 
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General features; 
There will reduction of body strength day by day and patient may not be in a a 
position to walk , in addition the following features may also appear ; headache, 
palpitation, frequent blurring of vision , vertigo, giddiness, breathlessness, anorexia, 
dislike to food and vomiting even if small quantity of food ingested, body becoming pale 
with shrinkage of skin, body become lean with pale and shiny appearance, clubbing of 
nails ,ulcer of the tongue or red appearance of the tongue as if the outer layer of the 
tongue has been scrapped ; sometimes, the tongue may also be pale with lubricity 
appearing like silk cloth and sore throat. 
If the disease occurs in women, the menstrual blood flow will be scanty and 
discoloured. However, in some women, there may be excessive menstrual blood flow. 
The disease may also occur as an associate illness of worm infestation and blood pitha 
disease which occur in children and elderly. 
For those people whose body is hot by nature the disease appears with the 
following clinical features; anaemia occurs first, indigestion of food taken, burning 
sensation of the body and sensation of fever, the tongue may become pale and appear red 
or it may become lubricant like silk cloth, inability to chew or swallow the food, frequent 
vomiting with small amount of bile, bitter taste of mouth, stomach disease and abdominal 
pain with frothy diarrhoea. 
If the signs and symptoms mentioned above increase day by day, the blood 
volume will decrease and will be discoloured. In addition the body will appear yellow as 
if jaundice has occurred. When the disease advances the patient may also develop the 
following features. 
 
Dosha and other features: 
As mentioned earlier, there will be loss of body strength with anorexia. The food 
ingested will not be digested properly; in view of these there will be defective 
haemopoiesis. The Pitha (Ranjitha pitha) which impart colour to the skin will also 
become hypovolumic and the Pitha dosha will aggravate; as a result the activities of the 
other doshas will be adversely affected; the potency of directional factor is also decreased 
and aggravates the disease. As the disease advances, Kapha also will increase. In 
addition, swelling of the body will also occur. 
 
Pulse:  If Sethuma pulse is altered it may denote Pandu.    
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3.4. MODERN ASPECT OF THE DISEASE 
Anaemia: 
 Anaemia is a decrease in number of red blood cells (RBCs) or less than the 
normal quantity of haemoglobin in the blood. However, it can include decreased oxygen-
binding ability of each haemoglobin molecule due to deformity or lack in numerical 
development as in some other types of haemoglobin deficiency. Because haemoglobin 
(found inside RBCs) normally carries oxygen from the lungs to the capillaries, anaemia 
leads to hypoxia (lack of oxygen) in organs. Since all human cells depend on oxygen for 
survival, varying degrees of anaemia can have a wide range of clinical consequences.  
Anaemia is the most common disorder of the blood. The several kinds of anaemia 
are produced by a variety of underlying causes. It can be classified in a variety of ways, 
based on the morphology of RBCs, underlying etiologic mechanisms, and discernible 
clinical spectra, to mention a few. The three main classes include excessive blood loss 
(acutely such as a haemorrhage or chronically through low-volume loss), excessive blood 
cell destruction (haemolysis or deficient red blood cell production 
(ineffective haematopoiesis). 
Prevalence of anaemia: 
 Anaemia is a major world health problem. The prevalence of anaemia has been 
studied in many populations but it is difficult to compare data from different sources 
because of variations in methodology and criteria adopted. Certain patterns emerge, 
however. An early survey carried out in Great Britain established that haemoglobin levels 
were low in a significant proportion of the population, particularly susceptible groups 
being children under the age of five years, pregnant women. A later random population 
study in the United Kingdom reported a prevalence of anaemia of 14% for women aged 
55-64 years and 3% for men aged 35-64 years. These and similar studies have shown that 
anaemia is commonest in women between ages of 15 and 44 years and that it then 
becomes relatively less frequent, although the prevalence increases again in the 75 year 
and over age group. Interestingly, it is only in the latter group that the prevalence in males 
and females is almost the same. Where the cause of the anaemia has been analysed in 
these surveys, the majority of cases have been due to iron deficiency. No doubt this 
prevalence data varies considerably between the developed countries, but it clear that 
nutritional anaemia is relatively common in most populations at certain periods during 
development and late in life. 
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Main causes of anaemia due to defective production of red cells: 
Reduced proliferation of precursors 
 Iron deficiency anaemia 
 Anaemia of chronic disorders 
Infections, malignancy, collagen disease, etc 
 Reduced erythropoietin production 
            Renal disease 
 Reduced oxygen requirements 
            Hyperthyroidism 
            Hyperpituitrism 
 Reduced O2 affinity of haemoglobin 
 Erythropoietin antibody production 
 Primary disease of the bone marrow 
 Aplastic anaemia 
Primary 
Secondary to drugs, irradiation, chemicals, toxins, etc 
Leukaemia 
   Lymphoma 
Defective maturation of precursors 
 Nuclear maturation 
   Vitamin B12 deficiency 
   Folate deficiency 
   Erythroleukaemia 
 Cytoplasmic maturation 
   Iron deficiency 
   Disorders of globin synthesis 
   Disorders of haem and iron metabolism 
   Disorders of porphyrin metabolism 
 Unknown mechanism 
   Congenital dyserythropoietic anaemias 
   Myelodysplastic syndrome 
   Infection  
   Toxins and chemicals. 
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Classification: 1.Anaemia associated with blood loss or increased blood destruction 
                    Causes: 
a) Haemorrhage 
b) Chronic – Peptic ulcer, Piles, Hookworm anaemia, 
Purpura,Uterine bleeding 
2. Haemolytic diseases causing anaemias 
a) Chemical and haemolytic poisons, eg lead, arsenic etc 
b) Specific infection – Malaria,septicaemia 
c) Abnormal structure of the red cell eg. Acholuric jaundice,splenic 
anaemia 
3. Anaemia due to Defective blood formation 
a)  Nutritional anaemia (iron deficiency anaemia) 
b) Lack or failure of utilization of specific anti anaemic factor, Ex,     
pernicious anaemia 
c) Aplastic anaemia, Failure of the red bone marrow to produced 
blood cells. Ex. Exposure to radio activity, chemicals and drugs. 
 
                              
                            Table.1 
WHO's Haemoglobin Thresholds used to define Anaemia (1 g/dL = 0.6206 mmol/L) 
Age or Gender group Hb threshold (g/dl) Hb threshold (mmol/l) 
Children (0.5–5.0 yrs) 11.0 6.8 
Teens (12–15 yrs) 12.0 7.4 
Women, Non-pregnant (>15yrs) 12.0 7.4 
Women, pregnant 11.0 6.8 
Men (>15yrs) 13.0 8.1 
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Symptoms:                                      
  
 
Figure.2 Symptoms of Anaemia 
Investigation: 
Doctors can easily detect anaemia by drawing a blood sample for a complete 
blood count. Based on the results of the test and thorough evaluation of the patient, the 
doctor may order more tests to determine the exact cause of anaemia. The complete blood 
count may be done as part of a routine general check-up or based upon the presence of 
signs and symptoms suggestive of anaemia. 
 
Lab tests for anaemia 
Complete blood count (CBC):  
Determines the severity and type of anaemia (microcytic anaemia or small-sized 
red blood cells, normocytic anaemia or normal-sized red blood cells, or  macrocytic 
anaemia or large-sized red blood cells) and is typically the first test ordered. Information 
about other blood cells (white cells and platelets) is also included in the CBC report. 
Haemoglobin (Hgb) and (Hct) measurements in a complete blood count test are 
commonly used to diagnose anaemia. They measure the amount of haemoglobin, which 
an accurate reflection of red blood cell (RBC) quantity in the blood. 
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Stool haemoglobin test: Tests for blood in the stool may detect bleeding from the 
stomach or the intestines (stool Guaiac test or stool occult blood test). 
Peripheral blood smear: Looks at the red blood cells under a microscope to determine 
the size, shape, number, and appearance as well as evaluate other cells in the blood. 
Iron level: A serum iron level may tell the doctor whether anaemia may be related to iron 
deficiency or not. This test is usually accompanied by other tests that measure the body's 
iron storage capacity, such as transferrin level and ferritin level. 
Transferrin level: Evaluates a protein that transports iron in the body. 
Ferritin: Evaluates at the total iron available in the body. 
Folate: A vitamin needed to produce red blood cells, which is low in people with poor 
eating habits. 
Vitamin B12: A vitamin needed to produce red blood cells and low in people with poor 
eating habits or in pernicious anaemia. 
Bilirubin: Useful to determine if the red blood cells are being destroyed within the body 
which may be a sign of haemolytic anaemia. 
Lead level: Lead toxicity was formerly one of the more common causes of anaemia in 
children. 
Haemoglobin electrophoresis: Sometimes used when a person has a family history of 
anaemia; this test provides information on sickle cell anaemia or thalassemia. 
Reticulocyte count: A measure of new red blood cells produced by the bone marrow 
Liver function tests: A common test to determine how the liver is working, which may 
give a clue to other underlying disease causing anaemia. 
Kidney function test: A test that is very routine and can help determine whether any 
kidney dysfunction exists. Kidney failure can result in erythropoietin (Epo) deficiency, 
leading to anaemia. 
 
3.5. LATERAL RESEARCH 
Anti oxidant, Anti microbial and cytotoxic activities of selected medicinal plants 
from Yemen. (MAPA) February 2008. Volume 30. No.1 
Ninety crude extracts, including dichloromethane, methanol and aqueous extracts 
from 30 medicinal plants used in the Yemeni ethanomedicine to treat common infections, 
were screened in vitro for antimicrobial activities. Most of the plants showed antibacterial 
activities, Extracts from Tamarindus indica flowers and Ficus vasta fruits have been the 
most active of the 30 plants tested 13 showed antifungal activity (40percent) against one 
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or more human pathogenic fungi. The strongest inhibition was exhibited by Azima 
tetracantha (fruits) Sansevieria ehrenbergii (fruits), and Solanum incanum(fruits) ten 
methanol extracts especially those of acacia asak barks and solanum nigrum fruits,showed 
effective free radical scavenging activities in the DPPH assay.remarkable cytotoxic 
activity against FL – cells  was shown only for 5 plants among them Plicosepalus 
curviflorus (stems). 
Screening of Antimutagenicity via Antioxidant activity in Cuban medicinal plants. 
October 2004, MAPA. Volume 26. No.5 
The reducing activity on the 1,1 – diphenyl 1-2 –picrylhydrazyl(DPPH) radical, oh radical 
scavenging potential, in vitro inhibition of lipid peroxidation and modulation of 
mutagenicity induced by terbutylhydroperoxide (TBH) in Escherichia coli were 
sequentially screened in 45 species of plants used with medicinal purposes in cuba, in a 
search for antioxidant agents which protect DNA against oxidative stree. Five species, e.g 
Tamarindus indica, Lippa alba, Pimentia dioica, Rheedia aristata and Curcuma longa 
displayed IC50 less than 30microg/ml in the DPPH radical reduction assay and IC50 less 
than 32microg/ml in lipid peroxidation inhibition testing. Pimenta diocia and curcuma 
longa showed also a 20 percent inhibition of the in vitro induced OH attack to 
deoxyglucose, Eugenol, the main constituent of the essential oil of Pimenta dioica, also 
inhibited oxidative mutagenesis by TBH in Escherichia coli, at concentration ranging 
from 150 to 400 µg/plate.   
A review on Artemisia absinthiumand, Tamarindus indica in the manangement of 
jaundice. MAPA 2011 June.Volume 33.No.3 
Jaundice is a disease, which is characterized by yellowish or blackish discoloration of 
skin. The cause of which is the accumulation of yellow or black humour in the cutaneous 
tissues and its nearby tissues.usually this humour is free of putrefaction. Based upon the 
nature of discoloration jaundice is classified into 2 types. 1.) yarqaan – e- asfar (yellow 
jaundice). 2) Yarqaan – e- aswad (black jaundice). This type of jaundice does not occur 
due to excess of bile. Hence it is not discussed here. In yarqaan -e –asfar (yellow 
jaundice) there is an abnormal excess flow of bile towards the circulatory system,ie, 
inside the blood cause discoloration of the entire skin, conjunctiva and other secretions 
and organs of the body. Benefits and authenticity of two drugs. Afsanteen and tamare – 
Hindi are described which are use for centuries to treat Yarqaan (jaundice) in Unani 
system of Medicine.   
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4. MATERIALS AND METHODS 
 
4.1. Preparation of chooranam: 
 The  Tamarindus indicus (Puli Ilai) leaves  10kg of fresh leaves were taken, then 
it undergone for shade dry after that the net weight of the leaves were around 3kg. 
 
Collection and authentication of the materials: 
 The Tamarind leaves used in this study were collected from Vadalur, Cuddalore 
(dt), TamilNadu, India during the month of May 2012. The collected leaves were 
authenticated by the Gunapadam experts in Department of P.G Gunapadam Govt.Siddha 
Medical College, Arumbakkam Chennai – 106 and Botanist, the Director Plant Anatomy 
Research Centre, Chennai. One specimen sample has been preserved in the Department 
for future reference. 
 
  Purification of the Raw Drug: 
 The collected leaves were washed in running tap water and dried in shade.   
 
Preparation of the Chooranam: 
 The preparation was taken from Gunapadam – Mooligai written by 
K.S.Murugesa Mudhaliyar. The dried Tamarind leaves were grounded into a fine powder. 
The powder was sieved through a clean white cloth to get a uniform particle size of 
Chooranam. 
 
Purification of Chooranam: 
 The prepared chooranam was purified by a process called Pittaviyal. For this 
process cow’s milk and water were taken in equal ratio and half filled in filled mud pot. A 
clean dry cloth was tied firmly around the mouth of the mud pot. Chooranam was placed 
over the tied cloth. Another mud pot of similar size was kept over the mouth of the mud 
pot. The gap between mud pots was tied with a wet cloth to avoid evaporation. The mud 
pot was kept on fire and boiled until the cow’s milk reduced to the lower pot. Then the 
chooranam was taken, dried, powdered finely.   
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Preservation: 
 The purified Chooranam was stored in a clean, air tight glass container. Since the 
life period of the Chooranam is only three month, the prepared Chooranam must be used 
within this period. 
 
Figure.3. Tamarindus indica (Puli ilai) 
 
                           
               
Figure.4. Puli ilai chooranam (Tamarindus indica) 
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Administration of the drug: 
Form of the medicine  : Chooranam 
 Route of Administration : Enteral 
 Dose    : 1gm 
 Anubanam (Vehicle)  : Honey 
 Times of Administration : Two times a day; before food 
 Duration    : 48 Days. 
4.2. STANDARDIZATION OF THE DRUG 
 
4.2.1. Pharmacognostic aspect: 
 
Macroscopically: 
Organoleptic evaluation: 
Organoleptic evaluation refers to evaluation of the formulation by Colour, Odour, 
Taste and texture etc. The Organoleptic characters of the sample were evaluated as per 
the reference of (Siddiqui et al 2002).  
 
Microscopically: 
Collection of specimens:  
The plant specimens for the proposed study were collected from Chennai. Care 
was taken to select healthy plants and normal organs. The required samples of different 
organs were cut and removed from the plant and fixed in FAA (Farmalin-5ml+ Acetic 
acid-5ml + 70% Ethyl alcohol-90ml).After 24 hrs of fixing, the specimens were 
dehydrated with graded series of tertiary –Butyl alcohol as per the schedule given by 
Sass, 1940. Infiltration of the specimens was carried by gradual addition of paraffin wax 
melting point 58-60 C) until TBA solution attained super saturation. The specimens were 
cast into paraffin blocks. 
Sectioning: 
The paraffin embedded specimens were sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10-12 μm. Dewaxing of the sections was 
by customary procedure (Johansen, 1940). The sections were stained with Toluidine blue 
as per the method published by O’Brien et al. (1964). Since Toluidine blue is a 
polychromatic stain. The staining results were remarkably good; and some cytochemical 
reactions were also obtained. The dye rendered pink colour to the cellulose walls, blue to 
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the lignified cells, dark green to suberin, violet to the mucilage, blue to the protein bodies 
etc. wherever necessary sections were also stained with safranin and Fast-green and 
IKI(for Starch). 
For studying the stomatal morphology, venation pattern and trichome distribution, 
paradermal sections (sections taken parallel to the surface of leaf) as well as clearing of 
leaf with 5% sodium hydroxide or epidermal peeling by partial maceration employing 
Jeffrey’s maceration fluid (Sass, 1940) were prepared. Glycerine mounted temporary 
preparations were made for macerated/cleared materials. Powdered materials of different 
parts were cleared with NaoH and mounted in Glycerine medium after staining. Different 
cell component were studied and measured. 
Photomicrographs: 
Microscopic descriptions of tissues are supplemented with micrographs wherever 
necessary. Photographs of different magnifications were taken with Nikon lab photo 2 
microscopic Unit. For normal observations bright field was used. For the study of 
crystals, starch grains and lignified cells, polarized light was employed. Since these 
structures have refrigerant property, under polarized light they appear bright against dark 
background. Magnifications of the figures are indicated by the scale-bars. Descriptive 
terms of the anatomical features are as given in the standard Anatomy books (Esau, 
1964). The result showed in Figure :5 and Figure: 6 
 
4.2.2. PHYSICO-CHEMICAL ANALYSIS 
 
ASH AND ACID INSOLUBLE ASH: 
 To the ash add 1:5 Hcl: Distilled water 15 ml boil, cooled and then filtered using 
Whatman filter paper (No.41) repeat 3 to 4 times till the yellow colour disappear or 
colourless, then remove the filter paper and add to the filter to the original dish and keep 
it in the muffle furnace at 600
o
 C and take constant weight and calculate the acid 
insoluble ash value. 
 
 Weight of acid insoluble residue x 100 
Acid insoluble ash (%)   
              Weight of  the sample 
 
Acid insoluble residue = Acid insoluble ash value – Empty weight of the dish 
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Loss on drying: 
 3gm of the drug is heated in a hot oven at 105
0
 c to constant weight. The % of 
weight was calculated. 
Loss on drying value at 105
0
 c - 10.96 %w/w 
 
Potential of hydrogen (ph): 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate alkaline or 
base solutions.  
Above mentioned Quantitative analysis results are showed in the table: 12 
 
Thin layer chromatography: 
Extract Preparation:  
4 gram of the chooranam was soaked overnight in chloroform. Boiled on a water 
bath for 10 minutes, filtered and concentrated to 10 ml. 
Procedure: 
 The extract was applied on the TLC using capillary and developed in the solvent 
system.  The developed TLC plate was air dried and photograph was taken in white light, 
then dipped in vanillin-sulphuric acid reagent, heated in an oven at 105°C until the 
development of coloured spots and photograph taken (Figure. 7) TLC results are showed 
in Table 14. 
 
 
4.2.3. QUALITATIVE PHYTOCHEMICAL ANALYSIS: 
Materials and methods:                        
 The leaves and aerial part of Tamarindus indica (L) were destalked, washed and shade 
dried exposing the leaves for desiccation. The leaves were later milled to obtain the fine 
powder using an electric blender. The yield of extract was calculated. Photochemical 
screening procedures carried out were adopted from this analysis determines the 
biologically active compounds that contribute to the flavour, colour and other 
characteristics of vegetable leaves. 
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S.I.No EXPERIMENT OBSERVATION INFERENCE 
1. Test for alkaloids: (Dragendorff’s 
Test) 
Few mg of extract in separate test tube 
was warmed with 2% Sulphuric acid 
for 2 minutes. And it was filtered in 
separate test tube and few drops of 
Dragendorff’s reagent were added. 
The absence of 
orange red 
precipitates 
indicates the 
presence of 
alkaloids. 
 
Absence of 
alkaloids. 
 
2. Triterpenoids (Noller’s Test) 
To fewmg of extract, add tin and 
thionyl chloride and heat in water 
bath. Purple colour indicates the 
presence of tritepenoids. 
 
Purple colour 
indicates. 
 
Presence of 
triterpenoids. 
 
 
3. 
 
Test for Flavonoids (Shinoda test): 
Substance is dissolved in alcohol, 
added with magnesium bits and 
concentrated hydrochloric acid.On 
heating over a water bath, 
 
The appearance 
of majenta 
colour.. 
 
 
Presence of 
flavonoids. 
4. Test for Saponins 
To few mg of extract distilled water is 
added and shaken well. 
The formation of 
foam indicates 
Presence of 
saponin. 
 
 
 
 
5. Test for Steroids (Lieberman 
Burchard Test) 
To few mg of the extract 2 ml of 
chloroform is added in a dry test tube. 
Few drops of acetic acid is added, 
heated and few drops of acetic 
anhydride and 2 drops of concentrated 
sulphuric acid are added. 
The green colour 
indicates 
 
The presence of 
steroid. 
 
6. Test for Proteins (Biuret test) 
To the sample solution in a test tube, 
add sodium hydroxide solution and 
then add a few drops of very dilute (1 
%) copper II sulphate solution and 
mix gently. 
Appearance of 
purple colour 
indicates. 
 
The presence of 
protein. 
 
7. Test for Cardiac glycoside (Keller-
Killani Test). Add 2 ml of 
glacialacetic acid containing a drop of 
ferric chloride solution  and and 0.5 
ml of concentrated sulphuric acid to 
the chloroform extract of the plant. 
The blue colour in 
the acetic acetic 
acid layer shows 
The presence of 
cardiac glycosides. 
 
8. Test for Acids: 
Extract is treated with sodium 
bicarbonate solution. 
Effervescence 
shows. 
The presence of 
acid. 
 
Table.2. Phyto chemical analysis. 
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Phytochemical screening: 
  Chemical tests were carried out using the aqueous extracts from Plants and or the 
powdered specimens, using standard procedures to identify the constituents as described 
by Sofowara (1993), Trease and Evans(1989) and Harborne(1973). The results are 
showed in Table: 13 
4.2.4. Bio -chemical analysis:  
Preparation of extract of test drug: 
Add 5 gm of Puli ilai chooranam to 50ml of distilled water. The solution is 
boiled for 20 minutes, and then it is cooled and then filtered in a 100ml volumetric flask. 
Use the Extract for the following tests. 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1. Test for Reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Presence of Green 
Precipitate 
Presence of 
Reducing Sugar 
2. Test for Starch : 
To 5 ml of extract add 2ml of 
acetic acid and then add few drops 
of N/50 Iodine Solution. 
Presence of of Blue 
Colour 
Presence of of 
Starch 
3. Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Presence of Violet  
Colour 
Presence of of 
Proteins 
4. Test for amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow to dry. 
Presence of Violet 
Colour 
Presence of  of 
Amino Acid 
5. Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Presence of Yellow 
Precipitate 
Presence of 
Albumin 
6. Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution 
and 2ml of concentrated Nitric 
Acid. 
Presence of Yellow 
Precipitate 
Presence of 
Phosphate 
7. Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
Presence of White 
Precipitate 
Presence of 
Sulphate 
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S.No  EXPERIMENT OBSERVATION INFERENCE 
8. Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Presence of Cloudy 
White Precipitate 
Presence of 
Chloride 
9. Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thiocynate solution and 
add 2ml of concentrated Nitric 
Acid. 
Presence of Red 
Colour 
Presence of Iron 
10. Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
Presence of White 
Precipitate 
Presence of Calcium 
11. Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame.  
Absence Yellow 
Flame 
Absence of Sodium 
12. Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Absence Yellow 
Precipitate 
Absence of 
Potassium 
13. Test for Zinc : 
To 2ml of extract, add few drops 
of Sodium Hydroxide. 
Absence White PPT Absence  of Zinc 
14. Test for Magnesium :To 2ml 
ofextract, add few drops of Sodium 
Hydroxide Solution 
Presence of White 
PPT 
Presence of 
Magnesium 
15. Test for Alkaloids : 
a. To 2ml of extract, add 2ml 
of Potassium Iodide 
Solution 
b. To 2ml of extract add 2ml 
of Picric Acid. 
c. To 2 ml of extract add 2ml 
of Phosphotunqstic Acid. 
 
Absence Red 
Colour. 
 
Absence Yellow 
Colour. 
Absence White 
Precipitate. 
 
Absence of 
Alkaloids 
 
Absence of 
Alkaloids 
Absence of 
Alkaloids 
16. Test for Tannic Acid :To 2ml of 
extract add 2 ml of Ferric Chloride 
Solution 
Presence of Black 
Precipitate. 
Presence of Tannic 
Acid 
Table.3 Bio – Chemical analysis 
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4.3. TOXICOLOGICAL STUDY 
Materials and methods:  
Acute toxicity:  
 Acute oral toxicity test for the Puli ilai Chooranam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight. After the substance has been administered, food 
was withheld for a further 2 hours in mice. The animals were observed continuously for 
the first 4 h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or changes in 
general behaviour and other physiological activities. Single animals are dosed in sequence 
usually at 48 h intervals. However, the time interval between dosing is determined by the 
onset, duration, and severity of toxic signs. Treatment of an animal at the next dose was 
delayed until one is confident of survival of the previously dosed animal.  
Observation of toxicity signs: 
 General behaviour, respiratory pattern, cardiovascular signs, motor activities, 
reflexes, change in skin and fur, mortality and the body weight changes were monitored 
daily. The time of onset, intensity, and duration of these signs, if any, was recorded. The 
results are showed in Table.No.15 
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4.4. PHARMACOLOGICAL STUDY: 
 
Haematinic Activity of Puli ilai chooranam in phenylhydrazine induced anaemic rats 
Materials and methods: 
Drug and Stock solution 
 The Puli Ilai Chooranam was prepared as per the procedure in traditional Siddha 
text recommendation and made into suspension using CMC as a suspending agent and 
used in this study. The resulting suspension was then grounded and filtered. The filtrate 
was stored in a refrigerator until use. The suspension was further diluted with 2% CMC 
so as to achieve 200mg/ml stock concentration. 
Animals 
 Male albino rats (150-180g) and Mice of either sex weighing 25-30g were used 
for the study. The rats were housed in wire-mesh cages with a 12 h light/dark cycle. They 
had continuous access to food and water during the entire period of experimentation. 
(Approval number: XIII/VELS/PCOL/44/2000/CPCSEA/IAEC/08.08.2012). 
Evaluation of Haematinic Activity  
 Six rats were kept as normal control group (Group 1), while 24 rats were made 
anaemic by oral intubations of phenylhydrazine (10 mg/kg body weight) daily for seven 
days. Rats that developed anaemia with haemoglobin concentration <14 g/dl were 
recruited for the study. Anaemic rats were randomly divided into 5 groups (2 to 6) and 
treated as follows: Group 1: received distilled water (1 ml) daily (normal control), Group 
2: received 2% CMC (1 ml) daily (anaemic control), Group 3: received oral single dose of 
the Puli Ilai Chooranam 100 mg/kg body weight/day Group 4: received oral single dose 
of the Puli Ilai Chooranam 200 mg/kg, Group 5: received oral single dose of the Puli Ilai 
Chooranam 400 mg/kg Group 6: received oral single dose of the heamatinic syrup 2ml/kg 
body weight/day. The treatment was continued for 2 weeks.  
Haematological investigation 
 Before and after treatment with drug Puli Ilai Chooranam blood was collected 
from the retro orbital vein of experimental animals after an overnight fast (T=0) and after 
1 and 2 weeks of treatment with Puli Ilai Chooranam, was used for the determination of 
red blood cell count (RBC), haemoglobin (Hb) concentration and packed cell volume 
(PCV). The mean cell volume (MCV), mean cell haemoglobin (MCH) and the mean cell 
haemoglobin concentration (MCHC) were calculated. 
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Statistical analysis 
 Experimental data was analysed using analysis of variance (ANOVA) and 
Dunnet’s‘t’ test to determine significant differences between means. The statistical 
analysis system (INSTAT-V3) package was used for this analysis. 
 
4.5. Clinical assessment: 
At the present time Life style changed the food habits. This condition made 
significant impact in changing the human physiology into pathology. Which leads to 
Haematalogical disorders are emerged although there is a lot of medications available for 
this disease, still there is a thrive for less adverse effect drugs. Herbal medicines are 
playing vital role on curing diseases without marked adverse effects even though on long 
term intake. From this plant kingdom I have selected this herb which proved its 
Haematinic activity pre clinically. Puli ilai chooranam, an herbal medicine was used for 
this clinical trial to prove its safety and efficacy against Pandu noi. 
 
Objectives: 
 The study was conducted on Anaemia patients to assess the “Haematinic” activity 
of “Puli ilai chooranam” clinically, both in-patients and out-patients of both sex and 
varying age groups.  
 
Study centre: 
 The clinical study for Anaemia was carried out in outpatient department and in 
patient department of Govt. Siddha Medical College Hospital Arumbakkam Chennai.  
Design of the study: 
Open clinical trial, Phase II B   
 
Selection: 
 50 patients from both sexes of various age groups were selected for clinical trial. 
Among 50 patients 40 patients were treated as out-patients, 10 patients were treated as in 
patients. The selection was based on the including and excluding criteria.  They were 
clinically diagnosed on the basis of Siddha principles with modern laboratory findings. 
 
 
 
30 
 
Registration process 
To register a patient, the following documents were completed by the investigator.  
 Copy of required laboratory tests  
 Signed patient consent form  
 Other appropriate forms (e.g., Trial proforma).  
This Clinical trial is an ethical and scientific quality standard for designing, 
conducting and recording trials that involve the participation of human subjects. 
Compliance with this standard provides assurance to public that the rights, safety and well 
being of trial subjects are protected, consistent with the principles enshrined in the 
Declaration of Helsinki and ensures that clinical trial data are credible. 
 
Inclusion criteria: 
 Hb – 7 to 10 gm% 
 Pallor of conjunctiva and nail beds.  
 Loss of appetite 
 Ulceration of mouth 
 Lassitude 
 Emaciation 
 Palpitation 
 Dyspnoea on exertion 
 Fatigue 
 Breathlessness 
 Tiredness 
 Age 20 to 60 yrs 
 Patient willing to attend the op once in 7 days or willing to be admitted in the 
IP for 30 to 45 days 
Exclusion criteria: 
 Chronic liver failure 
 Chronic renal failure 
 Myxoedema 
 Thalassemia 
 Worm Infestation 
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Withdrawal Criteria: 
 Any other acute severe illness 
 Drug intolerance 
 
Termination Criteria: 
 Voluntary termination 
 Not reporting subsequently. 
 
Clinical Pathological Examination: 
Blood Test: 
 Total count 
 Differential count  
 Haemoglobin 
 Erythrocyte sedimentation rate  
 Blood sugar 
 Blood urea 
 MCV - Mean Corpuscular Volume 
 PCV - Packed Cell Volume 
 
URINE EXAMINATION: 
 Albumin  
 Sugar 
 Deposits. 
MOTION EXAMINATION: 
 Ova 
 Cyst 
 Occult blood 
Administration of the drug: 
 Form of the medicine  : Chooranam 
 Route of Administration : Enteral 
 Dose    : 1gm 
 Anubanam (Vehicle)  : Honey 
 Times of Administration : Two times a day; before food 
 Duration    : 48 Days. 
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Diet and Medical advice: 
A diet rich in iron helps in increasing the haemoglobin levels. It is seen that iron 
from non-vegetarian sources (haeme-iron) is more readily absorbed than iron from 
vegetarian sources (non-haeme iron). The addition of vitamin C to the diet helps in the 
absorption of iron and hence squeezing some lime juice on your salads/food and eating or 
drinking foods rich in vitamin C along with your meals would facilitate iron absorption. 
Avoid drinking tea with your meals as the tannins present in the tea can interfere with the 
absorption of iron from the meal. 
Adults and children who are diagnosed of low haemoglobin count require an iron 
rich diet. Diet for anaemia contains iron rich veg/non-veg sources and is nutritionally rich 
in vitamins and folic acid. 
Do’s: 
1. Eat more iron rich foods. The very best sources of iron that is easily absorbed by the 
human body are: 
 Meat (especially organ meats like liver and kidneys) 
 Fish 
 Eggs (especially the yolk) 
 Cheese 
Commercial breakfast cereals are fortified with easily absorbable iron so they can also 
make a good contribution. 
2. Vitamin C improves iron absorption. Have a glass of fresh orange juice with your 
breakfast which could contain egg, the breakfast cereals, or a bit of fried liver. 
3. You also need folic acid to assist in preventing Anaemia. Folic acid is mainly found in 
green leafy vegetables, and you can also obtain a supplement if necessary. 
Dont’s: 
1. Don’t go on a vegetarian diet without consulting your doctor and dietician. 
2. Avoid iron-containing cocktails of vitamins since these generally do not contain 
enough iron and are expensive. 
3. Drugs that reduce acid production by the stomach such as Cimetidine (Tagamet) may 
inhibit iron absorption and these tablets should not be taken simultaneously. 
4. There are no quick fixes. It is necessary to continue iron therapy for four to six months 
to correct the Anaemia and replenish stores. 
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Trial conduct: 
 This study was conducted in compliance with the protocol approved by the 
Institutional Review Board, and according to Good Clinical Practice standards. No 
deviation from the protocol was implemented without the prior review and approval of 
the IRB except where it may be necessary to eliminate an immediate hazard to a research 
subject. In such case, the deviation was reported to the IRB as soon as possible. 
 
Follow up: 
 Assessment was taken for every three days before treatment and after treatment. 
During this period clinical assessment and laboratory investigation was carried out. 
Statistical analysis: 
The data were tabulated and analyzed by students ‘T’ test. The results were 
showed in Table 18 and 19.  
 
Ethical Review: 
The protocol and amendments were submitted to the Govt siddha medical college, 
Institutional Ethical Committee (IEC) and got formal approval for conducting the study. 
The decision of the IEC concerning the conduct of the study was made in writing to the 
investigator.All subjects for this study was provided a consent form describing this study 
and provided sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form was submitted with the protocol for review 
and approval by the IEC. The formal consent of a subject, using the IEC-approved 
consent form, was obtained before that subject is submitted to any study procedure. This 
consent form was signed by the subject or legally acceptable surrogate, and the 
investigator-designated research professional obtaining the consent.                               
The results of the Clinical trial are showed in Table: 16. 
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CLINICAL STUDY ON PULI ILAI CHOORANAM IN  - OUT PATIENTS DEPT. IN THE MANAGEMENT OF ANAEMIA 
 
 
Sl. 
No. 
O.P. 
No. 
Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) Hb(Gm) BT AT BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb 
Su
g 
Dep Alb Sug Dep Ova Cyst Ova Cyst 
P L E P L E 
1/2
hr 
1 
hr 
½ 
hr 
1hr 
1. 3114 MOORTHY 70/M 9000 53 41 6 9100 58 38 4 23 52 12 25 11.0 13.2 NIL ++ Opc NIL ++ NIL NIL NIL NIL NIL 
2. 6754 DEVI 32/F 9800 59 36 5 9900 62 34 5 45 88 40 62 10.2 12.7 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
3. 6865 DEENA 17/F 6100 44 51 5 6300 51 44 5 35 72 20 40 5.6 9.2 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
4. 3345 RAMESH 38/M 9800 59 36 5 9800 59 37 4 10 25 8 22 13.1 16.2 NIL NIL Fpc NIL NIL Fpc NIL NIL NIL NIL 
5. 5087 RAMASWAMY 56/M 9200 52 39 9 9200 58 38 4 12 30 10 15 9.0 11.5 NIL NIL Oec NIL NIL NIL NIL NIL NIL NIL 
6. 3241 RAJATHI 55/F 7600 49 46 5 8000 52 44 4 10 20 10 22 9.0 11.6 NIL + Opc NIL + Opc NIL NIL NIL NIL 
7. 2396 NARAYANAN 60/M 9400 57 36 7 10100 60 36 4 10 16 5 10 11.0 11.5 NIL + Opc NIL + NIL NIL NIL NIL NIL 
8. 4566 MURALIRAJ 50/M 8700 59 35 6 8800 58 56 6 2 7 5 15 13.0 14.2 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
9. 6444 PANGAJAM 47/F 10400 63 31 6 10400 62 33 5 40 75 20 40 13.0 14.5 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
10. 6373 SARANYADEVI 16/F 7600 48 46 6 7800 50 45 5 8 10 10 12 7.0 10.8 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
11. 3674 BHAVANI 12/F 9000 49 45 6 9200 50 45 5 10 18 10 15 12.0 14.2 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
12. 8062 PONNUTHAYE 70/F 7400 53 41 6 7600 52 40 8 50 71 30 60 8.0 10.4 NIL ++ NIL NIL ++ NIL NIL NIL NIL NIL 
13. 9665 SATHYAN 44/M 9400 57 38 5 9500 59 36 5 4 9 10 15 10.2 12.7 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
14. 5702 SREE KIRIJA 41/F 10100 60 34 6 10200 60 36 4 42 75 20 40 8.0 11.1 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
15. 9900 CHILAMBARASI 60/F 7800 55 38 7 7900 54 42 4 30 62 15 30 9.0 11.2 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
16. 2055 JAYAPAL 44/M 9800 55 39 6 9800 55 41 4 9 15 8 10 14.3 16.2 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
17. 8236 HARIHARAN 22/M 9700 60 36 4 9800 60 35 5 3 10 4 12 13.4 15.1 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
18. 8270 PERIASAMY 40/M 8600 55 39 6 8700 56 38 6 14 27 10 20 13.0 16.4 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
19. 4200 ARIVAZHAGI 54/F 8000 55 39 6 8000 57 37 6 35 62 20 40 10.0 12.4 NIL + NIL NIL + NIL NIL NIL NIL NIL 
20. 3838 SAVITHA 19/F 9200 61 36 3 9300 62 35 3 33 60 17 30 12.0 14.3 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
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CLINICAL STUDY ON PULI ILAI CHOORANAM IN  -  OUT PATIENTS DEPT. IN THE MANAGEMENT OF ANAEMIA 
 
  
    
Sl. 
No. 
O.P. 
No. 
Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) Hb(Gm) BT AT BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb 
Su
g 
Dep Alb Sug Dep Ova Cyst Ova Cyst 
P L E P L E 
1/2
hr 
1 
hr 
½ 
hr 
1hr 
21. 3322 SREESELVI 37/F 9400 55 32 13 9500 57 33 10 11 24 8 14 10.2 12.1 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
22. 3272 JAMUNA 11/F 7600 48 46 6 7800 52 43 5 8 10 10 12 10.6 12.0 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
23. 1243 RATHA 35/F 10400 66 29 5 10400 65 30 5 25 55 18 40 10.8 13.1 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
24. 7399 SHANTHI 40/F 9200 53 40 7 9200 53 42 5 20 45 15 30 11.0 13.1 NIL NIL Fpc NIL NIL Fpc NIL NIL NIL NIL 
25. 3478 GOPALAN 55/M 9100 57 30 13 9400 55 33 12 5 9 5 11 9.0 11.9 NIL ++ Opc NIL ++ NIL NIL NIL NIL NIL 
26. 9867 DHAMODHARAN 40/M 9800 59 37 4 9400 60 33 7 2 5 2 4 13.0 14.7 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
27. 9666 LALITHA 45/F 10700 63 34 3 10700 62 33 5 38 64 18 34 10.7 12.0 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
28. 3632 LOGESHWARAN 11/M 8000 49 47 4 8100 52 45 3 13 30 8 10 10.6 12.7 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
29. 3988 ABILASH 12/M 9000 55 30 15 9100 58 38 4 10 18 8 10 11.0 13.1 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
30. 4467 UMA 40/F 8400 58 36 6 8400 58 38 4 25 74 15 32 9.0 11.3 NIL NIL 1-2PC NIL NIL NIL NIL NIL NIL NIL 
31. 2234 INDHIRA 70/F 10000 62 34 4 10100 58 35 7 15 25 8 15 12.0 14.3 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
32. 7546 GOMATHY 32/F 9700 57 38 5 9600 58 37 5 15 45 15 30 11.0 12.6 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
33. 6234 NAGAMMAL 40/F 9600 59 36 5 9600 58 40 2 27 55 20 40 13.0 14.6 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
34. 6789 PRAVEENRAJ 14/M 9000 47 48 5 9100 50 45 5 10 20 10 18 11.0 13.0 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
35. 3456 MAHALAKSHMI 24/F 9400 55 39 6 9500 58 36 6 20 36 18 30 10.4 12.6 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
36. 1023 KAVIYA 35/F 9000 55 42 3 9200 57 40 3 10 18 10 17 12.0 14.4 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
37. 2874 AISHWARYA 32/M 9000 55 39 6 9100 54 40 6 18 35 15 30 12.0 14.7 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
38. 8236 SENTHIL KUMAR 29/M 9400 55 41 4 9500 55 42 3 10 22 12 20 13.0 14.7 NIL NIL Fec NIL NIL NIL NIL NIL NIL NIL 
39. 8345 RAMYA 29/F 8000 58 37 5 8100 59 37 4 11 26 8 15 10.0 12.4 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
40. 5567 THURAI 48/M 8800 59 38 3 8900 59 39 2 5 10 6 15 12.0 16.0 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
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CLINICAL STUDY ON PULI ILAI CHOORANAM -   IN PATIENTS DEPT. IN THE MANAGEMENT OF ANAEMIA 
 
 
 
Sl. 
No. 
O.P. 
No. 
Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) Hb(Gm) BT AT BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT Alb 
Su
g 
Dep Alb Sug Dep Ova Cyst Ova Cyst 
P L E P L E 
1/2
hr 
1 
hr 
½ 
hr 
1hr 
1. 4239 NAGULAN 70/M 9000 53 41 6 9100 58 38 4 23 52 12 25 11.0 13.2 NIL ++ Opc NIL ++ NIL NIL NIL NIL NIL 
2. 6543 SOUNDARYA 32/F 9800 59 36 5 9900 62 34 5 45 88 40 62 10.2 12.7 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
3. 9876 DARSINI 17/F 6100 44 51 5 6300 51 44 5 35 72 20 40 6.0 9.2 NIL NIL Opc NIL NIL NIL NIL NIL NIL NIL 
4. 3543 ZAHEER 38/M 9800 59 36 5 9800 59 37 4 10 25 8 22 13.1 16.2 NIL NIL Fpc NIL NIL Fpc NIL NIL NIL NIL 
5. 5087 RAMANAN 56/M 9200 52 39 9 9200 58 38 4 12 30 10 15 9.0 11.5 NIL NIL Oec NIL NIL NIL NIL NIL NIL NIL 
6. 6534 RAMANI 55/F 7600 49 46 5 8000 52 44 4 10 20 10 22 9.0 11.6 NIL + Opc NIL + Opc NIL NIL NIL NIL 
7. 4356 KIRUBAKARAN 60/M 9400 57 36 7 10100 60 36 4 10 16 5 10 11.0 11.5 NIL + Opc NIL + NIL NIL NIL NIL NIL 
8. 4654 MURUGAN 50/M 8700 59 35 6 8800 58 56 6 2 7 5 15 13.0 14.2 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
9. 6543 PALANIYAMMAL 47/F 10400 63 31 6 10400 62 33 5 40 75 20 40 13.0 14.5 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
10. 6654 VANAJA 16/F 7600 48 46 6 7800 50 45 5 8 10 10 12 7.0 10.8 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
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CLINICAL STUDY ON PULI ILAI CHOORANAM IN - OUT PATIENTS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No O.P .No Name Duration 
1 3114 MOORTHY 1-7-12 to 25-7-12 
2 6754 DEVI 5-7-12 to 29-7-12    
3 6865 DEENA 6-7-12 to 30-7-12 
4 3345 RAMESH 6-7-12 to 30-7-12 
5 5087 RAMASWAMY 1.8.12 To 31.8.12 
6 3241 RAJATHI 6-7-12 to 30-7-12 
7 2396 NARAYANAN 2.8.12 To 30.8.12 
8 4566 MURALIRAJ 8-7-12 to 1-8-12 
9 6444 PANGAJAM 8.8.12 To 5.9.12 
10 6373 SARANYADEVI 10-8-12 to 9-9-12 
11 3674 BHAVANI 18-8..12 To 4.9.12 
12 8062 PONNUTHAYE 20-8-12 to 8-9-12 
13 9665 SATHYAN 22-8-12 to 20-9-12 
14 5702 SREE KIRIJA 24-8-12 to 22-9-12 
15 9900 CHILAMBARASI 24-8-12 to 24-9-12 
16 2055 JAYAPAL 25-8-12 to 25-9-12 
17 8236 HARIHARAN 27-8-12 to 26-9-12 
18 8270 PERIASAMY 28-8-12 to 27-9-12 
19 4200 ARIVAZHAGI 28-8-12 to 14-9-12 
20 3838 SAVITHA 28-8-12 to 15-9-12 
21 3322 SREESELVI 28-8-12 to 18-9-12 
22 3272 JAMUNA 30-8-12 to 25-9-12 
23 1243 RATHA 2-9-12 to 1-10-12 
24 7399 SHANTHI 2-9-12 to 28-9-12 
25 3478 GOPALAN 3-9-12 to 27-9-12 
26 9867 DHAMODHARAN 4-9-12 to 25-9-12 
27 9666 LALITHA 5-9-12 to 28-9-12 
28 3632 LOGESHWARAN 8-9-12 to 30-9-12 
29 3988 ABILASH 10-9-12 to 10-10-12 
30 4467 UMA 12-9-12 to 12-10-12 
31 2234 INDHIRA 15-9-12 to 10-10-12 
32 7546 GOMATHY 20-9-12 to 18-10-12 
33 6234 NAGAMMAL 25-9-12 to 22-10-12 
34 6789 PRAVEENRAJ 28-9-12 to 20-10-12 
35 3456 MAHALAKSHMI 1-10-12 to 25-10-12 
36 1023 KAVIYA 5-10-12 to 30-10-12 
37 2874 AISHWARYA 10-10-12 to 12-10-12 
38 8236 SENTHIL KUMAR 12-10-12 to 12-11-12 
39 8345 RAMYA 14-10-12 to 14-11-12 
40 5567 THURAI 15-10-12 to 20-11-12 
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CLINICAL STUDY ON PULI ILAI CHOORANAM – IN PATIENTS DEPARTMENT  
S.No  OP.No Name Duration 
1 4239 NAGULAN 5-6-12 to 2-7-12 
2 6543 SOUNDARYA 6-7-12 to 20-7-12 
3 9876 DARSINI 15-7-12 to 5-8-12 
4 3543 ZAHEER 20-7-12 to 5-8- 12  
5 5087 RAMANAN 1-8-12 to 25-8-12 
6 6534 RAMANI 15-8-12 to 30-8-12 
7 4356 KIRUBAKARAN 2-9-12 to 25-9-12 
8 4654 MURUGAN 25-9-12 to 15-10-12 
9 6543 PALANIYAMMAL 5-10-12 to 25-10-12 
10 6654 VANAJA 17-10-12 to 2-11-12 
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CLINICAL ASSESSMENT 
Age wise distribution Table.7. 
 
 
 
 
 
 
 
Inference: 
Among 50 patients, 
 10 Patient belongs to the age group of 10-20 years 
 4   Patient belongs to the age group of 21-30 years 
 14  Patients belongs to the age group of 31-40 years 
 9   Patients belongs to the age group of 41-50 years 
 9   Patients belongs to the age group of 51-60 years 
 2   Patients belongs to the age group of 61-70 years 
SL. NO AGE IN YEARS NO. OF PATIENTS PERCENTAGE (%) 
1 10-20 10 20 
2 21-30 4 8 
3 31-40 14 28 
4 41-50 9 18 
5 51-60 9 18 
6 61-70 2 4 
TOTAL 50 100 
10 
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28 
18 18 
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10 
20 
30 
40 
50 
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Table.8 
SEX DISTRIBUTION  
SL. NO SEX NO. OF 
PATIENTS 
PERCENTAGE 
1 Male 22 44 
2 Female 28 56 
TOTAL 50 100 
 
 
                             
 
 
INFERENCE: 
Among 50 patients, 
 22patients were Male 
 28 patients were Female 
 
 
 
MALE, 22 
FEMALE, 28 
SEX DISTRIBUTION 
MALE 
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Table.9. 
SOCIO-ECONOMIC STATUS 
SL. NO SOCIO – ECONOMIC 
STATUS 
NO. OF 
PATIENTS 
PERCENTAGE (%) 
1 Poor 25 50 
2 Lower middle 10 20 
3 Upper middle 10 20 
4 Rich 5 10 
TOTAL 50 100 
 
SOCIO-ECONOMIC STATUS 
 
INFERENCE:          Among 50 patients, 
 25 patients were poor. 
 10 patients were lower-middle. 
 10 patients were upper middle. 
 5  patients were rich. 
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              Table.10 
 OCCUPATIONAL STATUS 
SL. NO OCCUPATION NO. OF 
PATIENTS 
PERCENTAGE (%) 
1 Students 10 20 
2 Home makers 15 30 
3 Retired persons 3 6 
4 Drivers 10 20 
5 Workers 12 24 
TOTAL 50 100 
 
OCCUPATIONAL STATUS 
 
INFERENCE:      Among 50 patients, 
 10 Patients were Students. 
 15  Patients were Home makers. 
 3  Patients were Retired persons. 
 10 Patients were Drivers. 
 12 Workers 
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Table.11 
PERSONAL HABITS 
 
SL. NO PERSONAL HABITS NO. OF 
PATIENTS 
PERCENTAGE (%) 
1 Vegetarian 15 30 
2 Non-vegetarian 25 50 
3 Smoking 5 10 
4 Alcohol 5 10 
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5. RESULTS AND DISCUSSION: 
Regarding the drug availability, the source of this study drug always meets the 
demands for the treatment for the whole year. It is a tree easy to collect. Here, various 
studies have been carried out in this study drug. The study includes literary 
collections, Pharmacognostic study, Physico and Phyto chemical analysis, 
toxicological study, pharmacological study, and clinical study. The drug has been 
selected for the treatment of Pandu noi  in reference with Gunapadam mooligai. 
  Literary collections about the drug from various text books were done. It 
indicates the efficacy of the drug in the treatment of Pandu noi. Botanical aspect deals 
with the identification description, cultivation and ethno medicinal importance of the 
plant. Gunapadam aspect expressed that the drug possess good effect to treat 
Anaemia.  
 
4.2.1. Pharmacognostic: Study showed Macroscopical and Microscopical 
Macroscopical: 
Colour  - Greenish colour 
Odour   - Odourless  
Taste   - Sour 
 
Microscopical:  
Microscopic features of the leaflet: 
  The leaflet has less prominent midrib and thick lamina with smooth and even 
surfaces (Fig5.a). The midrib is flat in the adaxial side and slightly raised into shallow 
convex on the abaxial side (Fig5.b). The midrib is 220µm thick. The epidermal layer 
of the midrib is narrow the cells being cylindrical and thin walled. The palisade cells 
are transcurrent across the midrib vascular bundle, below the adaxiall epidermis. 
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 The vascular bundle of the midrib is single, large and circular and measures 
160µm in diameter. It consists of an are of 4 or 5short parallel rows of wide and thin 
walled xylem elements and a thick are of phloan cells to eated on the lower end of the 
xylem strand (Fig6.a). The entire vascular strand is encircled by thick axes of 
sclerenchyma cells on the adaxial and abaxial portious of the bundle (Fig 6.a,b) 
Lamina (Fig 5.a):  
The lamina is 160µm thick. It is dorsi ventral with distinction of adaxial and 
abaxial sides. The adaxial epidermis consists of wide and thick cells with thin 
cuticular layer(Fig5.c). The cells are20µm thick. The abaxial epidermis is 
comparatively thin;the cells are either cylindricalor broadly conical; the epidermis is 
stomatiferous. The mesophyll tissue is differentiated into adaxial zone of two layers 
of narrow cylindrical, compact cells.The abaxial zone micludes about eight layers of 
small lobed cells, loosely arranged cells with intracellular spaces(Fig5.c) 
Leaf margin (Fig.6.c) 
The marginal part of the lamina is thick and conical. It is 90µm thick. The epidermal 
cells along the marginal part are reduced in size; they are squares or rectangular thick 
walled with thick cuticle. A circular thick vascular bundle is located within the 
marginal part. The bundle consists of thick sclerenchymetous bundle sheath enclosing 
a few, thick walled xylem element and a few phloem elements. 
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PHARMACOGNOSTICAL FIGURE OF   (Tamarindus indica). 
 
           Fig 5.a T.S of leaf through Lamina              Fig 5.b T.S of Leaf  through 
       Lamina Midrib - enlarged 
                                                                                                        
                       
 
                                                                                          
                                         Figure 5.c Transverse Section of  Lamina 
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Figure 6.a Vascular Bundle of the                Figure.6.b.Vascular Bundle of the                      
Midrib – Enlarged                                         Midrib -As seen under  polarized  
       light 
                   
 
 
                         Figure 6.c Transverse section of leaf  Through margin 
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Table .12. 
               4.2.2. PHYSICO – CHEMICAL ANALYSIS: 
 
S.No Parameter Mean Value 
1 Loss on Drying at 105°C 4.5 % 
2 Total Ash  6.75 % 
3 Acid insoluble Ash   0.85 % 
4 Water Soluble Extractive 28.9 % 
5 Alcohol Soluble Extractive 22.2 % 
6 Particle size Completely passes through 
sieve no. 44 
7 pH 3.0 
 
 
 
4.2.3.QUALITATIVE PHYTOCHEMICAL TESTS 
Table. 13 
S.No Parameter Mean value 
1 Alkaloids - ve 
2 Triterpenes + ve 
3 Flavonoids   + ve 
 4 Saponin   + ve 
5 Steroids + ve 
6 Protein + ve 
7 Glycoside + ve 
8 Acid + ve 
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TLC: 
 
Figure. 7. TLC 
                 After spray with visualizing agent Table .14. 
 
 
 
Sl.No After Dipping in Vanillin-Sulphuric acid 
 
Rf value Colour of the spot 
 
1 0.04 Purple 
2 0.21 Yellow 
3 0.27 Yellow 
4 0.42 Yellow 
5 0.63 Yellowish brown 
6 0.69 Purple 
7 0.75 Yellow 
8 0.81 Purple 
9 0.95 Purple 
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Solvent system: 
Toluene : Ethyl acetate (4:1.5). 
TLC plate: 
  Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness 
(Merck). 
Developing chamber: 
 Camag’s twin trough chamber. 
Visualizing reagent: 
 Vanillin-sulphuric acid reagent. 
 
4.2.4. BIO – CHEMICAL ANALYSIS: 
  The Bio – Chemical analysis of  Puli ilai chooranam showed following 
chemicals, 
Reducing sugar, starch, protein, aminoacids, albumin, phosphate, sulphate, 
chloride, iron, calcium, magnesium, tannin. 
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4.3. TOXICOLOGICAL STUDY: 
Acute Toxicity: 
Table 15: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 2000 + + - + + + - - - - - - - - - - - - - - 
2 5000 + + - + + + - - - - - - - + - - - - - - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. 
Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
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4.4. PHARMACOLOGICAL STUDY: 
The present study aimed to evaluate the effect of Puli Ilai Chooranam on the 
haemolytic   anaemia induced by phenylhydrazine in albino rats. The Puli Ilai 
Chooranam appears safe for use since the tolerability of Puli Ilai Chooranam was 
greater than 5 g/kg. It has been demonstrated previously that intraperitoneal 
administration of phenylhydrazine decreased haemoglobin concentration, red blood 
cells number and haematocrit. In this study, PHZ altered the function of RBC by 
haemolysis characterized by decrease in RBC, Hb concentration, WBC and PCV. 
However, these parameters were restored to normal range after treatment with Puli 
Ilai Chooranam suggesting that have significant haematinic effect. The results of this 
study indicated that the Puli Ilai Chooranam increased significantly the concentration 
of haemoglobin, red blood cell count, white blood cell count and the packed cell 
volume mainly one week after of treatment.  
 Iron is essential for cellular metabolism, viability, and growth regulation. On 
the other hand, free iron is pro-oxidant and can, therefore, damage cells owing to the 
attack of reactive oxygen species and lipid peroxidation products on bioactive 
macromolecules, such as proteins and nucleic acids. Anaemia is a major cause of 
morbidity and mortality in malaria endemic areas of tropical regions of the world. 
Anaemia in malaria is caused by destruction of red blood cells in the body or the 
depression of red blood cell production in the bone marrow. As the red blood cells 
become less, the patient weakens. In severe cases the patient is unable to deal with 
basic life essential tasks and may die. There are various causes and types of anaemia, 
these include: sickle-cell anaemia, iron deficiency anaemia, vitamin B12 anaemia, 
drug induced anaemia as side effect of drug therapy.  
 The Puli Ilai Chooranam had a positive effect on the haemopoietic system of 
the test rats. It significantly increased the red cell mass, haematocrit, haemoglobin 
concentration and total white cell count while decreasing lymphocyte and monocyte 
counts. In the treatment of diseases like malaria and anaemia, the beneficial effects of 
analyzed drug materials especially from plants are mainly attributed to the presence of 
constituents like alkaloids, saponin, terpenoids, anthraquinones, essential oils, 
flavonoids, tannins, etc.  
 The efficacy of these constituents could also be influenced by inorganic 
components known as the trace elements. Micronutrient deficiencies and infectious 
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disease often coexist and show complex interactions leading to mutually reinforced 
detrimental clinical effects especially in underprivileged people of developing 
countries, particularly in rural regions. Several micronutrients such as trace elements 
(Zn, Fe, Se) modulate immune function and influence the susceptibility of the host to 
infection. Some trace elements have been found beneficial in the control of anaemia 
under this condition. The increase in the blood indices was progressive giving the 
highest effect on the second week of Puli Ilai Chooranam treatment may be more 
beneficial in the anaemic conditions.  
 Under normal condition, the body can generate new RBCs to replace the lost 
red cells; this will take much longer time as shown in this study. The recovery time of 
two weeks for untreated rats has earlier been reported when rats were bled 20% of 
their total blood volume to induce haemorrhagic anaemia. The increases in the 
haematological indices exhibited by Puli Ilai Chooranam might be related to the 
vitamin and mineral contents of the Puli Ilai Chooranam. These constituents are well 
known haemopoietic factors that have direct influence on the production of blood in 
the bone marrow.  
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4.5. CLINICAL ASSESMENT 
 Table .16. IMPROVEMENTS IN SIGNS AND SYMPTOMS 
 
SL. 
NO 
SIGNS AND 
SYMPTOMS 
NO. OF PATIENTS 
BT AT IMP. IMPROVEMENT 
(%) 
1   Dyspnoea 50 3 47 94 
2   Pallor  45 4 41 91 
3   Lethargy 30 8 22 73 
4   Malaise  40 6 34 85 
5   Anorexia  29 5 24 82 
6   Palpitation  18 6 12 66 
7 Swelling of the body 30 7 24 80 
 
 
 
IMPROVEMENTS IN SIGNS AND SYMPTOMS 
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INFERENCE: 
Among 50 patients, 
 47 out of 50 patients were relieved from Dyspnoea. 
 41 out of 45 patients were relieved from Pallor. 
 22 out of 30 patients were relieved from Lethargy. 
 34 out of 40 patients were relieved from Malaise. 
 24 out of 29 patients were relieved from Anorexia. 
 12 out of 18 patients were relieved from  Palpitation. 
 24 out of 30 patients were relieved from Swelling of the Body. 
 
Gradation result 
Grading of Anaemia: 
Grade 0 - With in normal level 
Grade 1 - Lower normal limit 10g/dl 
Grade 2 -  8 – 10 g/dl 
Grade 3 - 6.5 – 8 g/dl 
Grade 4 - < 6.5 g/dl 
Grade 5 -  Death.  
 
Table, 17. Grading of Anaemia 
 
S.No  GRADE NO OF PATIENTS PERCENTAGE(%) 
1 Grade 0  40 80 
2 Grade 1 4 8 
3 Grade 2 5 10 
4 Grade 3 1 2 
5 Grade 4 0 0 
6 Grade 5 0 0 
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GRADATION RESULT: 
 
Clinical study: 
 50 patients of both sexes were selected .Among the 50 patients, 40 patients 
were treated as out- patients in the Post graduate department of Gunapadam, 
Govt.Siddha medical college hospital and Govt. Arignar Anna hospital, 
Arumbakkam, Chennai- 106.  10 patients were treated as in - patients.The patients 
were observed regularly. 
 The trial drug Puli  ilai chooranam was given to the patients at the dose of 1 
gm twice a day with hot water before meals. On administration of Puli ilai 
chooranam 1 gm twice a day for 7 weeks should significant Haematinic activity. 
Honey which was used as vehicle also has iron containing property as per classical 
siddha literature.   
Among 50 patients, 47 out of 50 patients were relieved from Dyspnoea. 41 out 
of 45 patients were relieved from Pallor . 22 out of 30 patients were relieved from 
Lethargy. 34 out of 40 patients were relieved from Malaise. 24 out of 29 patients were 
relieved from Anorexia. 12 out of 18 patients were relieved from Palpitation. 24 out 
of 30 patients were relieved from Swelling of the body. The results revealed that the 
drug possess 80% Grade 0, 8% Grade 1, 10% Grade 2, 2% Grade 3. 
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STATISTICAL ANALYSIS 
DESCRIPTIVE STATISTICAL FOR IMPROVEMENT OF SIGNS & 
SYMPTOMS IN “ANAEMIA” 
PAIRED “t” TEST RESULT: 
Table.18.“p” value & statistical significance:  
Treatment Signs & 
symptoms 
Mean S.D S.E.M 
Before treatment 7 34.57 10.98 4.15 
After treatment 7 30.00 13.04 5.32 
 
 From the table we calculated the descriptive statistic like Mean, S.D & S.E.M 
of Mean for the improvement score before and after treatment. 
 
“t” Table: 19 
t-Table S.D “t” Value “p” Value 
Pre vs Post 0.715 7.46 0.0007 
  
The two-tailed P value is less than 0.0007 
  By conventional criteria, this difference is considered to be extremely statistically 
significant.  
 
RESULT AND DISCUSSION: 
 Improvements of signs and symptoms by statistical analysis shows the two 
tailed “p” value equals 0.0007, by conventional criteria, this difference is considered 
to be extremely statistically significant. From the above results p < 0.05, it shows the 
improvement in the subjective parameters produced by Puli ilai chooranam 
statistically significant. 
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6. CONCLUSION 
 
The trial drug of “Puli ilai Chooranam” has been selected and its efficacy was 
analyzed in the treatment of Anaemia. 
The drug is simply available and preparation is very easy. 
The trial medicine is cost effective. 
The drug shows good Haemataenic activity. 
No adverse effects were produced during the entire clinical trial. 
From the above observation, I conclude that the drug “Puli ilai chooranam” 
(Tamarindus indica) gives a new hope in the field of Anaemia Treatment.  
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7. SUMMARY 
The tree Tamarindus indica  leaves were  collected from Vadalur, Cudalore 
(Dt)  and purified then powered and stored. This drug was subjected to various 
studies.  
Puli ilai Chooranam was selected for this study to estimate the  Haemataenic           
activity, and  proved its efficacy and safety in Anaemia disease.  
I was collected the information about the drug, various text books, Literature 
was referred. From them, i came to an idea about the drug and its worth on Anaemia. 
A brief description about botanical aspect of the herb Puli ilai and its 
identifying characters and Phyto chemical data’s were given. 
The pharmacological analysis showed that the drug has got significant 
Haemataenic activity. 
In clinical study, the drug has showed marked improvement in 80% of cases. 
The patients were responding well from the beginning of the treatment and no 
adverse effects were reported. 
This present study suggests that Puli ilai Chooranam has the remarkable 
medicinal value against the disease Anaemia without any adverse effect. 
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1. INTRODUCTION 
 In the world more than 20,000 traditional forms of medical systems are available. 
Some of them are popular as well as mostly used by the people for their basic and 
primary health care even today. 
Siddha Medical system or Tamil Medical system is one of the ancient systems 
of medicine, which is being in existence. It has got valid scientific, significant, the 
most respectable and of high order of medical system. It is being practiced extensively 
in Southern India, Srilanka, Malaysia and Singapore, where the Tamil civilization had 
taken its roots.  
The typical characteristic features of the Siddha Materia Medica are utilization of 
metal and mineral based preparations to a greater extent in comparison with other 
traditional systems of medicine. The Siddhars were the pioneer in the use of metals 
and minerals in the treatment of diseases. 
It has been noted that metallic or mineral medicines can help tremendously in 
patients with chronic or degenerative diseases and have been tried by all other 
medical systems and that too after treating primarily with herbal medicines. The same 
thing is conveyed by Siddhars before many years. They laid down the line of 
treatment to give first preference to herbal medicines and then to go on with herbo- 
mineral and then to metallic preparations. This is revealed in the following verse as  
“Ntu;ghU jioghU kpQ;rpdf;fhy; 
nky;y nky;y gw;g nre;J}uk; ghNu” 
rpj;j kUj;Jthq;f RUf;fk;   gf;fk; 473 
Treating the minerals with herbal juices may lead to reduction (trituration) in 
particulate size even up to Nano levels (less than 100 nm) which enable increased 
potency. These drugs are known to be effective even in low concentration. This 
reduction of particle size of Parpam, Chendooram and Chunnam are intimately 
connected with the size of today’s so called “Nano particles”. The prevailing “Nano 
medicine system” would be the basic tool for developing new drugs, which is prime 
dream for every scientist. But this secret was already established and documented by 
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our Siddhars prior to many generations. This is considered to be one of the gems in 
the field of Siddha Medicines. This shows their vast knowledge about the medicine 
and hence for the reason, they are considered to be immortals and the Siddha system 
of medicine is the perfect medical science of the past, present and future. One of the 
unique and vital categories in Siddha System of Medicine is Parpam.  
Basically, Parpam is considered as one of the alkaline medicines which 
contains mainly calcium and is used for various medical purposes. Scientists have 
found that most diseases thrive in an acid environment, but cannot survive in an 
alkaline environment. It is a proven scientific fact that the bodily fluids (e.g., blood, 
spinal fluid, saliva, etc.) of a healthy human body are alkaline (with a high pH 
reading), whereas the bodily fluids of a person who is sick are acidic (with a low pH 
reading).  
Charam are often considered the medicine cabinets of the 21
st
 century. But the 
focus on The unique medical properties of Charam were recognized by Siddhars in 
pre-historic period itself.  
Purified charam are grinded into powder and can be used to cure diseases of 
liver. Charam is given as a protective amulet.  
Liver is the largest internal organ in the body and has more functions than any 
other human organ. It plays a central role in many essential physiological process, 
including glucose homeostasis, plasma protein synthesis, lipid and lipoprotein 
synthesis, bile acid synthesis and secretion and vitamin storage (B12, A, D, E and K). 
It is also the principal organ related to metabolism and excretion of a wide variety of 
environmental pollutants and also therapeutic agents.  
As per the global estimates, there are about 18, 00,000 deaths every year due 
to liver cirrhosis, mainly caused by hepatitis. Although viruses remain the main cause 
of liver diseases, the liver lesions arising due to imbalance of enzymatic levels which 
result from xenobiotics, excessive drug therapy, environmental pollution and 
alcoholic intoxication are among the secondary reasons (Handa SS, 1991).  
Based on the above facts, the liver disorders are one of the leading serious 
world health problems prevailing today.  Despite its frequent occurrence, high 
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morbidity and high mortality, its medical management is currently not satisfactory 
and inadequate. No therapy has successfully prevented the progression of hepatic 
diseases. In the absence of reliable hepato-protective drugs in the market, herbal, 
mineral and animal derived preparations play a vital role in the management of 
various liver disorders. Numerous medicinal plants and their compound formulations 
are used for liver disorders in Siddha medical practices and other traditional systems 
of medicine in India.  However, there is increasing problem of liver disorders which 
demands for more precise, safe and effective treatments for the same is the need of the 
hour.  
So, the search for effective hepato-protective drug still continues... 
 With the statements made above, charam, with the preparation, can be 
considered as one of the primary Siddha medicines which could fetch effective results 
for the cure of liver disorders. So, the author is interested to evaluate the Chara 
parpam, a unique herbo- mineral drug preparation for its hepato-protective activity. 
This Siddha drug “Chara parpam” is yet remained unexplored for its exact 
chemical, pharmacological and clinical values in terms of scientific research. To fill 
these scientific lacunae, the present work was undertaken to evaluate the chemical, 
pharmacological and clinical efficacy of Chara Parpam. 
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2. AIM AND OBJECTIVES 
Liver diseases are among the important health disorders affecting millions of 
people worldwide. Since 300 million people (about 5% of the world population) 
suffer from various hepatic disorders which are the main cause of cirrhosis and liver 
cancer, particularly in developing countries like India. 
Apart from viral origin, common liver disorders are mainly induced by 
hepatotoxins, which includes alcoholic hepatitis and drug induced hepatitis. 
Hepatotoxicity is a growing concern of today’s modern society. The 
increasing incidence of alcoholism, cigarette smoking, fast foods and other 
xenobiotics have contributed to the morbidity and mortality due to liver disease. 
Jaundice and hepatitis are two major hepatic disorders that accounts for a high death 
rate. Especially liver disorder is one of the common causes of death between the age 
of 25 and 44. 
Modern medicine has little to offer for alleviation of hepatic diseases and even 
most of them are based on herbal preparations only. But there are not much drugs 
available for the treatment of liver disorder. (Karan et al, 1999, Chaterrjee 2000). In 
absence of reliable liver protective drugs in modern medicine, there exists a challenge 
for pharmaceutical scientists to explore the potential of hepatoprotective activity using 
natural sources. In this situation traditional medical systems play an important role in 
the treatment of various hepatic disorders. 
Among the various sources for the development of potent hepatoprotective 
drugs, compounds from living organisms especially from marine origin are of 
particular significance. In fact, one coral reef ecologist Andrew W.Bruckner says that, 
we are 300 to 400 times more likely to find new drugs in the ocean than on land. 
. 
 The present study was focused to evaluate the hepatoprotective potentials of 
Chara parpam in experimental animals with CCl4 induced hepato toxicity. 
 
 It was also carried out to determine the clinical efficacy of Chara parpam in 
patients with Jaundice (hyperbilirubinaemia) due to hepatic pathology.  
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2.1. OBJECTIVE: 
 This scientific study on Chara parpam was carried out in the following stages. 
 To Collect the literature evidences related to the trail drug 
 To Get the proper authentication of Raw drugs 
 Preparation of the trial drug, according to the text in a classic method. 
 Physico-chemical, Chemical Analysis for the trial drug to identify the active 
mechanism  
 Toxicological studies to prove the safety of the drug.  
 Pharmacological study to evaluate the hepatoprotective efficacy of the drug 
 Clinical studies Evaluating the therapeutic efficacy of Chara parpam through 
open clinical trial on KAMALAI patients 
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3. REVIEW OF LITERATUE 
3.1. Gunapadam aspect of the drug: 
3.1.1. ethr;rhuk; 
NtWngau;: 
,\;bif 
Ry;ypif 
R+spif 
gL 
mRud; 
ethr;rhuj;jpd; Njhw;wk;: 
 fw;R+isfspy; ,J fpilf;Fk; 
 ,J xl;lfk; Kjypa kpUfq;fspd; rhzr;rhk;gYld; epyf;fupiaAk; 
cg;igAq; $l;bg; gjq;fpj;J vLf;fg;gLfpd;wd. 
gz;G: 
filfspy; fpilf;Fk; ruf;F ghu;itf;F fl;bahAk; thridapd;wpAk; 
ehu;ehuhAk; J}s;nra;a fbdkhAk; ,Uf;Fk;. ePupYk; rhuhaj;jpYk; 
fiuaf;$baJ. ethr;rhuk; nraw;if cg;G tifia rhu;e;jJ. 
Rhuj;jpd; itg;G 
 Ahid> Fjpiu> fOij> ML> khL> xl;lfk;> gd;wp> kdpjd; ,tw;wpd; 
rpWePu; rkmsthf Nru;j;J mjw;F 1/8 gq;F R+lDk;> rPdKk;$l;b ghz;lj;jpy; 
vupj;J fl;bahd gpd; nghbnra;J xU tha;Ftpe;j ghz;lj;jpy;  1/2gq;Ftiu 
Nghl;L rpy;ypl;L rPiy nra;J mLg;Ngw;wp 5 ehs; fkyhf;fpdpahf vupj;J Glk; 
Nghl;L 5 ehs; cilj;J ghu;j;jhy; rhuk; gyifahFk;. 
  
etr;rhuj;jpd; rj;JU kpj;jpU: 
rj;JU 
fy;Yg;G   Rf;fhd; 
,e;Jg;G   fhuPak; 
gbfk;    fly;Eiu 
tisaYg;G   mg;gpufk;   
,Uk;G    rTL 
fhe;jk;   fpspQ;rpy; 
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kpj;JU 
jhsfk;   rpiy      fy;ehu;  ehfk; 
ntbAg;G  tPuk;       epkpis  nrk;G 
,ypq;fk;   ntq;fhak;;  
 
epwk;: mOf;F gbe;j ntz;ik (m) fgpy epwKilaJ. 
 
Rit: frg;G> Gspg;G %j;jpu ntFl;ly; cilaJ. 
 
Rj;jpKiw: 
  ethr;rhuj;ij nte;ePupy; fiuj;J R+lhapUf;Fk;NghJ tbfl;b 
Fspu; Mwpdgpd; thafd;w ghj;jpuj;jpypl;L nta;apypy; itf;f cg;G ciwAk;. 
mij Gl;bapy; milj;J gj;jpug;gLj;jTk;. 
 
nra;if: 
  Fiwe;j mstpy; ehl;glf; nfhLj;jhy; cly;Njw;wpahFk;. 
mjpfmstpy; nfhLf;f ntg;gKz;lhf;fpahFk;. 
  Nfhioafw;wp> tpau;itngUf;fp> rpWePu;ngUf;fp> tpuzKz;lhf;fp> 
gpj;jkfw;wp. 
  ,J Kf;fpakhf epzeuk;Gfs>; khkprf;fpue;jpfs; kPJ jd; 
Ntfj;ijr; nrYj;Jk;. 
  
nghJf;Fzk;: 
   
“ Fd;kk; Flw;R+iy nfhy;Yk; kNfhjuj;ij 
 td;ikAW fy;yilg;ig khw;Wq;fhz; - rd;kf; 
 ftpr;RKj; Njhlq; fdthj ePf;Fk; 
 etr;rhu khNj etpy;.” 
 
etr;rhuk; tapw;Wtyp; Flypy;Fj;jy;> ngUtapW> fy;yilg;G> rUkj;jpy; 
Gyhy;thrk;> jpupNjhlk;> fdthA ,itfis ePf;Fk;.  
 cg;Grk;> fy;yPuy;tPf;fk;> gpyPfNeha>; ePu;f;Nfhit> ,uj;jfhrk;> Kfr;re;ep> 
R+upahtu;j;jthjk;> R+jff;fl;L> ff;fpUky;> Kiwf;fha;r;ry;> tplhf;fha;r;ry; 
,itfl;Fk; cgNahfpf;fyhk;. 
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gad;fs;:  
 kQ;rs;fhkhiy CJfhkhiy fy;yPuy;tPf;fk; fy;yPuypy; cz;lhFk; fl;b 
Kjypa Neha;fSf;F ethr;rhuj;ij ePu;Ks;spf;FbePupy; nfhLf;f rpWePiug; 
ngUf;fpg; gpzpia ePf;Fk;. 
 
NrUkUe;Jfs;: 
 
1.ethr;rhuf;Fok;G: 
 
1 gyk;(35fpuhk;) ethr;rhuj;ijf; fy;tj;jpypl;Lf; nfhbf;fs;spg;ghy; tpl;L 
ed;wha; ikNghyiuj;Jr; rpkpopy; gjdk; gz;zpf; nfhs;sTk;. 
 
msT :    Fd;wpasT (130kp.fp) 
 
jPUk;Neha;fs;:   kyf;fl;L ryf;fl;L ngUtapW thAfl;b ePuhk;gy;. 
2.,ytzf; Fok;G: (mDNghf itj;jpa etePjk; ghfk; 3) 
 fwpAg;G  5 gyk; 
 mg;gsfhuk;> ntz;fhuk;>        midj;Jk; 
 etr;rhuk;> fw;G+uk;>            tiff;F 1 / 2 gyk;  
 ntbAg;G> fly;Eiu  
 rPdhf;fhuk;> ngUq;fhak;> 
 ,e;Jg;G> rTf;fhuk;> 
   gRtpd; ePu; - 2 gb 
       gidnty;yk; - 10 gyk; 
Nkw;gb nty;yj;ijf; fiuj;J cg;GfisAk; kw;w ruf;FfisAk; Ez;ikahfg; 
nghbj;J mjpw;Nghl;L mLg;Ngw;wp rpW jPahf vLj;J nkOF gjj;jpy; gPq;fhd; 
ghj;jpuj;jpy; itj;Jf;nfhs;sTk;. 
msT:  1 Kjy; 11/2 tuhfd; vil fhiy khiy ,uz;L NtisAk;  
  cgNahfpf;fyhk; 
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jPUk; Neha;fs;: 
 kNfhfjuk;> ngUtapW> ghz;LNeha;> fhkhiy Neha;fs;> fTir fl;bfs;> 
 gPypiff; fl;bfs;> mfl;LthA> ghz;L Kjypa Neha;fs; jPUk;. 
3.etr;rhuhjpf;Fok;G 
 etr;rhuk;> ,e;Jg;G> ntbAg;G> Xkj;J}s;> rTf;fhuk;> fhe;jj;J}s>; 
fLFj;J}s; J}a;ik nra;j Neu;thsg;gUg;G> kQ;rs;> fLf;fha;j;Njhy; R+uzk;> 
,it tiff;F 1 gyk; (35gyk;) 5 gyk;(175fpuhk;) kQ;rs; fLf;fha; Njhiy 
xd;iwg;gb jz;zPupy; Nghl;L miug;gbahfr; Rz;litj;J jpwe;J tbfl;bd 
FbePu; nry;yj;jf;f msT. 
nra;Kiw: Muk;gj;jpy; thsj;ijf; fy;tj;jpypl;Lj; J}s; nra;J 
kw;witfisAk; KiwNa xt;nthd;whf Nru;j;jiuj;J> Kbthf vy;yhtw;iwAk; 
xd;whfr; Nru;j;J Nkw;gb FbePiur; rpWfr; rpWf thu;j;J 4 rhkk; miuj;J 
nkOF gjj;jpy; gPq;fhd; rpkpopy; gj;jpug;gLj;jTk;.  msT: 2 – 3 
Fd;wpvil. 
JizkUe;J: rpw;whkzf;F vz;nza;> ,Q;rpr;rhW> Rf;Ff;FbePu;> Nrhk;GFbePu;. 
jPUk;Neha;fs;: ePuhik> ngUtapW> ftpir> tapw;Wf;fl;b;> gpj;jfhkhiy> 
vl;Ltifghz;L. 
 
3.2.2.ntbAg;G 
POTASSH NITRAS;  POTASSIUM NITRATE.SALT PETRE;  NITRATE OF 
POTASH. 
NtWngau;: 
nghl;bYg;G 
,zq;fd; 
giluhrd; 
G+kp $u;ik 
etr;rhu kpj;U 
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itg;G Kiw: 
 Xub fdj;j kl;ghz;lj;jpy; cg;G cju;e;j kz;izf; nfhl;b ePu;tpl;Lf; 
fyf;fpg; gpwF FUJ fl;b jkupl;L itf;Nfhy; nrhUfp Nkw;gb ePiu tpl;Lj; 
njspntLj;J mjid fha;r;r cg;ghFk;. 
 ,t;Tg;G 1 f;F ePu; ehd;Fgq;F tpl;Lf;fha;r;Rk;NghJ Kg;gj;jpw;F 1 gq;F 
Gspj;j Nkhu; gor;rhW ,tw;iw tpl;L fha;r;rp cg;ngLf;fTk;.,g;gb 4 my;yJ 
5 Kiw fha;r;rp vLf;f cg;G fk;gp fk;gpaha; epw;Fk;. ,J thjj;jpw;F Ntu;.fha; 
,iy G+ vd;gu;. 
Rj;jpKiw: 
ntbAg;G  - 1 gq;F 
jz;zPu;  - 4 gq;F tpl;L mLg;Ngw;wp rpW jPahy; vupj;Jf; 
nfhjpfpsk;Gk;NghJ>1 tPir cg;Gf;F 4 Nfhop Kl;il ntz;fUitr; Nru;f;f 
Ntz;Lk;. NkNy mOf;Fj; jpuSk;. mjid mfg;igahy; topj;J ePf;fp> 
ciwAk; gjj;jpy; kWrl;bapy; rPiyfl;bmjpy; tbj;Jf; fhw;wpy;yh tplj;jpy; 
itj;J>kWehs; ePiu tbj;Jtpl;L>R+upanthspapy; cg;ig cyu;j;jTk;. ,t;thW 
7 Kiw nra;ar; Rj;jpahk;. 
NtWKiw: 
ntbAg;G 1 gq;F fly;ePu; my;yJ ePu; 2 gq;F vLj;J cg;ig 
Ez;ikaha;g; nghbnra;J ePupy; fye;Jitf;f ePupy; fye;JNghk;. njspntLj;J 
ntz;ikahd ,Ug;Gg; ghz;lj;jpy; tpl;Lf;fha;r;rp ciwAk; gjj;jpy; NtW xU 
nrg;Gg;ghz;lj;jpy; nfhl;b Fspu;e;j ,lj;jpy; Mwitf;f cg;ghFk;. ,ij 
vLj;J ,jw;F 2 gq;F ePu; tpl;L Nkw;gbahfNt fha;r;rp cg;ghf;fTk;. ,g;gb 
nkhj;jj;jpy; 5 Kjy; 7Kiw nra;a Rj;jpahk;. 
Rj;jp nra;j cg;G fk;gpfshAk; ntz;ikahAk; ehf;fpypl;lhy; 
Fspu;r;rpahAk; ,Uf;Fk;. neUg;gpypl nghupAk;. 
nra;if: 
cl;gpuNahfk;;: 
Fspu;r;rpAz;lhf;fp 
tpau;it ngUf;fp 
rpWePu;ngUf;fp 
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ntspg;gpuNahfk;: 
Fspu;r;rpAz;lhf;fp 
nghJFzk;;;;: 
ky;yhU kl;lFd;k khjUj uf;fl;b 
fy;yh kijg;GePu;f; fl;lUf – nyy;yhNk 
fk;gpfk;gp nad;Wq; fUTz;lh kq;fpepd;w 
fk;gpfk;gp nad;Wiuf;Fq;fhy. 
 
 R+jfthAnthL Nrhzpjj;jpd; thjKk;Nghk; 
 Thjtyp Fd;kkpit khWq;fhd; - kPjhq; 
 Nfhba tapwpopAq; Nfhiofg NkFk; 
 ntbAg;Gj; jd;id tpsk;G. 
       Fd;kk; fUg;ghraf;fl;b Nrhig %j;jpufpupr;ruk; ePu;RUf;F 
R+jpfhthjk; thjNrhzpjk; ngUtapW <is fgNjhlk; ,it xopAk;.Ngupsk; 
ngz; gUtq; fle;j khju;fl;Fk; fUg;gk; cz;lhFk;. 
,jdhy; Ruk; tPf;fk; fPy;thjk; ,uj;jgpj;jk; gpuNkfk; fz;Nzha; 
njhz;il tpuzk; Rthrfhrk; KjypadTk; ePq;Fk;. 
 
3.1.3.MlhNjhil: 
NtWngau;fs;:   MlhNjhil > thir 
gad;gLk; cWg;Gfs;: ,iy> G+> gl;il> Ntu;. 
Rit  - ifg;G 
jd;ik  - ntg;gk; 
gpupT  - fhu;g;G 
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nghJFzk;:  
“MlhNjh ilf;fpuj;j gpj;jkWq; fhr 
khde;j thAld; Nkypisg;G Nkfk; 
R+lhFk; jhgRuk; gpj;jfg thj 
RuNuhfQ;  re;epgh jQ;R+iy Fl;lk; 
XlhNth the;jp tpf;fy; %yNuhfk; 
xspNjhlk; cl;fdYk; xopAe; jhNd 
thlhJ kdf;fpsu;r;rp ahFkpjd; ngUik 
tFj;Jiuj;jhu; Kd;Ndhu;fs; tho;e;jplah tUNk.” 
 
FUjpaoy;> ,Uky;> Nkypisg;G> the;jp> tpf;fy;> R+iy> <it NghFk;.
  
3.1.4. JizkUe;J: 
rPufk;:  
NtWngau;: 
 mir> rPup> ew;rPup> Nkj;jpak;> gpj;jehrpdp> NghrdFNlhup. 
gad;gLk; cWg;G: tpij 
Rit: fhu;g;G ,dpg;G jd;ik: jl;gk; gpupT: ,dpg;G 
nra;if: 
mfl;Ltha;tfw;wp 
ntg;gKz;lhf;fp 
grpj;jPj;J}z;b 
Jtu;g;gp 
 
nghJFzk;: 
“gpj;jnkD ke;jpupiag; gpd;dg; gLj;jpatd; 
rj;JUit Ae;Jwe;J rhjpj;J – kj;jndDk; 
uhridA kPntd;W ez;igg; gyg;gLj;jp 
NghrdF lhupnrAk; Nghu;”    - Njud; ntz;gh. 
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gad;fs;: 
rPufj;ij ifahe;jfiu rhw;wpy; Cwg;Nghl;L vLj;j nghb 4 fpuhk;> vil 
ru;f;fiu 2fp vil> Rf;Fg;nghb 2fp vil> ,k;%d;iwAk; fye;J 
jpdkpUNtisAk; cl;nfhs;s fhkhiy jPUk;. 
rPufk; 34fp cg;G Njitahd msT Nru;j;jiuj;J> nea;tpl;Lj; jhspj;J 
Njd; my;yJ ru;f;fiuAld; fye;J  jP Fw;wj;jhy; gpwe;jNeha;fSf;F 
nfhLf;fyhk;. 
 
 
3.2. CHEMICAL ASPECT: 
 
3.2.1.Ammonium chloridum (or) Ammonium chloride. 
  
Vernacular name:  
Sans :     Sal Ammoniae 
Arab:    Armina 
Ben:    Navasagara, Nishadal 
Hindi:    Navasadara 
Guj.Mah&Kon :   Navasagar 
Tamil:    Navacharum 
Burm:     Lovas, Zarasa. 
Source:  
 It is obtained by the combustion of excretions of various animals (or) of 
animal matters (or) by burning coals (or) common salt. It is a secondary product in the 
manufacture of coal gas. It is  generally very impure in dirty white or brownish 
translucent cakes. It is manufactured from a kind of day found at karnal in the Punjab. 
 It is generally obtained in india from unburnt extremities of brick kilns in 
which manure of animals. 
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Characters: 
 Obtained in white granular crystals or transparent masses. It is readily soluble 
in water and is highly deliquescent. It has a saline disagreeable, nauseous and pungent 
taste. It can be purified and made into a powder by dissolving in hot water and 
evaporating to dryness and then bottling. 
Action: 
 It is alternative, expectorant which cholagogue in small doses, in large doses 
purgative. It has a marked stimulating action on the mucuous membranes. Increasing 
their secretion also on the absorbent system and on gland structures. 
Uses: 
 It relieves hepatic congestion and modifies hepatic secretions. 
 Useful in cases of hepatic abscess, chronic hepatic congestion and in dropsy 
connected with the liver and ovarian diseases. 
 In cirrhosis and in jaundice from catarrh of the bile ducts. 
 For hepatitis, Sal – ammoniac 8 – 15 grains, mixed with 105 grains of 
absinthium (warm wood), rubbed well in a mortar with a little water and given 
in a single dose will give relief. 
 It is valuable combined with liquid extract of glycyrrhiza or group of country 
liquorice and with a few grains of powdered cinnamon, in cases of whooping 
cough. 
 In Amenorrohea, Dysmenorrhoea, gleet, leucorrhoea, chronic dysentery, and 
other similar chronic discharge from lungs stomach and other internal organs. 
 In hysteria, nervousness, jaundice, and other liver complains and gastric 
catarrh, doses of 10- 20 grains three times daily are beneficial. 
 It is often prescribed as a stimulating expectorant in chronic bronchitis and in 
pneumonia in the stage of resolution[chopra] 
 In various form of neuralgia, in chronic liver diseases, organic or functional in 
rheumatic affections of the face. 
 Externally its solution combined with nitre is a nice cooling and stimulating 
application to the head in headache. 
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3.2.2.VEDIYUPPU 
[ Potassium nitrate (KNO3) ] 
Vernacular name: 
  Arab      - Abkar 
Burma     - Yand Zeing 
Canada     - Patluppu 
English     - Potassium Nitrate (KNO3) 
Hindi     - Shora 
Maharashtra    - Shora – Mithra 
Malay      - Sundawa 
Malayalam    - Veti – Uppu 
Sanskrit    - Saind larea 
Tamil      - Pottil – Uppu 
Telugu     - Pattu – Uppu 
 
Availability of Vediyuppu: 
 It occurs extensively in Bengal, Punjab and Northern India naturally as an 
efforesence on the soil. But the drug available now in the market is unnatural,  
For medicinal use:  
It act on the vascular system and thus reduces the frequency of the pulse. 
Given in the solid form or in concentrated solution it acts as irritant. 
It is useful also in the early stages of dropsy, in cases of smallpox, measles, 
influenza, catarrh, gonorrhea, acute rheumatism, bleeding from the lungs, stomach, 
uterus or other internal organs attended by fever. 
A compound preparation known as Laghu Sankha Dravakam, which smells 
strongly of nitrous fumes and which is made of country nitre 6 palams, yavakshara, 
Ammonium chloride, Borax and vit salt 2 palams each and Gandhaka vediuppu(a 
nitre variety), soda carbonas, ferrous sulphate, copper sulphate and black salt 
(suvarchala – uppu) 1 palam each, all powdered and distilled, is recommended for the 
relief of all liver complaints, by Vaidyas. 
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3.2.3. Justicia adatoda 
Vernacular name: 
Sanskrit    - Sinhaparn, Vasaka 
Hindi     - Adosa, Arusha 
Benghal    - Adulsa 
Persia     - Basnsa 
Tamil     - Adhatodai 
Malayalam    - Ataloetakam 
Gujarathi    - Aduraspee  
 Punjab     - Bhekkar 
 
Habitat:  The plant grows in most parts of India especially in the lower Himalayan 
ranges. 
Parts Used:  Leaves, roots, flowers and bark. 
Constituents:  Fat, Resin, Vasicine, Adatodic acid, Gum, Colouringmatter, Salts. 
Properties:  
The base visicine or vasicine, is monobasic and occurs as white needle – 
shaped crystals and has a melting point of 190 – 191: or 182 C. it is easily soluble in 
alcohol, is slightly soluble in cold water but more so in hot water with an alkaline 
reaction. 
Visicine hydrochloride occurs in light, cream – coloured crystals, has a melting 
point of 180c and is very soluble salt. The molecular weight of viscine was 
determined and found to be 188 which agree with the empirical formula C11 H12 
N2O found by analysis. 
Action:     
Expectorant, 
Diuretic 
Antispasmodic 
Alterative. 
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3.3. SIDDHA ASPECTS OF THE DISEASE: 
 
3.3.1. kQ;rs;Neha; (fhkhiy): 
 
NtWngau;fs;: 
fhkhiy>  
gpj;J Neha;>    
fhkpyh 
fhkyh> 
 
,ay;G: 
  rpWePu;> fz;> eh> cly; ahTk; kQ;rs; epwj;ijg; ngWk; Nehahk;. 
 
Neha; tUk;top: 
gpj;jj;ij ngUf;ff;$ba nray;> msTf;F mjpf czitAk; 
nfhs;spd;> Nflile;j Fw;wj;jpd; mstha; FUjpnfl;L> gpj;jePiu FUjpapYk;. 
cly; cWg;Gfshfpa jir> Njhy;> fz;> ehf;F ,tw;wpy; jq;fnra;J Nehia 
cz;lhf;Fk;. 
Kw;FwpFzq;fs;: 
 
“gUfNt cs;sq;fh Ys;sq; iffs; 
gfu;Kfq;fz; Zlk;Gkpf ntSg;G fhZq; 
fUfNt fhy;iff Nsha;r;r yhFq; 
fdkhf eLf;fpNa ,isg;Gz; lhf;FQ; 
RUfNt kye;jhDk; twz;L fl;Le; 
J}aKf kQ;rspl epwk jhFk; 
ntUfNt tPf;fkha;f; fisg;Gz;lhFk; 
kpff;fhJ ke;je;jiy fdg;Gz;lhFk;." 
           
       -A+fpKdp 
 tha; ePu; Cwy;>   
 tha;Fkl;ly;>  
 eifj;jy;>   
 cztpy; ntWg;G> 
 cz;zpYk; nrupahik>   
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 cly; twl;rp>  
 Njhy; RUq;fp jtis Njhiy xj;jy; vd;Dk; FwpFzq;fis 
fhl;b>  
 fz;> eff;fz;> Kfk;> clypd; Njhy; KjypatfSk;> rpWePUk; 
kQ;rspf;Fk;.  
 md;wpAk; ,jpy; cs;sq;fhy;> if> Kfk;> fz;> clk;G ,it 
ntSj;jy;> 
 ifAk; fhYk; Nrhu;jy;> 
 cly; eLf;fy;>  
 mbf;fb ,isg;G Njhd;wy;>  
 vU fl;Lgl;L jPa;e;J ntspahjy;>  
 kpfj;J}f;fk;>  
 jiyfdj;jy;> Kjypa FwpFzq;fisf; fhl;b cly; KOJk; 
kQ;rspf;Fk; 
 
 
 
Neha; vz;: 13 
 
1. CJ fhkhiy 
2. tws; fhkhiy 
3. tsp fhkhiy 
4. moy; fhkhiy 
5. Ia fhkhiy 
6. tspIa fhkhiy 
7. moy;Ia fhkhiy 
8. Kf;Fw;w fhkhiy 
9. kQ;rs; fhkhiy 
10. moF fhkhiy 
11. nrq;fky fhkhiy 
12. Fk;g fhkhiy 
13. Fd;k fhkhiy 
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Fw;wNtWghLfs;: 
          jP Fw;wj;ijg; ngUf;ff;$ba czTg;nghUs;fshYk;> nta;apypy; 
jpupjy;> ,uhf;fz;tpopj;jy;> KjypaitfshYk; moy; Fw;wk; kpFe;J> mf;Fw;wk; 
jdf;F Jizahf Iaj;ijf; $l;bf;nfhz;L> tpahddpd; njhopiy nfLj;J 
,uj;jj;jpd; td;ikia Nflilar; nra;tjhy; ,e;Neha; gpwf;Fk;. gpj;JePUk; 
ngUj;J ,aw;ifahf fopahJ FUjpNahL $b> nfLjpfis cz;lhf;Fk;.  
ehbeil:  
1. gz;ghd gpj;jj;jpy; Nrj;J kehb 
…………………………………… 
fz;fhJ eadkyk; ePU kQ;rs;. 
   (rjf ehb) 
2. rhWklh gpj;jke;j thjj;jp Nywpy; 
jsQ;nra;Ak; ghz;L fhkhiy jhDk; 
   (ehb E}y;) 
gpj;jIaf; fyg;ghYk;> gpj;jthjf; fyg;ghYk; kQ;rs;Neha; cw;gj;jpahFk; 
vd;gjhk;. 
kUj;Jtk;: 
fopr;rYf;F: 
1. jpuhl;rhjp FbePu; 
2. fPohney;yp rhw;wpy;> NgjpAg;G Nru;j;J toq;f Ntz;Lk; 
3. rQ;rPtp khj;jpiuia ,iyf;fs;sp rhw;wpy; toq;f Ntz;Lk; 
cs; kUe;J: 
1. fw;fk:;  
rPe;jpy; 
fPohney;yp 
fLf;fha; ,tw;wpid miuj;j fw;fk; 5fp> ghYld; 
toq;fTk; 
fuprhiy 
neUQ;rpy; 
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2. ,sePu; xd;iw fz;jpwe;J mjpy; 4 Njw;whd; tpijia jl;bg; Nghl;L 
,utpy; itj;jpUe;J fhiyapy; Nkw;gb ,sePu; tpl;L Njw;whd; tpijia 
miuj;J ,sePupy; fyf;fp mUe;jTk;. ,t;thW 3 – 5 ehl;fs; fhiy 
kl;Lk; juyhk;. 
 
 
3. FbePu; : 
 fPo;f;fha; ney;ypapd; rhW Xu; Mohf;fpy; vl;L 
Kjy; 10 tuhfndil NgjpAg;Gf; $l;b rpWjPapy; vupj;J cg;G fiue;j clNd 
tbj;Jf; fhiyapy; nfhLf;ff; fopar; nra;Ak;. 
 
4. khj;jpiu: rhe;j re;jpNuha khj;jpiu 
 
5. gw;gq;fs;: 
 
ez;Lf;fs; gw;gk;  
Ff;fpy; gw;gk; 
rpyhrj;J gw;gk;  
gyfiw gw;gk; 
 
6. nre;J}uq;fs;: 
fhsNkf euhaz nre;J}uk; 
Nyhfkz;^u nre;J}uk; 
ntbmd;dNgjp nre;J}uk; 
manre;J}uk; 
 
7. Rz;zk;: 
ethr;rhu Rz;zk; 
ntbAg;G Rz;zk; 
 
Neha; jLg;G: 
1. Nkhu;> khJis> fUk;GrhW cz;zyhk;. 
2. cg;G> Gsp>  nea; vz;nza;>  Kjypa nfhOg;G nghUs; ePf;fTk;. 
3. Mkzf;F nfhOe;ij rhW gpope;J nts;shl;Lg; ghypy; fye;J 200 
kpyp toq;fTk; 
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3.4. MODERN ASPECTS OF THE DISEASE 
Jaundice: 
Definition: Jaundice (icterus) is the yellow appearance of the skin, sclerae and 
mucous membranes resulting from an increased bilirubin concentration in the body 
fluids. 
  It is detected clinically when the plasma bilirubin exceeds 50 µmol/l (3mg/dl) 
Hepatic Jaundice: 
Hepatic causes include acute hepatitis, hepatotoxicity and alcoholic liver 
disease, whereby cell necrosis reduces the liver's ability to metabolise and excrete 
bilirubin leading to a build up in the blood.  
Less common causes include primary biliary cirrhosis, Gilbert's syndrome (a 
genetic disorder of bilirubin metabolism which can result in mild jaundice, which is 
found in about 5% of the population) and metastatic carcinoma. 
  Jaundice seen in the newborn, known as neonatal jaundice, is common, 
occurring in almost every newborn as hepatic machinery for the conjugation and 
excretion of  bilirubin does not fully mature until approximately two weeks of age. 
 
Normal Bilirubin Metabolism: 
      It can be described under 4 main headings. 
 
1.Source of Bilirubin: About 80-85% of the bilirubin is derived from the catobolism 
of haemoglobin preasent in senescent red blood cells.The remaining 15-20% of the 
bilirubin comes partly from non haemoglobin heam containing pigments such as 
myoglobin,catalases and cytocromes,and partly from inaffective erythropoiesis. 
2. Transport of bilirubin: Bilirubin on release from macroptages circulates as 
unconjucated bilirubin in plasma tightly bound to albumin. 
3. Hepatic phase:   On coming in content with the hepatocyte surface unconjugated 
bilirubin is preferably metabolised in 3 steps. 
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I).Hepatic uptake: 
Albumin bound unconjugated bilirubin upon enjoy into the hepatocytes, is 
disassosiated into bilirubin and albumin gets bound to cytoplasmic protein 
glutathione-8- transferose. 
II).Conjucation and unconjucation: 
Bilirubin in the blood is normally almost all unconjucated and because it is not water 
soluble,it is bound albumin and does not the urine.unconjucated bilirubin is 
conjucated by glucuronyl transferase into water soluble conjucates which are exported 
into the bile. 
III).Secretion into bile: 
Conjucated bilirubin is rapidly transported directly into bile canaliculi by 
energy dependent process and then excreted into the bile. 
4. Intestinal phase: 
Appearance of conjucated bilirubin in the intestinal lumen is followed by 
either direct excretors in the stool as stercobilinogen or may be metobolised to 
urobilinogen. 
Pathophysiology: 
In most cases, hyperbilirubinomia itself has little pathophysiology effect.there 
are two important differences between the forms of bilirubin.unconjucated bilirubin is 
virtually insoluble in water at physiologic pH and is tightly compleed to serum 
albumin.this form cannot be excreted in the urine even when blood are 
high.normally,a very small amount of unconjucated bilirubin is present of unbound 
bilirubin may diffuse into tissue, particularly the brain in infants, and produce toxic 
injury. 
             The unbound plasma fraction may increase in severe hemolytic disease or 
when protein binding drugs displace bilirubin  from albumin.hence,hemolytic 
diseaseof the newborn may be lead to accumulation of unconjucated bilirubin in the 
brain,which can cause severe neurologic damage,referred to as kernicterous in 
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contrast,conjucated bilirubin is water soluble,nontoxic, and only loosely bound to 
albumin.because of its solubility and weak association  with albumin,excess 
conjucated bilirubin in plasma can be excreted in urine. 
            Jaundice occurs when the equilibrium between bilirubin productin and 
clearance is disturbed by one (or) more of the foolowing mechanism: 
 1. Excessive production of Bilirubin. 
   2. Reduced Hepatocyte uptake 
   3. Impaired conjucation. 
   4. Decreased Hepatocellular excretion. 
   5. Impaired bile flow (Both intra hepatic and Extra hepatic) 
Hepatic events 
The unconjugated bilirubin then travels to the liver through the bloodstream. Because 
this bilirubin is not soluble, however, it is transported through the blood bound to 
serum albumin. Once it arrives at the liver, it is conjugated with glucuronic acid (to 
form bilirubin diglucuronide, or just "conjugated bilirubin") to become more water 
soluble. The reaction is catalyzed by the enzyme UDP-glucuronyl transferase. 
This conjugated bilirubin is excreted from the liver into the biliary and cystic ducts as 
part of bile. Intestinal bacteria convert the bilirubin into urobilinogen. From here the 
urobilinogen can take two pathways. It can either be further converted into 
stercobilinogen, which is then oxidized to stercobilin and passed out in the feces, or it 
can be reabsorbed by the intestinal cells, transported in the blood to the kidneys, and 
passed out in the urine as the oxidised product urobilin. Stercobilin and urobilin are 
the products responsible for the coloration of feces and urine, respectively. 
Signs and symptoms mentioned in various sources for Hepatocellular jaundice: 
 Liver diseases 
 Jaundice 
 Increased plasma bilirubin levels  
 Anorexia  
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 Nausea 
 Vomiting  
 Fatigue 
 Insomnia  
 Yellow colored sclera  
 Yellow colored urine  
 Pain in abdomen  
 Fever  
 Diarrhoea  
 Hematemesis 
Hepatocellular diseases  
Viral hepatitis  
 Hepatitis A, B, C, D, and E 
 Epstein-Barr virus (EBV)  
 Cytomegalovirus (CMV) 
 Herpes simplex 
Drug toxicity  
 Classified as either predictable or unpredictable  
 Predictable reactions are dose-dependent and affect all patients who ingest 
toxic dose; classic example is acetaminophen hepatotoxicity.  
 Unpredictable or idiosyncratic drug reactions are not dose-dependent and 
occur in few patients. 
 Many drugs can cause idiosyncratic hepatic injury. 
Environmental toxins include:  
 Industrial chemicals such as vinyl chloride  
 Herbal preparations containing pyrrolizidine alkaloids (e.g., Jamaica bush tea) 
and kava kava  
 Mushrooms Amanita phalloides or Amanita verna that contain highly 
hepatotoxic amatoxins 
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Alcoholic hepatitis 
Can be differentiated from viral and toxin-related hepatitis by pattern of 
aminotransferase in serum. 
Viral Hepatitis: 
 Viral hepatitis is almost always caused by one or other of the specific hepatitis 
viruses; hepatitis due to other viruses accounts for only about 1-2% of cases. All these 
viruses give rise to illnesses which are similar in their clinical and pathological 
features and which are frequently anicteric or asymptomatic. 
Alcoholic (Ethanolic) liver disease: 
In many societies alcohol is the most common cause of chronic liver disease. 
Alcohol is metabolised almost exclusively in the liver. It is first converted to 
acetaldehyde, mainly by mitochondrial enzyme alcohol dehydrogenase but also by the 
mixed-function oxidase enzymes of the smooth endoplasmic reticulum. Alcohol is a 
powerful inducer of the mixed-function oxidases. 
 The hepatic lesions of alcoholic liver disease are attributable directly to 
alcohol. The risk of developing alcoholic liver disease is related to alcohol intake 
above 30 g(3units) in men and 20 g(2units)in women. More than 5 years of drinking, 
and usually more than 10 years, are required to produce alcoholic chirrhosis. 
 Fatty change is attributed to an impaired excretion and enhanced synthesis of 
triacylglycerol by hepatocytes. The development of alcoholic hepatitis, fibrosis and 
cirrhosis is much more obsure. Biochemical mechanisms involving the production of 
toxic metabolites, called adducts, during the conversion of  acetaldehyde to acetate 
and an immune reaction to liver cells altered by alcohol may be involved in these 
forms of liver damage. Alcohol causes several different lesions in the liver which can 
occur together in any combination. 
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FATTY LIVER 
Accumulation of fat in a liver beyond the level which is normally encountered 
may be a result of a normal physiological response to increased peripheral lipolysis, 
obesity or the action of hepatotoxins. 
 
Fatty liver disease 
Fatty liver disease can range from fatty liver alone (steatosis) to fatty liver 
associated with inflammation (steatohepatitis). This condition can occur with the use 
of alcohol (alcohol-related fatty liver) or in the absence of alcohol (non-alcoholic fatty 
liver disease [NAFLD].  
Fatty liver can be associated with the use of alcohol. This may occur with as 
little as 10 oz of alcohol ingested per week. Identical lesions also can be caused by 
other diseases or toxins. Fatty change in the liver results from excessive accumulation 
of lipids within hepatocytes. Simple fatty liver is believed to be benign, but NASH 
can progress to cirrhosis and can be associated with hepatocellular carcinoma. The 
main risk factors for simple fatty liver (NAFLD) and NASH are obesity, diabetes, 
high triglyceride levels, or a high fat diet.  
Non-alcoholic fatty liver disease: 
  NAFLD is one cause of a fatty liver, occurring when fat is deposited 
(steatosis) in the liver not due to excessive alcohol use. It is related to insulin 
resistance and the metabolic syndrome and may respond to treatments originally 
developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as 
weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) 
is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis 
of the liver of unknown cause.  
Exams and Tests        Physical examination: 
 Nutritional assessment  
 Yellowing of the sclerae is usually the first detectable sign of jaundice.  
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 Darkening of urine  
 Skin examination for icterus  
 Stigmata of chronic liver disease  
 Abdominal examination 
 Enlarged and tender liver 
 Fluid in the abdomen (ascites) that can become infected 
Blood tests 
These may initially include  
 Complete blood count – TC ,DC, ESR, Cholesterol  
 Liver function test 
 In women, a pregnancy test may be obtained.  
Urine alysis: Urine analysis for bile salts and bile pigments 
Laboratory tests: 
 Abdominal ultrasound 
 Autoimmune blood markers 
 Hepatitis virus serologies 
 Liver function tests 
 Liver biopsy to check for liver damage 
 Paracentesis if fluid is in abdomen 
Tests for Liver Function 
Bilirubin: 
Bilirubin is one of the most important factors indicative of hepatitis. It is a red-
yellow pigment that is normally metabolized in the liver and then excreted in the 
urine. In patients with hepatitis, the liver cannot process bilirubin, and blood levels of 
this substance rise. High levels of bilirubin cause the yellowish skin tone known as 
jaundice. 
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Liver Enzymes (Aminotransferases): 
Enzymes known as aminotransferases, including aspartate (AST) and alanine 
(ALT), are released when the liver is damaged. Measurements of these enzymes, 
particularly ALT, are the least expensive and most noninvasive tests for determining 
severity of the underlying liver disease and monitoring treatment effectiveness. 
Enzyme levels vary, however, and are not always an accurate indicator of disease 
activity.  
Alkaline Phosphatase (ALP): High ALP levels can indicate bile duct blockage.  
GGT (gamma glutamyl transpeptidase) is often elevated in those who use alcohol or 
other liver-toxic substances to excess. 
Serum Albumin: 
Serum albumin measures protein in the blood (low levels indicate poor liver 
function). Total protein. Serum total protein measures protein in the blood (low 
levels indicate poor liver function).  
Prothrombin Time (PT): 
The PT test measures in seconds the time it takes for blood clots to form (the 
longer it takes the greater the risk for bleeding  
3.5. EARLIER STUDIES ON HEPATOPROTECTIVE 
 Hydro alcoholic extract of tubers of Momordica tuberosa was subjected to 
preliminary phytochemical screening and evaluated for in vitro and in vivo 
antioxidant and hepatoprotective activity against CCl4 induced liver damage in rats. 
Pretreatment with 70% ethanolic extract of M. tuberosa reversed CCl4 induced 
elevation of levels of serum biomarkers to near normal levels, suggesting that the 
tubers of M. tuberosa possess hepatoprotective property and this property may be 
attributed to the antioxidant property of the plant. (Pramod Kumar el al, 2008). 
Hepatoprotective and antioxidant effects of tender coconut water (TCW) were 
investigated in carbon tetrachloride (CCl4)-intoxicated female rats. Liver damage was 
evidenced by the increased levels of serum glutamate oxaloacetate transaminase 
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(SGOT), serum glutamate pyruvate transaminase (SGPT) and decreased levels of 
serum proteins and by histopathological studies in CCl4 intoxicated rats. Increased 
lipid peroxidation was evidenced by elevated levels of thiobarbituric acid reactive 
substance (TBARS) viz, malondialdehyde (MDA), hydroperoxides (HP) and 
conjugated dienes (CD), and also by significant decrease in antioxidant enzymes 
activities, such as superoxide dismutase (SOD), catalase (CAT) and also reduced 
glutathione (GSH) content in liver. On the other hand, CCl4 intoxicated rats treated 
with TCW retained almost normal levels of these constituents. Decreased activities of 
antioxidant enzymes in CCl4 intoxicated rats and their reversal of antioxidant enzyme 
activities in TCW treated rats, shows the effectiveness of TCW in combating CCl4 
induced oxidative stress. Hepatoprotective effect of TCW is also evidenced from the 
histopathological studies of liver, which did not show any fatty infiltration or necrosis, 
as observed in CCl4 intoxicated rats.  (Anthony Loperito Loki and Rajamohan, 2003) 
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4. MATERIALS AND METHODS 
4.1. Preparation of Chara parpam: 
1. Navacharam.(Ammonium chloride) 
2. Vediyuppu (Potassium nitrate) 
3. Aadathodi  ( Justicia adatoda )  
4.1.1. Navacharam: Raw Navacharam was bought from the TAMCOL sales counter, 
Arumbakkam, Chennai -106. The raw material was identified and authenticated by 
PG Gunapadam dept.Govt.Siddha Medical college, Chennai. 500gm Navacharam was 
taken and purification process was done. After purification weight of the drug was 
450gm. 
 4.1.2. Vediyuppu:  Raw Vediyuppu was bought from the TAMCOL sales counter, 
Arumbakkam, Chennai -106. The raw material was identified and Authenticated by 
PG Gunapadam dept.Govt.Siddha Medical college, Chennai. 500gm Vediyuppu was 
taken and purification process was done. After purification weight of the drug was 
450gm. 
Purification of Navacharam: 100gm of Navacharam is dissolved in cow’s urine then 
filtered and boiled and dried in sunlight. 
Purification of Vediyuppu:With 100gm of vediyuppu add 500 ml of water and heat 
it, when boiled add one egg white to it,dust particles will accumulated in the upper 
surface  should be removed and filtered. Next day it is dried in sunlight. This above 
said procedure is repeated for 7 times. 
4.1.3. Aadathodi Juice: The juice was collected from the leaves of the plants around 
6a.m at Vadalur, Cuddalore(dt). Tamilnadu. 
Method of Preparation:   Fine powders of Navacharam and Vediyuppu. These drugs 
are mined together and grounded with Aadathodai juice for 12 hours and made in 
small cakes (villai) and dried in sunlight. These cakes are then kept in a suitable pan 
of mud vessel and sealed with 7 layers of clay cloth (seelai Mann). Then the sealed 
vessel (kavasam) is dried and burned for 12 hours. Allow it to cool at room 
temperatures then the kavasam is opened. The material found in white in colour which 
is called as Chara Parpam. 
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PREPARATION OF CHARA PARPAM. 
                
  
                
       
                                                     
                                                        
              
 
           Fig.8. Purified Charam 
cccccCccCharaCNavacharam 
         Figure.11.    Chara Parpam 
           Figure.12. Charaparpam 
 
Figure.9. Purified Vediyuppu 
Figure.10. Aadathoda Juice  
 
91 
 
4.2. STANDARDIZATION OF THE DRUG 
4.2.1. Physico-chemical analysis 
4.2.1.1. Ash and acid insoluble ash: 
 To the ash add 1:5 Hcl: Distilled water 15 ml boil, cooled and then filtered 
using whatman filter paper (No.41) repeat 3 to 4 times till the yellow colour disappear 
or colourless, then remove the filter paper and add to the filter to the original dish and 
keep it in the muffle furnace at 600
o
 C and take constant weight and calculate the acid 
insoluble ash value. 
 Weight of acid insoluble residue x 100 
Acid insoluble ash (%)   
                   Weight of  the sample 
 
Acid insoluble residue = Acid insoluble ash value – Empty weight of the dish 
 Loss on drying: 
 3gm of the drug is heated in a hot oven at 105
0
 c to constant weight. The % of 
weight was calculated. 
Loss on drying value at 105
0
 c - 10.96 %w/w 
Potential of Hydrogen (ph): 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate 
alkaline or base solutions. 
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4.2.2 SCANNING ELECTRON MICROSCOPE: 
A scanning electron microscope (SEM) is a type of electron microscope that 
produces images of a sample by scanning it with a focused beam of electrons. The 
electrons interact with electrons in the sample, producing various signals that can be 
detected and that contain information about the sample's surface topography and 
composition. The electron beam is generally scanned in a raster scan pattern, and the 
beam's position is combined with the detected signal to produce an image. SEM can 
achieve resolution better than 1 nano meter. Specimens can be observed in high 
vacuum, low vacuum and in environmental SEM specimens can be observed in wet 
condition. 
Figure.13 
 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12 x to greater than 1, 00,000 X 
The SEM has a large depth of field, which allows a large amount of the 
sample to be in focus at one time. The SEM also produces images of high resolution, 
which means that closely spaced features can be examined at a high magnification. 
Preparation of the samples is relatively easy since most SEM one require the sample 
to be conductive. 
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The combination of higher magnification, larger depth of focus, greater 
resolution, and easy of sample observation marks the SEM one of the most heavily 
used instruments in research areas today. 
 
MECHANISMS: 
Figure.14. Mechanism of SEM 
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4.2.3. FOURIER TRANSFORM INFRARED SPECTROSCOPY 
 (FTIR): 
Insrumental details: 
Figure.15 
          
 
Model   :  Spectrum one: FT-IR Spectrometer  
Scan Range   :  MIR 450-4000 cm-1  
Resolution   :  1.0 cm-1  
Sample required :  50 mg, solid or liquid. 
 
 Fourier Transform Infrared Spectroscopy (FTIR) is an analytical technique 
used to identify mainly organic materials. FTIR analysis results in absorption spectra 
which provide information about the chemical bonds and molecular structure of a 
material. The FTIR spectrum is equivalent to the "fingerprint" of the material and can 
be compared with cataloged FTIR spectra to identify the material. 
Infrared spectrum is useful in identifying the functional groups like -OH, -CN, 
-CO, -CH, -NH2, etc. Also quantitative estimation is possible in certain cases for 
chemicals, pharmaceuticals, petroleum products, etc. Resins from industries, water 
and rubber samples can be analyzed.  
The drug sample was analyzed by the FTIR to identify the chemical bonds and 
molecular structure of a material. 
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Mechanisam of FTIR:   
                                             Figure.16. 
  
                        
 
FTIR Study on Chara Parpam: 
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4.2.4. Bio -chemical analysis:  
Preparation of extract of test drug: 
Add 5 gm of Chara parpam to 50ml of distilled water. The solution is boiled 
for 20 minutes, then it is cooled and then filtered in a 100ml volumetric flask. Use the 
Extract for the following tests. 
 
S.No 
 
 
Experiment 
 
Observation 
 
Inference 
1. Test for Reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Absence of Green 
Precipitate 
Absence of 
Reducing Sugar 
2. Test for Starch : 
To 5 ml of extract add 2ml of 
acetic acid and then add few drops 
of N/50 Iodine Solution. 
Absence of Blue 
Colour 
Absence of 
Starch 
3. Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate 
Solution. 
Absence of Violet  
Colour 
Absence of 
Proteins 
4. Test for amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow to dry. 
Absence of Violet 
Colour 
Absence of 
Amino Acid 
5. Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Absence of Yellow 
Precipitate 
Absence of 
Albumin 
6. Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution 
and 2ml of concentrated Nitric 
Acid. 
Absence of Yellow 
Precipitate 
Absence of 
Phosphate 
7. Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
Presence of White 
Precipitate 
Presence of 
Sulphate 
8. Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Presence of Cloudy 
White Precipitate 
Presence of 
Chloride 
97 
 
9. Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thiocynate solution 
and add 2ml of concentrated 
Nitric Acid. 
Presence of Red 
Colour 
Presence of Iron 
10. Test for Calcium : 
To 2 ml of extract, add 2 ml of 
4% ammonium Oxalate Solution. 
Presence of White 
Precipitate 
Presence of 
Calcium 
11. Test for Sodium : 
Make a paste with 2 pinches of 
the sample with Hcl and Introduce 
it into the blue flame.  
Absence Yellow 
Flame 
Absence of 
Sodium 
12. Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Presence of Yellow 
Precipitate 
Presence of 
Potassium 
 
4.3. TOXICOLOGICAL STUDY ON CHARA PARPAM 
Animals:  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were 
obtained from the animal house of Vels University. The animals were used with the 
approval of the Institute animal ethics committee and obtained from Vels University, 
Chennai. They were fed with a balanced standard pellet diet and maintained under 
standard laboratory conditions, providing 24-28
0
C temperature, standard light cycle 
(12 h light, 12 h dark) and water ad libitum. Animals were kept in cages with raised 
floors of wide mesh to prevent coprophagy. Animal welfare guidelines were observed 
during the maintenance period and experimentation. The rats were randomly assigned 
to control and different treatment groups, six animals per group. The animals were 
acclimatized for one week under laboratory conditions.  
 
Acute Toxicity Study: 
 Acute oral toxicity test for the Chara Parpam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The 
test substance is administered in a single dose by gavage using a stomach tube or a 
suitable intubation cannula. The fasted body weight of each animal is determined and 
the dose is calculated according to the body weight. After the substance has been 
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administered, food was withheld for a further 2 hours in mice. The animals were 
observed continuously for the first 4 h and then each hour for the next 24 h and at 6 
hourly intervals for the following 48 h after administering of the test drug, to observe 
any death or changes in general behaviour and other physiological activities. Single 
animals are dosed in sequence usually at 48 h intervals. However, the time interval 
between dosing is determined by the onset, duration, and severity of toxic signs. 
Treatment of an animal at the next dose was delayed until one is confident of survival 
of the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
changes were monitored daily. The time of onset, intensity, and duration of these 
signs, if any, was recorded.  
Sub Acute Toxicity: 
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided 
into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were administered 
daily with the Chara Parpam (p.o.) for 28 days at a dose of 2.5, 5.0 and 10.0mg/kg 
respectively. The animals were then observed daily for gross behavioural changes and 
any other signs of subacute toxicity. The weight of each rat was recorded on day 0 
and weekly throughout the course of the study, food and water consumption per rat 
was calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4
o
C for 10 min to separate 
the serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological 
and blood chemical analyses were taken from retro orbital vein. Heparinized blood 
samples were taken for determining complete blood count (white blood cell count, 
differential white blood cell count, platelet count, red blood cell count, hematocrit, 
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and hemoglobin) by semiautomated hematology analyzer. The serum from non-
heparinized blood was carefully collected for blood chemistry and enzyme analysis 
glucose, creatinine, total protein, albumin, total and direct bilirubins, serum 
glutamate-oxaloacetate transaminase (SGOT), serum glutamate pyruvate 
transaminase (SGPT), and alkaline phosphatase (ALP)) were automatically 
determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes 
and colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, 
Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were 
excised from all rats to visually detect gross lesions, and weighed to determine 
relative organs’ weights and preserved in 10% neutral formalin for histopathological 
assessment. The tissues were embedded in paraffin, and then sectioned, stained with 
haematoxylin and eosin and were examined microscopically. 
Statistical analysis 
Values were represented as mean ± SEM. Data were analysed using one-way analysis 
of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
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4.4. PHARMACOLOGY STUDY. 
Hepatoprotective activity of chara parpam in ccl4 induced rats: 
 
Materials and methods 
Chemicals 
 Estimation Kits for AST, ALT, ALP, T.P, etc were obtained from SPAN 
diagnostics and Standard drug Silymarin and hepatotoxin CCL4 (Sigma-aldrich 
chemical Pvt. Ltd., Bangalore.) were used in the present study. 
 
Stock Solution 
Animals 
 Wistar albino rats (150-200 g) and Mice of either sex weighing 25-30g were 
procured from animal housing facility of School of Pharmaceutical Sciences, Vels 
University, Chennai and used for the study. The animals were housed in well 
ventilated cage and animals had 12 hours day and night schedule with temperature 
between 28 ±20C. The animals were housed in large spacious hygienic cages during 
the course of the experimental period. The animals were allowed free access to 
standard laboratory pellets and drinking water ad libitum.  The study has got the 
approval from the Institutional Animal Ethical Committee (IAEC) of Committee for 
the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). 
(Approval number: XIII/VELS/PCOL/01/2000/CPCSEA/IAEC/08.08.2012). 
Determination of acute oral toxicity 
Acute toxicity of Chara Parpam was done according to the OECD guidelines 
No.425. The overnight fasted mice were given in various doses (2000, 1000, 500, 
250, 100 and 50mg/kg b.w.), the animal were observed continuously for the first two 
hours and at 24 hours to detect changes in behavioural responses and also for tremors, 
convulsion, salivation, diarrhoea, lethargy, sleep, coma and also were monitored up to 
14 days for the toxic symptoms and mortality.  
Evaluation of Hepatoprotective activity 
 CCL4 induced hepatotoxicity in rats model was used for evaluation of hepato-
protective activity for the Chara Parpam. Animals were divided into five groups, each 
group containing six animals.  
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Group I (normal) received distilled water or 2% CMC for 14 days. Group II (Control) 
received CCl4 1ml/kg, i. p. 1:1 dilution with coconut oil on 5th day. Groups III-IV, 
received Chara Parpam (5mg/kg and 10mg/kg p.o) for 14 days and CCl4 induction on 
5th day. Group V received standard marketed drug silymarin (25mg/kg per day, p.o.) 
for 14 days and CCl4 induction on 5
th
 day.  
 After 14 days of experimental period blood sample had been collected 
individually for all the animals by retro-orbital puncture method and the blood was 
allowed to clot for 30 min; serum was separated by centrifuging and was used for 
various parameter estimations. Later all the animals were sacrificed by cervical 
dislocation, liver samples were collected and the individual weights of the livers were 
estimated. For histopathological study, liver tissue was quickly removed after autopsy 
and fixed in 10% formalin in saline.  
Biochemical parameters studied 
 The activities of serum glutamate pyruvate transaminase, and serum glutamate 
oxaloacetate transaminase were estimated using standard methods. Estimation of 
serum ALP, serum bilirubin and electrolytes were also carried out to assess the acute 
hepatic damage caused by CCl4.  
Statistical analysis 
 The data obtained from the study were subjected to statistical analysis by one 
way ANOVA followed by Dunnet ‘t’ test, and results were expressed in terms of 
Mean±SEM values. Statistical analysis was performed using INSTAT- V3 Software 
programme. 
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4.5. CLINICAL ASSESSMENT: 
 
Liver disease is at a standstill a international health problem. Regrettably 
conventional or synthetic drugs used in the treatment of liver diseases are inadequate 
and sometimes can have serious side effects. (Manokaran et al, 2008) In view of 
severe unwanted side effects of synthetic agents, there is growing focus to follow 
systematic research methodology and to evaluate scientific basis for the herbo mineral 
drug that are claimed to possess hepatoprotective activity.The pre clinical study of 
this drug has been showed the marked hepatoprotective efficacy. The clinical study 
was conducted to establish the efficacy and safety of the Chara Parpam  for Kamalai. 
Objectives: 
 To evaluate the Hepatoprotective effect of Chara Parpam. 
 To discover the efficacy and safety of Chara Parpam in patients with liver 
disorder. 
Design of the study: 
 Open clinical trial Phase II B 
Study centre: 
Arignar Anna Government Hospital of Indian Medicine and Homeopathy, 
Arumbakkam, Chennai – 106 
Study participants: 
Both men and women and members of all races and ethnic groups are eligible 
for this trial. Treatment was administered on an inpatient/outpatient basis. The 
patients were selected from the In-patient and Out-patient department of Arignar 
Anna Government Hospital of Indian Medicine and Homeopathy, Chennai – 106. 
 
 
Number of subjects: 
Number of participants will be 50. 
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Selection: 
 . 50 patients from both sexes of various age groups were selected for clinical 
trial. Among 40 patients were treated as out-patients, 10 patients were treated as  in – 
patients. The selection was based on the including and excluding criteria.  They were 
clinically diagnosed on the basis of siddha principles with modern laboratory findings 
 
Registration process: 
To register a patient, the following documents have been produced. 
 Copy of required laboratory tests 
 Signed patient consent form 
 Other appropriate forms (e.g., Eligibility Screening Worksheet, Registration 
Form). 
Then I verified the eligibility and assigned a patient study number, drug dose and 
registered the patient on the study. 
 
Criteria for inclusion: 
Patients with liver disease are eligible for entry to the trial if the following criteria 
are satisfied. 
 Co operative patients 
 The previous drug regimen if any have been with held for 24 hours before the 
clinical trial. 
Criteria for exclusion: 
 AIDS 
 Malignancy 
 Pregnant and lactating women 
 TB 
 Renal diseases 
 Cardio vascular disorder 
 Age below 10 year 
 Syphilis 
 The patient requires systemic steroid for the control of symptoms 
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Withdrawal criteria: 
Patients were removed from study when any of the criteria listed below 
applies. In the absence of treatment delays due to adverse events, treatment may 
continue for 2 cycles or until one of the following criteria applies: 
 Disease progression, 
 Deterioration of vital signs with cardiac, respiratory, hepatic, renal and 
CNS changes. 
 Intercurrent illness that prevents further administration of treatment, 
 Unacceptable adverse event(s), 
 Patient decides to withdraw from the study, or  
 General or specific changes in the patient’s condition render the patient 
unacceptable for further treatment in the judgment of the investigator. 
 
Routine examination and assessment: 
The full details of history and physical examination of the patients were 
recorded as per the proforma .The clinical assessment was done initially at the end of 
7 days, 14 days and 21 days during treatment and at the end of the 21 days follow up 
was done. The laboratory investigation and the physiological parameters werew 
recorded initially at the end of the treatment and at the end of follow up as per the 
proforma. 
 
Dosage: 
 The trial drug Chara Parpam  was given in the dose of 130 mg to 260 mg 
with  Seeraga kudineer depending upon the severity of the case. 
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Administration of the drug: 
 Form of the medicine  : Parpam   
Route of Administration : Enteral 
 Dose    : 130 – 260 mg  
 Anubanam (Vehicle)  : Seeraga kudineer 
 Times of Administration : Two times a day; after food 
 Duration   : 7 weeks 
Diet restriction and Medical advice:  
The patients were instructed to follow fat free, salt free easily digestible foods. 
 They were advised to take tender coconut, sugar cane juice and vegetables like 
radish, juice of plantain stem. 
 The patient was advised to cold damp climate. 
 The patient was advised to take rest. But prolonged immobilization should be 
avoided. 
 The clinical improvement was observed and recorded daily in the proforma of 
case sheet. 
Trail conduct: 
The study was conducted in compliance with the protocol approved by the 
Institutional Review Board, and according to Good Clinical Practice standards. No 
deviation from the protocol was implemented without the prior review and approval 
of the IRB except. 
Classification of results: 
       1.        Good Response 
a. Relief of Symptoms above 70% 
b. Laboratory parameter findings towards normalcy. 
2. Fair Response 
a. 50% to 70% relief in symptoms. 
b. Significant improvement in laboratory parameter. 
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3. Poor Response 
20% to 49% relief in symptoms and minimal improvement in laboratory 
parameters. 
4. No Response 
No relief in symptoms and no significant improvement in laboratory 
parameters. 
 
Follow up: 
Assessment will take for every three days before treatment and after treatment. 
During this period clinical assessment and laboratory investigation was carried out. 
 
Statistical analysis: 
The data will be tabulated and analyzed by students ‘T’ test. 
 
Ethical review: 
 
 The protocol and any amendments were submitted to Govt siddha medical 
college, Chennai – 106 (IEC) and got formal approval to conduct the study. The 
decision of the IEC concerning the conduct of the study was made in writing to the 
investigator. All subjects for this study was provided a consent form describing this 
study and provided sufficient information for subjects to make an informed decision 
about their participation in this study. This consent form was submitted with the 
protocol for review and approval by the IEC. The formal consent of a subject, using 
the IEC-approved consent form, was obtained before that subject was submitted to 
any study procedure. This consent form was signed by the subject or legally 
acceptable surrogate, and the investigator-designated research professional obtaining 
the consent. 
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CLINICAL STUDY ON CHARAPARPAM IN – OUT PATIENTS DEPT IN THE MANAGEMENT OF KAMALAI. 
SI 
NO 
Op. 
No 
Name/ Age/ 
Sex 
Complaints 
Duration of 
Days 
BT 
& 
AT 
INVESTIGATION  
 
Results 
BLOOD    
Blo
od 
CL 
Urine  
TC 
cells/c
umm 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
mg
/dl 
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
1. 1818 Amudhan 
18/Male 
Anorexia, Nausea, 
Vomiting, skin 
itching, Fatigue, 
Insomnia, Yellow 
colored sclera. 
24.7.12 
To 
24.8.12 
BT 9200 52 45 3 17 19 13 101 21 173 NIL NIL  PCS 
Satisfactory 
 AT 9200 50 47 3 14 24 13 96 18 168 NIL NIL NIL 
2. 3436 Babu 
44/Male 
Anorexia, Nausea, 
Vomiting, skin 
itching, Fatigue, 
Insomnia, Yellow 
colored sclera. 
1.8.12 
To 
31.8.12 
BT 9700 57 39 4 15 24 11 94 24 158 NIL NIL  FPC Good 
 
AT 9700 59 36 5 14 20 11.3 96 22 152 NIL NIL NIL 
3. 2857 Kalaivani 
45/Female 
Anorexia, Nausea, 
Vomiting, skin 
itching, Fatigue, 
Insomnia, Yellow 
colored sclera. 
2.8.12 
To 
30.8.12 
BT 9100 58 39 4 26 44 10.5 130 23 165 NIL NIL FPC Good 
 
AT 9200 55 40 5 27 43 10.6 117 20 154 NIL NIL NIL 
4. 6798 SathiyaThilaga 
25/Female 
Anorexia, Nausea, 
Vomiting, skin 
itching, Fatigue, 
Insomnia, Yellow 
colored sclera. 
8.8.12 
To 
5.9.12 
BT 8600 61 34 5 10 15 12 95 24 159 NIL NIL  FPC Good 
 
AT 8700 58 39 3 14 20 12 93 18 165 NIL NIL NIL 
5. 4673 Vasanth 
37/male 
Anorexia, Nausea, 
Vomiting, skin 
itching, Fatigue, 
Insomnia, Yellow 
colored sclera. 
8.8.12 
To 
4.9.12 
BT 9100 60 34 6 15 33 10 85 21 158 NIL NIL NIL  
Moderate  
 
                   
AT 9100 61 37 2 15 30 10.5 86 19 144 NIL NIL NIL 
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6. 4534 Seetharam 
46/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
9.8.12 
To 
7.9.12 
BT 9300 53 42 5 6 13 10 73 21 164 NIL NIL PCS Good 
 AT 9300 52 44 4 6 13 10 72 19 163 NIL NIL NIL 
7. 7089 Mahendran 
27/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
16.8.12 
To 
14.9.12 
 
BT 8700 58 37 5 14 24 13.
5 
88 19 190 NIL NIL NIL Good 
 
AT 8700 58 37 5 14 20 13.
6 
86 20 185 NIL NIL NIL 
8. 6897 Sudha 
56/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
16.8.12 
To 
12.9.12 
BT 9100 56 38 6 13 16 11 101 20 150 NIL NIL FPC Good 
 
AT 9200 55 40 5 13 16 11 96 21 144 NIL NIL NIL 
9. 5768 Maran 
22/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
18.8.12 
To 
16.9.12 
BT 9600 58 38 4 10 15 10 90 23 159 NIL NIL NIL Good 
 AT 9600 58 38 4 10 15 10.
5 
89 20 168 NIL NIL NIL 
10. 8609 David 
40/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
20.8.12 
To 
17.9.12 
BT 9800 55 40 5 15 20 13 95 21 161 NIL NIL FPC Good 
 
 
                   
AT 9800 56 39 5 15 20 13 94 18 157 NIL NIL NIL 
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P 
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½ 
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11. 8978 Ragu 
28/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
22.8.12 
To 
19.9.12 
BT 9300 57 38 5 13 25 12.
5 
95 26 168 NIL NIL PCS Good 
 
AT 9200 57 38 5 13 25 12.
5 
96 28 162 NIL NIL NIL 
12. 9032 Ravi 
40/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
22.8.12 
To 
21.9.12 
BT 8700 55 41 4 20 40 10 128 21 171 NIL NIL NIL Good 
 
AT 8800 53 41 6 20 45 10 103 19 164 NIL NIL NIL 
13. 9098 Madhavan 
52/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
22.8.12 
To 
19.9.12 
BT 10000 59 36 5 18 20 14 105 18 170 NIL NIL FPC Good 
 
AT 10000 58 37 5 18 20 14 106 20 173 NIL NIL NIL 
14. 253 Kumar 
22/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
25.8.12 
To 
21.9.12 
BT 8500 63 30 7 25 20 13 85 23 159 NIL NIL NIL Moderate 
AT 8700 63 30 7 25 20 13 88 19 165 NIL NIL NIL 
15. 162 Lakshmi 
45/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
25.8.12 
To 
21.9.12 
BT 9900 54 41 5 20 30 12 95 16 162 NIL NIL FPC  
 
Good 
 
                   
AT 9900 53 42 5 20 30 13 92 19 166 NIL NIL NIL 
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16. 294 Vaithilingam 
49/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
25.8.12 
To 
21.9.12 
BT 9500 57 38 5 20 43 12 85 19 160 NIL NIL PCS Mild 
                   
AT 9600 58 37 5 20 43 12.4 85 21 159 NIL NIL FPC 
17. 355 Visalatchi 
42/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
26.8.12 
To 
23.9.12 
BT 9100 56 38 6 14 20 12.7 95 20 158 NIL NIL NIL Good 
 
AT 9200 55 39 6 14 20 12.7 90 22 160 NIL NIL NIL 
18. 405 Kumari 
35/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
26.8.12 
To 
24.9.12 
BT 9500 58 37 5 15 25 10.2 86 21 159 NIL NIL FPC Poor 
 
AT 9700 59 38 3 15 25 10.2 85 20 160 NIL NIL NIL 
19. 776 Santhosh 
26/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
26.8.12 
To 
23.9.12 
BT 8100 63 34 3 20 40 12 99 21 155 NIL NIL NIL Good 
 
AT 8200 63 34 3 20 40 12 94 19 166 NIL NIL NIL 
20. 2457 Mohammad 
mustafa 
51/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
2.9.12 
To 
28.9.12 
BT 9400 62 34 4 12 24 13.5 108 28 168 NIL NIL PCS  
Moderate 
 
                   
AT 9400 61 35 4 12 24 13.5 104 26 165 NIL NIL FPC 
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21. 3001 Thangaraj 
29/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
5.9.12 
To 
3.10.12 
BT 9200 56 38 6 14 30 14 99 21 162 NIL NIL PCS Good 
 
AT 9300 56 38 6 14 30 14 98 19 158 NIL NIL FPC 
22. 4347 Dhandapani 
40/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
8.9.12 
To 
5.10.12 
BT 10300 55 40 5 10 24 13 120 24 153 NIL NIL PCS Good 
 
AT 10200 56 39 5 10 24 13.2 116 20 155 NIL NIL NIL 
23. 5675 Ravisankar 
45/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
17.9.12 
To 
15.10.12 
BT 8600 63 34 3 11 24 12.8 85 21 162 NIL NIL  FPC Good 
 
AT 8800 63 34 3 11 25 12.8 88 18 164 NIL NIL NIL 
24. 5674 Vinoth 
55/Male 
  Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
22.9.12 
To 
19.10.12 
BT 10000 57 38 5 22 30 10 115 20 157 NIL NIL PCS Moderate 
AT 10100 58 37 5 22 30 10.3 112 19 160 NIL NIL FPC 
25. 9555 Punitha 
44/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
22.9.12 
To 
21.10.12 
BT 9700 60 34 6 35 60 11.5 77 18 157 NIL NIL NIL  
Good 
 
 
                   
AT 9800 61 33 6 30 55 11.5 75 21 160 NIL NIL NIL 
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26. 2198 Rajapriyan 
33/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
29.9.12 
To 
26.10.12 
BT 8200 62 35 3 12 25 15 88 21 163 NIL NIL FPC Good 
 
AT 8300 62 34 4 12 25 15 87 23 161 NIL NIL NIL 
27. 3651 Geetha devi 
28/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
3.10.12 
To 
31.10.12 
BT 9500 59 38 3 13 15 13 85 19 163 NIL NIL PCS Good 
 
AT 9400 59 38 3 13 15 13.4 84 20 161 NIL NIL NIL 
28. 5707 Saravanan 
24/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
10.10.12 
To 
6.11.12 
BT 8900 65 31 4 14 22 15 98 20 159 NIL NIL NIL Good 
 
AT 9000 65 31 4 14 22 15 93 18 160 NIL NIL NIL 
29. 3897 Deepak 
31/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
4.10.12 
To 
2.11.12 
BT 9600 59 38 3 10 15 14 98 24 167 NIL NIL PCS  
      Poor 
             AT 9600 59 37 4 10 15 14.2 105 21 168 NIL NIL FPC 
30. 6671 Mahalingam 
43/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
12.10.12 
To 
9.11.12 
 
BT 10200 57 38 5 14 22 13 87 12 159 NIL NIL FPC  
 
Good 
                   
AT 10100 57 38 5 14 22 13 88 19 160 NIL NIL NIL 
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31. 3453 Suganthi 
45/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
2.11.12 
To 
4.11.12 
BT 8700 65 32 3 10 15 9 98 22 163 NIL NIL NIL Good 
 
AT 8400 63 32 5 10 15 10 98 20 162 NIL NIL NIL 
32. 3850 Janaki 
42/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
4.11.12 
To 
2.12.12 
BT 9400 60 37 3 8 16 11 100 22 159 NIL NIL PCS Good 
 
AT 9500 60 37 3 8 16 11 98 18 158 NIL NIL FPC 
33. 5400 Murugan 
38/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
9.11.12 
To 
7.12.12 
BT 9600 65 32 3 10 24 14 88 19 167 NIL NIL PCS Moderate 
AT 9800 65 31 4 10 24 14 89 20 165 NIL NIL FPC 
34. 5506 Karthi 
40/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
9.11.12 
To 
7.12.12 
BT 8800 58 37 5 14 30 13.
5 
100 23 147 NIL NIL FPC Good 
 
AT 8700 55 40 5 14 30 13.
5 
97 20 149 NIL NIL NIL 
35. 4319 Vikesh 
32/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
26.12.12 
To 
2.1.13 
BT 9400 67 29 4 17 24 12.
9 
89 21 158 NIL NIL NIL  
Good 
 
                   
AT 9400 67 29 4 17 24 12.
9 
91 18 164 NIL NIL NIL 
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36 1923 Natraj 
18/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes. 
25.12.12 
To 
3.1.13 
BT 9300 53 43 4 18 20 14 100 20 173 NIL NIL  PCS 
Good 
 AT 9300 53 43 4 15 25 14 96 18 168 NIL NIL NIL 
37 2538 Mariyammal 
44/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
26.12.12 
To 
1.1.13 
BT 9800 59 37 4 15 24 11 94 24 158 NIL NIL  FPC Good 
 
AT 9800 59 36 5 15 20 11.3 96 22 152 NIL NIL NIL 
38 2897 Narasimman 
45/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
27.12.12 
To 
4.1.13 
BT 9200 57 39 4 26 44 10.5 130 23 165 NIL NIL FPC Good 
 
AT 9200 55 40 5 27 43 10.6 117 20 154 NIL NIL NIL 
39. 6567 Thamari 
25/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
29.12.12 
To 
5.1.13 
BT 8600 61 34 5 10 15 12 95 24 159 NIL NIL  FPC Good 
 
AT 8700 58 39 3 14 20 12 93 18 165 NIL NIL NIL 
40 4355 Sudhar 
37/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored eyes 
 
30.12.12 
To 
5.1.13 
BT 9100 60 34 6 15 33 10 85 21 158 NIL NIL NIL  
Moderate  
 
                   
AT 9100 61 37 2 15 30 10.5 86 19 144 NIL NIL NIL 
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1. 550/ 
2512 
Pandu 
55/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
30.9.12 
To 
19.10.1
2 
BT 9800 6
0 
3
7 
3 1
5 
40 9 106 18 153 NI
L 
NI
L  
PCS  
- 
 
 
Poor 
A
T 
9700 6
0 
3
8 
2 1
0 
48 9.5 102 20 159 NI
L 
NI
L 
NIL 
2. 575/ 
5202 
Varadhan 
50/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
7.10.12 
To 
28.10.1
2 
BT 9600 5
7 
4
1 
2 1
8 
25 10.
5 
114 23 155 NI
L 
NI
L  
PCS  
- 
Good 
 
A
T 
9700 5
7 
4
1 
2 1
1 
33 11 108 20 150 NI
L 
NI
L 
NIL 
3. 744/ 
1449 
Rajamanikam 
58/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
30.10.1
2To 
13.11.1
2 
BT 1020
0 
6
2 
3
4 
4 9 19 10 106 19 170 NI
L 
NI
L 
FPC  
- 
Satisfactor
y 
 
A
T 
9800 6
0 
3
5 
5 9 20 10.
7 
102 23 173 NI
L 
NI
L 
NIL 
4. 985/ 
485 
Selvakumar 
65/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
22.11.1
2 
To 
9.12.12 
BT 9800 6
0 
3
5 
5 6 13 9.6 108 18 169 NI
L 
NI
L  
FPC  
- 
Good 
 
A
T 
9100 6
0 
3
6 
4 8  19 10 102 21 163 NI
L 
NI
L 
NIL 
5. 948/ 
1398 
Sagundhala 
36/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
24.11.1
2 
To 
12.12.1
2 
BT 9400 6
5 
3
3 
2 6 10 9 110 20 166 NI
L 
NI
L 
NIL  
- 
 
Satisfactor
y                   
A
T 
9100 6
3 
3
4 
3 4 12 9.6 106 23 160 NI
L 
NI
L 
NIL 
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CLINICAL STUDY ON CHARAPARPAM IN – OUT PATIENTS DEPT IN THE MANAGEMENT OF KAMALAI 
 
SI 
N
O 
IP. 
No 
Name/ Age/ 
Sex 
Complaints 
Duration 
of Days 
BT 
& 
A
T 
INVESTIGATION  
 
Results 
BLOOD    
Blo
od 
CL 
Urine X ray 
bms/ 
Endoscop
y 
TC 
cells/
cum
m 
DC (%) ESR(mm) Hb 
Gm 
Sgr 
mg/
dl 
Ur 
m
g/
dl 
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
6. 538/ 
2112 
Palanisami 
67/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
30.9.12 
To 
18.10.1
2 
BT 9800 6
0 
3
7 
3 1
5 
40 9 106 18 153 NI
L 
NI
L  
PCS  
- 
 
 
Poor 
A
T 
9700 6
0 
3
8 
2 1
0 
48 9.5 102 20 159 NI
L 
NI
L 
NIL 
7. 537/ 
3342 
Valarmathi 
60/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
8.10.12 
To 
29.10.1
2 
BT 9600 5
7 
4
1 
2 1
8 
25 10.
5 
114 23 155 NI
L 
NI
L  
PCS  
- 
Good 
 
A
T 
9700 5
7 
4
1 
2 1
1 
33 11 108 20 150 NI
L 
NI
L 
NIL 
8. 740/ 
1339 
Ranjith 
58/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
29.10.1
2 
To 
19.11.1
2 
BT 1020
0 
6
2 
3
4 
4 9 19 10 106 19 170 NI
L 
NI
L 
FPC  
- 
Satisfactor
y 
 
A
T 
9800 6
0 
3
5 
5 9 20 10.
7 
102 23 173 NI
L 
NI
L 
NIL 
9. 901/ 
3390 
Saroja 
45/Female 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
21.11.1
2 
To 
13.12.1
2 
BT 9800 6
0 
3
5 
5 6 13 9.6 108 18 169 NI
L 
NI
L  
FPC  
- 
Good 
 
A
T 
9100 6
0 
3
6 
4 8  19 10 102 21 163 NI
L 
NI
L 
NIL 
10. 949/ 
1988 
Manikandan 
36/Male 
Anorexia, Nausea, 
Vomiting, Fatigue, 
Insomnia, Yellow 
colored sclera 
25.11.1
2 
To 
13.12.1
2 
BT 9400 6
5 
3
3 
2 6 10 9 110 20 166 NI
L 
NI
L 
NIL  
- 
 
Satisfactor
y                   
A
T 
9100 6
3 
3
4 
3 4 12 9.6 106 23 160 NI
L 
NI
L 
NIL 
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LIVER FUNCTION TEST 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total protein 
g/dl 
Albumin 
g/dl 
1.  
1818 
Amudhan 
18/Male 
24.7.12 
To 
24.8.12 
BT  
100 
 
97 
 
133 
 
2.6 
 
4.8 
 
4.1 
AT  
41 
 
31 
     
112   
 
1.4 
 
6.1 
 
4.4 
2. 3436 Babu 
44/Male 
1.8.12 
To 
31.8.12 
BT  
40 
 
45 
 
77 
 
2.5 
 
4.5 
 
2.8 
AT  
19 
 
26 
 
68 
 
1.7 
 
4.6 
 
2.8 
3. 2857 Kalaivani 
45/Female 
2.8.12 
To 
30.8.12 
BT  
57 
 
62 
 
95 
 
3.2 
 
6.3 
 
3.2 
AT  
35 
 
27 
 
93 
 
1.2 
 
7.1 
 
4.1 
4. 6798 SathiyaThilaga 
25/Female 
8.8.12 
To 
5.9.12 
BT  
60 
 
58 
 
74 
 
2.8 
 
6.8 
 
5.1 
AT  
24 
 
38 
 
71 
 
1.3 
 
7.6 
 
5.3 
5. 4673 Vasanth 
37/male 
8.8.12 
To 
4.9.12 
BT  
65 
 
43 
 
85 
 
3.4 
 
5.1 
 
2.7 
AT  
32 
 
25 
 
69 
 
1.2 
 
6.1 
 
3.6 
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S. 
No 
 
OP No 
 
                   
   
Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total 
protein 
g/dl 
Albumin 
g/dl 
6.  
4534 
 
Seetharam 
46/Male 
9.8.12 
To 
7.9.12 
BT  
68 
 
55 
 
79 
 
2.8 
 
4.1 
 
2.5 
AT  
22 
 
20 
     
74    
 
1.4 
 
4.6 
 
2.9 
7. 7089 Mahendran 
27/Male 
16.8.12 
To 
14.9.12 
 
BT  
63 
 
58 
 
86 
 
2.6 
 
6.1 
 
4.1 
AT  
27 
 
24 
 
70 
 
1.2 
 
7.1 
 
4.5 
8. 6897 Sudha 
56/Female 
16.8.12 
To 
12.9.12 
BT  
76 
 
64 
 
98 
 
1.3 
 
6.1 
 
3.5 
AT  
24 
 
25 
 
91 
 
0.8 
 
7.3 
 
3.8 
9. 5768 Maran 
22/Male 
18.8.12 to 
16.9.12 
BT  
58 
 
53 
 
75 
 
3.8 
 
5.1 
 
2.7 
AT  
37 
 
36 
 
72 
 
1.4 
 
6.2 
 
3.7 
10. 8609 David 
40/Male 
20.8.12 
To 
17.9.12 
BT  
56 
 
50 
 
85 
 
2.5 
 
7.2 
 
4.4 
AT  
34 
 
41 
 
81 
 
0.8 
 
7.5 
 
4.9 
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LIVER FUNTION TEST 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total protein 
g/dl 
Albumin 
g/dl 
11.  
8978 
Ragu 
28/Male 
22.8.12 
To 
19.9.12 
BT  
56.5 
 
65 
 
124 
 
2.1 
 
5.2 
 
3.8 
AT  
30 
 
36 
     
109 
 
1.6 
 
5.4 
 
4.9 
12. 9032 Ravi 
40/male 
22.8.12 
To 
21.9.12 
BT  
56 
 
53 
 
82 
 
2.5 
 
5.1 
 
2.8 
AT  
28 
 
21 
 
65 
 
1.2 
 
6.4 
 
3.9 
13. 9098 Madhavan 
52/male 
22.8.12 
To 
19.9.12 
BT  
57 
 
44 
 
97 
 
2.4 
 
6.1 
 
3.1 
AT  
54 
 
39 
 
95 
 
1.0 
 
6.4 
 
3.4 
14. 253 
 
Kumar 
22/male 
 
 
25.8.12 
To 
21.9.12 
 
BT  
88 
 
70 
 
98 
 
2.8 
 
5.4 
 
3.7 
AT  
45 
 
31 
 
91 
 
1.2 
 
6.4 
 
4.0 
15. 162 Lakshmi 
45/female 
25.8.12  
 To 
21.9.12 
BT  
56 
 
48 
 
102 
 
2.8 
 
6.3 
 
3.5 
AT  
43 
 
31 
 
97 
 
1.2 
 
7.1 
 
4.9 
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LIVER FUNTION TEST 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total protein 
g/dl 
Albumin 
g/dl 
16. 294 Vaithilingam 
49/Male 
25.8.12  
To 
21.9.12 
 
BT  
56 
 
46 
 
95 
 
3.2 
 
6.3 
 
4.3 
AT  
24 
 
19 
 
91 
 
1.3 
 
5.7 
 
4.8 
17. 355 Visalatchi 
42/Female 
26.8.12 
To 
23.9.12 
BT  
130 
 
72 
 
102 
 
1.3 
 
6.4 
 
3.4 
AT  
28 
 
26 
     
97 
 
0.8 
 
6.8 
 
4.2 
18. 405 Kumarai 
35/Female 
26.8.12 
To 
24.9.12 
BT  
78 
 
60 
 
122 
 
1.6 
 
6.4 
 
3.6 
AT  
36 
 
40 
 
101 
 
1.0 
 
6.9 
 
3.8 
19. 776 Santhosh 
26/Male 
26.8.12 
To 
23.9.12 
BT  
440 
 
480 
 
170 
 
1.5 
 
7.2 
 
4.1 
AT  
55 
 
41 
 
120 
 
1.1 
 
6.5 
 
4.9 
20. 2457 Mohamed Mustafa 
51/male 
2.9.12 
To 
28.9.12 
BT  
260 
 
220 
 
120 
 
1.9 
 
7.8 
 
3.9 
AT  
55 
 
48 
 
110 
 
0.8 
 
7.3 
 
3.6 
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LIVER FUNTION TEST 
 
 
 
 
 
 
 
 
 
 
S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total protein 
g/dl 
Albumin 
g/dl 
21.  
3001 
Thangaraj 
29/Male 
5.9.12 
To 
3.10.12 
BT  
325 
 
166 
 
106 
 
1.8 
 
8.2 
 
5.3 
AT  
42 
 
34 
     
99   
 
1.3 
 
8.1 
 
5.0 
22. 4347 Dhandapani 
40/Male 
8.9.12 
To 
5.10.12 
BT  
428 
 
216 
 
124 
 
1.6 
 
5.8 
 
3.2 
AT  
34 
 
45 
 
110 
 
1.1 
 
5.4 
 
3.0 
23. 5675 Ravisankar 
45/Male 
17.9.12 
To 
15.10.12 
BT  
228 
 
197 
 
110 
 
1.9 
 
6.4 
 
4.5 
AT  
26 
 
27 
 
98 
 
0.8 
 
6.3 
 
4.5 
24. 5674 Vinoth 
55/Male 
 
22.9.12 
To 
19.10.12 
BT  
280 
 
97 
 
114 
 
1.6 
 
5.8 
 
3.3 
AT  
36 
 
26 
 
100 
 
1.1 
 
6.4 
 
4.2 
25. 9555 Punitha 
44/Female 
 
22.9.12 
To 
21.10.12 
BT  
97 
 
52 
 
138 
 
1.8 
 
5.6 
 
3.6 
AT  
33 
 
22 
 
103 
 
1.1 
 
5.2 
 
3.4 
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LIVER FUNTION TEST 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total protein 
g/dl 
Albumin 
g/dl 
26.  
2198 
Rajapriyan 
33/Male 
29.9.12 
To 
26.10.12 
BT  
285 
 
98 
 
143 
 
4.8 
 
7.3 
 
4.6 
AT  
52 
 
42 
     
110   
 
1.6 
 
7.1 
 
4.1 
27. 3651 Geethadevi 
28/Female 
3.10.12 
To 
31.10.12 
BT  
165 
 
87 
 
118 
 
2.1 
 
6.5 
 
3.3 
AT  
30 
 
33 
 
96 
 
1.1 
 
6.8 
 
3.7 
28. 5707 Saravanan 
24/male 
10.10.12 
To 
6.11.12 
BT  
560 
 
610 
 
180 
 
1.6 
 
6.2 
 
3.4 
AT  
36 
 
44 
 
115 
 
0.9 
 
6.4 
 
3.6 
29. 3897 Deepak 
31/.Male 
4.10.12 
To 
2.11.12 
BT  
428 
 
512 
 
164 
 
1.7 
 
6.6 
 
4.5 
AT  
48 
 
52 
 
110 
 
1.1 
 
6.8 
 
4.1 
30. 6671 Mahalingan 
43/Male 
12.10.12 
To 
9.11.12 
BT  
587 
 
494 
 
130 
 
1.9 
 
6.3 
 
2.7 
AT  
48 
 
39 
 
99 
 
0.8 
 
5.9 
 
3.4 
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S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 
AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total protein 
g/dl 
Albumin 
g/dl 
31  
3453 
Suganthi 
45/Female 
2.11.12 
To 
4.11.12 
BT  
120 
 
72 
 
102 
 
1.3 
 
6.4 
 
3.4 
AT  
28 
 
26 
     
97    
 
0.8 
 
6.8 
 
4.2 
32 3850 Janaki 
42/Female 
4.11.12 
To 
2.12.12 
BT  
85 
 
78 
 
114 
 
1.6 
 
6.8 
 
4.5 
AT  
21 
 
24 
 
98 
 
1.1 
 
7.1 
 
4.8 
33 5400 Murugan 
38/Male 
9.11.12 
To 
7.12.12 
BT  
766 
 
685 
 
108 
 
2.8 
 
7.5 
 
4.7 
AT  
172 
 
154 
 
96 
 
1.4 
 
7.8 
 
5.2 
34 5506 Karthi 
40/Male 
9.11.12 
To 
7.12.12 
BT  
675 
 
560 
 
140 
 
1.6 
 
5.2 
 
4.3 
AT  
165 
 
139 
 
102 
 
1.1 
 
5.8 
 
4.8 
35 4319 
 
Vikesh 
32/Male 
26.12.12 
To 
2.1.13 
BT  
724 
 
674 
 
130 
 
1.8 
 
7.3 
 
5.1 
AT  
120 
 
136 
 
112 
 
1.4 
 
7.1 
 
5.4 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. 
No 
 
OP No 
 
                   
   Name/age/sex 
 
Duration of 
Treatment 
 
 
Duration 
 
LIVER FUNCTION TEST 
 AST(SGOT) 
(IU/L) 
ALT(SGPT) 
(IU/L) 
ALP 
(IU/L) 
Total  
Bilirubin 
(mg/dl) 
Total 
protein 
g/dl 
Albumin 
g/dl 
36 1923 Natraj 
18/Male 
25.12.12 
To 
3.1.13 
BT  
536 
 
496 
 
125 
 
1.8 
 
7.6 
 
3.4 
AT  
112 
 
120 
     
102  
 
1.2 
 
7.4 
 
3.8 
37 2538 
 
Mariyammal 
44/Female 
 
26.12.12 
To 
1.1.13 
 
BT  
182 
 
96 
 
98 
 
1.3 
 
6.7 
 
3.8 
AT  
34 
 
25 
 
93 
 
0.9 
 
6.9 
 
3.9 
38 2897 
 
Narasimman 
45/Male 
 
 
27.12.12 
To 
4.1.13 
 
BT  
658 
 
592 
 
124 
 
1.4 
 
6.4 
 
4.3 
AT  
129 
 
131 
 
106 
 
 
1.1 
 
6.9 
 
4.8 
39 6567 Thamari 
25/Female 
 
29.12.12 
To 
5.1.13 
 
BT  
46 
 
52 
 
125 
 
1.4 
 
6.7 
 
3.9 
AT  
18 
 
22 
 
110 
 
0.8 
 
6.9 
 
4.0 
40 4355 
 
Sudhar 
37/Male 
30.12.12 
To 
5.1.13 
 
BT  
482 
 
283 
 
120 
 
1.7 
 
5.8 
 
2.8 
AT  
98 
 
34 
 
99 
 
0.8 
 
6.7 
 
3.4 
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AGE WISE DISTRIBUTION 
SL. NO AGE IN YEARS NO. OF PATIENTS PERCENTAGE (%) 
1 15-20 3 6 
2 21-30 10 20 
3 31-40 12 24 
4 41-50 16 32 
5 51-60 7 14 
6 61-70 2 4 
TOTAL 50 100 
 
AGE WISE DISTRIBUTION 
 
INFERENCE: Among 50 patients, 
 3 patient belongs to the age group of 15-20 years 
 10 patient belongs to the age group of 21-30 years 
 12 patients belongs to the age group of 31-40 years 
 16 patients belongs to the age group of 41-50 years 
 7 patients belongs to the age group of 51-60 years 
 2 patients belongs to the age group of 61-70 years 
3 
10 
12 
16 
7 
2 
6 
20 
24 
32 
14 
4 
0 
10 
20 
30 
40 
50 
15-20 21-30 31-40 41-50 51-60 61-70 
NO.OF 
PATIENTS 
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SEX DISTRIBUTION 
SL. NO SEX NO. OF 
PATIENTS 
PERCENTAGE 
1 Male 32 64 
2 Female 18 36 
TOTAL 50 100 
 
 
 
 
INFERENCE: 
Among 50 patients, 
 24 patients were Male 
 26 patients were Female 
 
 
 
32 
18 
MALE FEMALE 
0 
5 
10 
15 
20 
25 
30 
35 
SEX DISTRIBUTION 
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SOCIO-ECONOMIC STATUS 
SL. NO SOCIO – ECONOMIC 
STATUS 
NO. OF 
PATIENTS 
PERCENTAGE (%) 
1 Poor 30 60 
2 Lower middle 10 20 
3 Upper middle 5 10 
4 Rich 5 10 
TOTAL 50 100 
 
 
INFERENCE: 
 Among 50 patients, 
 30 patients were poor. 
 10 patients were lower-middle. 
 5 patients were upper middle. 
 5 patients were rich. 
 
0 
10 
20 
30 
40 
50 
60 
70 
POOR LOWER 
MIDDLE 
UPPER 
MIDDLE 
RICH 
SOCIO-ECONOMIC STATUS 
NO. OF PATIENTS 
PERCENTAGE (%) 
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 OCCUPATIONAL STATUS 
SL. NO OCCUPATION NO. OF 
PATIENTS 
PERCENTAGE (%) 
1 Students 8 16 
2 Home makers 15 30 
3 Retired persons 3 6 
4 Drivers 10 20 
5 Workers 14 28 
TOTAL 50 100 
 
OCCUPATIONAL STATUS 
 
INFERENCE:      Among 50 patients, 
 8 patients were Students. 
 15  patients were Home makers. 
 3  patients were Retired persons. 
 10 patients were Drivers. 
 14 Workers 
8 
15 
3 
10 
14 
16 
30 
6 
20 
28 
0 
10 
20 
30 
40 
STUDENTS HOME 
MAKERS 
RETIRED 
PERSONS 
DRIVERS WORKERS 
NO. OF PATIENTS PERCENTAGE (%) 
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PERSONAL HABITS 
 
SL. NO PERSONAL HABITS NO. OF 
PATIENTS 
PERCENTAGE (%) 
1 Vegetarian 10 20 
2 Non-vegetarian 25 50 
3 Smoking 5 10 
4 Alcohol 10 20 
 
 
 
 
 
 
 
 
 
10 
25 
5 
10 
20 
50 
10 
20 
0 
15 
30 
45 
60 
75 
Vegetarian Non-Vegetarian Smoking  Alcohol 
NO. OF PATIENTS PERCENTAGE (%) 
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5. RESULTS AND DISCUSSION: 
5.1.PHYSICOCHEMICAL PROPERTY OF CHARA PARPAM: 
Table.21 
S.No Parameter Mean Value 
1.  Loss on Drying at 105°C 0.7 % 
2.  Total Ash  98.9 % 
3.  Acid insoluble Ash    4.5 % 
4.  Particle size Completely passes through 
sieve no.44 
5.  pH 7.5 
 
5.2.FOURIER TRANSFORM INFRARED SPECTROSCOPY 
(FTIR) 
 
Table.22. FTIR RESULTS of CHARA PARPAM 
CHARACTERISTIC 
ABSORPTION(S)  (cm
-1
) 
FUNTIONAL GROUPS 
3853 Amide  (N- H stretch) 
 3430 Alcohol/ Phenol O-H stretch 
 2925 Carboxylic Acid  O-H stretch 
 2139 Nitrile C₌N stretch 
 1638 Alkenyl C₌C stretch 
 1396 Aromatic C₌C Bending 
 1161 Alkenes C₌H stretch 
 798 Aromatic C₌H Bending 
  
 
131 
 
Figure.17. SCANNING ELECTRON MICROSCOPE (SEM): 
 
 
Figure.18 
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Results:  
  SEM picture shows Nano particle (Micro level 14.0 nm) size of the sample.  
 Physical properties of known elements and materials can change as their 
surface to area ratio is dramatically increased, i.e. when nano scale sizes are achieved. 
These changes do not take place when going from macro to micro scale. Changes in 
physical properties such as colloidal properties, solubility and catalytic capacity have 
been found very useful in areas of bioremediation and drug delivery. The extremely 
small size of nano particles allows them to penetrate cells and interact with cellular 
molecules. Due to nano particle size a low dose of the drug can cure the diseases. 
5.4. BIO – CHEMICAL ANALYSIS OF  CHARA PARPAM: 
Results:  
The  bio – chemical analysis of Chara Parpamshowed the following chemicals, 
Sulphate, Chloride, Iron,Calcium, Potassium. 
5.5.TOXICOLOGICAL STUDY: 
Acute  and sub acute toxicity study on Chara parpam in Rodents: 
 The results of haematological investigations conducted on day 28, revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls; However, the increase or decrease in the 
values obtained was within normal biological and laboratory limits. Biochemical 
investigations revealed significant changes in the values of different parameters 
studied when compared with those of respective controls; The animals from control 
survived throughout the dosing period of 28 days but the 10 mg/kg chara parpam 
treated dose group animals were shown toxic symptoms and mortality on 13
th
 day 
after treatment. Signs of major or significant intoxication were observed in animals in 
higher dose groups during the dosing period of 28 days.  
 Animals from all the treated dose groups exhibited comparable body weight 
gain in the second half duration with that of control. Food consumption of control and 
treated animals was found to be comparable throughout the dosing period of 28days. 
Ophthalmoscopic examination, conducted prior to and at the end of dosing period on 
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animals from control and all the treated dose groups did not reveal any significant 
abnormality except liver enlargement. Functional observation tests conducted at 
termination revealed no abnormalities. Urine analysis, conducted at the end of the 
dosing period in week 4 and at the end of recovery period in week 6, revealed no 
abnormality attributable to the treatment. Organ weight data of animals sacrificed at 
the end of the dosing period was found to be comparable with that of respective 
controls. Histopathological examination revealed abnormality in kidney, lung and 
brain. 
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Table 23: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 50 + - - + - + - - - - - - - - - - - - - - 
2 100 + - - + - + - - - - - - - - - - - - - - 
3 250 + + - + - + + - - - - - - - - - - - + + 
4 500 + + - + - + + - - + - - + - - + - + + + 
5 1000 + + - + - + + - + + - - + + - + - + + + 
6 2000 + + - + - + + - + + - - + + - + - + + + 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. 
Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration   20. Mortality. 
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Table 24.The effects of the Chara Parpam on weight changes in control and treated rats. 
 
Group Initial Weight Weeks 
1 2 3 4 
Normal 162.20±11.10 164.11±7.78 172.65±14.74 176.20±0.77 182.24±5.22 
2.5mg/kg 168.25±14.00 176.55±14.12 183.15±11.45 185.14±12.30 185.20±10.46 
5mg/kg 164.74±13.12 167.32±11.20 175.29±10.25 179.28±11.94 184.34±4.11 
10 mg/kg 164.63±8.15 166.42±12.34 174.17±12.11 176.22±11.42 182.52±12.15 
Mean ± SEM (n=6) 
ns
P>0.05 Vs. Control group. 
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Table 25.The effects of the Chara Parpam on Kidney, Heart, Liver and Brain in control and treated groups. 
 
Organ Control 2.5mg/kg 5mg/kg 10mg/kg 
Heart (g) 0.42±0.05 0.44±0.05 0.46±0.02 0.48±0.03 
Kidney (g) 0.74±0.10 0.76±0.15 0.75±0.24 0.75±0.18 
Liver (g) 3.90±0.06 4.22±0.53 4.14±0.50 4.38±0.45 
Brain (g) 1.20±0.16 1.25±0.12 1.15±0.15 1.14±0.18 
Mean ± SEM (n=6) 
ns
P>0.05 Vs. Control group. 
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Table 26.Effects on of Daily administration of the Chara Parpam for 28days Biochemical Profiles. 
Parameter Control 2.5mg/kg 5mg/kg 10mg/kg 
Glucose (mg/dl) 104.61±0.35 105.51±0.42 114.10±0.33 108.28±0.48 
Cholesterol(mg/dl) 44.15±0.42 42.27±0.23* 41.50±0.41 44.22±0.34 
Triglyceride(mg/dl) 78.72±0.15 85.84±0.12* 86.72±0.14** 88.23±0.32** 
HDL (mg/dl) 105.12±0.04 104.8±0.07 113.12±0.07** 111.00±0.08** 
LDL (mg/dl) 78.32±2.31 82.40±3.42 92.58±2.35** 94.15±2.26** 
Protein (mg/dl) 7.11±0.30 7.82±0.28 7.71±0.32 6.99±0.27 
Albumin 3.10±0.20 3.18±0.22 3.12±0.24 3.56±0.20 
Globulin 3.16±0.07 3.15±0.06 3.16±0.08 3.14±0.07 
Creatinine (mg/dl) 0.20±0.04 0.27±0.04* 0.24±0.05 0.25±0.04 
AST IU/L 54.10±1.12 55.21±2.31 55.10±2.20 56.24±2.14 
ALT IU/L 25.42±1.76 26.10±2.28 22.18±2.36 24.42±3.22 
ALP IU/L 62.26±3.30 65.12±3.11 62.10±1.54 59.88±2.37 
Mean ± SEM (n=6) *P<0.05; **P<0.01 Vs. normal group. 
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Table 27. Serum Bilirubin (µmol/l) levels of rats treated with Chara Parpam for 28 days. 
Group Total Bilirubin Direct Bilirubin Unconjugated Bilirubin 
Normal 14.66±2.00 15.51±1.52 4.32±2.02 
2.5mg/kg 14.32±1.11 16.42±1.12 4.56±1.20 
5mg/kg 15.14±1.14 15.73±0.72 5.34±1.28 
10 mg/kg 16.26±1.22 15.17±0.35 10.22±1.62** 
Mean ± SEM (n=6) **P<0.01 Vs. Normal group. 
Table 28. Renal function Parameter of rats treated with Chara Parpam for 28 days. 
Group Urea(µmol/l)  Creatinine(µg/dl)  Uric acid(mg/dl) 
Normal 6.28±0.50 255.11±4.56 3.32±0.06 
2.5mg/kg 7.12±0.15* 265.26±4.32 1.95±0.09** 
5mg/kg 7.65±0.22* 270.22±4.15* 2.12±0.07* 
10 mg/kg 8.78±0.12** 272.30±5.22* 1.35±0.08** 
Mean ± SEM (n=6) *P<0.05; **P<0.01 Vs. Normal group. 
139 
 
 
 
Table 29. Serum Electrolyte levels (mmol/l) of rats treated with Chara Parpam for 28 days. 
Group Sodium Potassium Bicarbonate 
Normal 151.22±0.72 6.10±0.55 27.40±0.50 
2.5mg/kg 149.00±1.31 5.82±1.12 25.11±0.66 
5mg/kg 147.84±1.12 5.76±0.09 24.42±0.50* 
10 mg/kg 145.15±0.45** 4.97±0.10* 25.71±1.32 
Mean ± SEM (n=6) *P<0.05; **P<0.01 Vs. Normal group. 
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Table.30. Urine Analysis 
 
Parameters Control 2.5mg/kg 5mg/kg 10 mg/kg 
Colour Yellow Yellow Yellow
 
Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
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SUBACUTE TOXICITY OF CHARA PARPAM: 
Figure.19.Bone 
 LOWER DOSE  MID DOSE   HIGH DOSE 
                                        
Figure.20.Brain 
               LOWER DOSE  MID DOSE   HIGH DOSE                              
                                     
 
Figure.21.Heart 
               LOWER DOSE        MID DOSE                          HIGH DOSE                              
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SUBACUTE TOXICITY OF CHARA PARPAM: 
Figure.22 Intestine 
 LOWER DOSE  MID DOSE   HIGH DOSE 
                                        
Figure.23.Kidney 
               LOWER DOSE  MID DOSE   HIGH DOSE                              
                                     
 
Figure.24. Liver 
               LOWER DOSE        MID DOSE                          HIGH DOSE                              
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SUBACUTE TOXICITY OF CHARA PARPAM: 
Figure.25. Lung 
 LOWER DOSE  MID DOSE   HIGH DOSE 
                                        
Figure.26. Ovary 
               LOWER DOSE  MID DOSE   HIGH DOSE                              
                                     
 
Figure.27.Pancrease 
               LOWER DOSE        MID DOSE                          HIGH DOSE                              
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SUBACUTE TOXICITY OF CHARA PARPAM: 
Figure.28. Spleen 
 LOWER DOSE  MID DOSE   HIGH DOSE 
                                        
Figure.29. Stomach 
               LOWER DOSE  MID DOSE   HIGH DOSE                              
                                     
 
Figure.30. Testis. 
               LOWER DOSE        MID DOSE                          HIGH DOSE                              
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5.6. PHARMACOLOGICAL ASPECT: 
Result and Discussion: 
 The results of acute oral toxicity study suggested that the Chara Parpam was 
safe up to 50mg/kg. As per the above study, dose fixation was done and 5mg/kg, and 
10mg/kg have been selected as low and high doses respectively for the 
hepatoprotective study. Administration of Chara Parpam has shown variations in 
various biochemical parameters in animals induced liver damage by CCL4 as there 
was significant increase in liver weight due to damage caused by administration of 
CCL4 in control animals as compared to normal group. In animals treated with 
Silymarin and Chara Parpam, there was significant reduction in liver weight 
compared to toxic group. Histopathological study of the liver from different groups of 
rats corroborated the hepatoprotective efficacy of Chara Parpam. Various pathological 
changes like steatosis, centrilobular necrosis and vacuolization seen in group II 
(toxicant rats) is due to oxidative damage by free radical generation. These 
pathological changes were prevented to moderate extent in both test groups.  
 CCL4 administration  caused significant elevation of ALT, AST,ALP, direct 
bilirubin and total bilurubin by inducing hepatic damage in control animals as 
compared to normal animals while, standard drug silymarin treatment reduced 
concentration in animals of standard group and those were almost equivalent to 
normal. There was dose dependent significant reduction in serum ALT levels in Chara 
Parpam treated animals as compared to control group. In positive control group 
animals treated with CCL4, there was significant decrease in serum total protein, 
albumin and serum ionic concentration due to liver damage when compared to saline 
alone treated animals but administration of silymarin caused significant rise in total 
protein compared to control group. In animals administered with Chara Parpam there 
was significant increase total protein level and it was dose dependent. Histological 
profile of the control animals showed normal hepatocytes.  
 In toxicant administered animal liver exhibited intense centrilobular necrosis, 
vacuolization and macrovesicular fatty change. The sections of liver from the standard 
drug silymarin treated showed hepatic architecture, which was similar to that of 
normal. The animals treated with Chara Parpam exhibited significant liver protection 
against the toxicant as evident by presence of normal hepatic cords, absence of 
necrosis and lesser fatty infiltration. The administration of CCL4 was resulted into 
146 
 
complete loss of the normal architecture of livers in positive control animals with the 
appearance of vacuolated hepatocytes and degenerated nuclei. Vacuolization, fatty 
changes and necrosis of hepatocytes were severe in the centrilobular region.  The 
toxic metabolites of CCL4 caused excessive formation and deposition of connective 
tissue and development of scars. The nodular transformation of liver architecture was 
revealed of liver in the liver sections of rats treated with Chara Parpam 5mg/kg with 
loss of structure of hepatic lobules. But liver sections treated with high doses of Chara 
Parpam showed more or less normal lobular pattern with tiny and a mild degree of 
fatty change, necrosis and lymphocyte   infiltration almost comparable to the control 
and silymarin treated groups. Fatty change or fatty liver is the main consequence of 
liver toxicity which is characterized by the deposition of fat in liver. Due to the 
deposition of fat and triglycerides, total weight of liver increases in drug induced 
hepatic damage. In positive control group, there was significant rise in liver weights 
but silymarin and Chara Parpam could able to normalize weight of livers in 
therapeutic groups by decreasing toxicity of liver. Liver is important storage organ 
and stores various serum enzymes like ALT and AST which are involved in 
transamination reactions for various amino acids.  Alkaline phosphatise is 
isoenzyme synthesized mainly by liver and has vital role in dephosphorylation of 
various biomolecules. In liver disease, liver cannot store ALT and AST and increased 
synthesis of ALP observed due to liver parenchymal damage caused by liver toxicity. 
Among various, one of the important functions of liver is detoxification of bilirubin 
which is breakdown product of haem. The bilirubin uptake by liver parenchyma cells 
from the blood and conjugates with glucoronic acid in presence of enzyme glucuronyl 
transferase, later congjugated product excreted into bile.  
 In liver toxicity total bilirubin and direct bilirubin concentration in serum 
increases due to abnormality in hepatic parenchymal cells. In our present study, CCL4 
elevated levels of ALT, AST, ALP, direct bilirubin and total bilirubin was observed in 
control animals which may be due to reduced function of liver due to toxicity. 
Treatment with silymarin and Chara Parpam significantly reduced concentration of 
above serum parameters in animals of therapeutic groups which could be due to 
possible protection given by Chara Parpam. Serum total protein, also called plasma 
total protein or total protein, is a biochemical test for measuring the total amount of 
protein in blood plasma or serum. The albumin and globulin are the main components 
of total protein in the plasma and albumin mainly synthesized by the liver. In CCL4 
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induced hepatotoxicity, albumin synthesis will be decreased due to cirrhosis and leads 
to reduction in total protein. Hence serum albumin and total protein are the two 
important biomarkers of liver function.  
 The ascites and edema are the two main complications of liver injury which is 
due to accumulation of fluids in extravascular sites of the body and hence serum 
sodium and potassium moves into fluids which finally lead to reduced concentration 
of these ions in blood. In our present study in control animals treated with CCl4, there 
was significant reduction in concentration of serum albumin, total protein, serum 
sodium and potassium due to toxicity. In therapeutic animals treated with standard 
drug silymarin and Chara Parpam significant increase in serum albumin, total protein, 
serum sodium and potassium was observed as compared to toxic group.  
 Histopathological studies of liver in toxicant group cause fatty changes, 
granular degeneration and inflammation. Also showed marked reduction in fatty 
degeneration and necrosis in animals treated with standard drug silymarin and Chara 
Parpam. It is evident that the Chara Parpam caused regeneration of liver parenchyma 
cells and treated hepatic cell damage due to CCL4 toxicity. 
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HISTOPATHOLOGY OF LIVER 
 
                      Figure.31             Figure.32                                                                                                                            
      
 
Figure.33.                                     Figure.34. 
                
 
Figure.31.     Group I  (Normal Liver) 
Figure.32.     Group II (Control) 
Figure.33     Group III (Chara Parpam 5mg) 
Figure.34     Group IV (Chara Parpam 10mg)
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Table 31: Effect of Chara Parpam on liver weight 
GROUP LIVER WEIGHT (gm) 
Normal Saline 5.76± 0.10 
Positive Control 8.42±0.68 
Chara Parpam 5mg/kg 6.54±0.14* 
Chara Parpam 10mg/kg 5.66±0.10** 
Silymarin 25mg/kg 4.2±0.04** 
Values are mean ± S.E.M, n=6; 
ns
p>0.05, *p<0.05, **p<0.01 Vs positive control. 
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Table 32:Effect of Chara Parpam on serum biochemical parameters 
GROUP ALT IU/L AST IU/L ALP IU/L T. Bilurubin g/l D. Bilurubin g/dl 
Normal Saline 58.21±1.6 112.5±0.52 78.32±1.8 0.36±0.02 0.022±0.010 
Positive Control 176.42±26.1 239.2±3.3 465.16±4.05 0.92± 0.02 0.28± 0.03 
Chara Parpam 
5mg/kg 
98.33±2.8** 184.22±1.4** 262.01±2.0** 0.64±0.018** 0.12±0.004** 
Chara Parpam 
10mg/kg 
72.59±2.0** 140.10±2.0** 188.2±1.6** 0.47±0.012** 0.094±0.004*** 
Silymarin 25mg/kg 66.10±1.2** 134.2±1.4** 84.3±1.65** 0.40±0.01** 0.092±0.02** 
Values are mean ± S.E.M, n=6; 
ns
p>0.05, *p<0.05, **p<0.01 Vs control. 
Table 33: Effect of Chara Parpam on serum parameters Total protein, Albumin and ions 
 
GROUP Total protein g/dl Albumin g/dl Sodium mEq/L Potassium mEq/L 
Normal Saline 5.1±0.10 4.2± 0.11 140.12± 0.7 4.85± 0.26 
Positive Control 2.2±0.12 2.4± 0.05 75.41± 0.9 2.00± 0.08 
Chara Parpam 5mg/kg 3.32± 0.2* 2.55±0.17 84.23± 2.0* 2.81±0.17* 
Chara Parpam 10mg/kg 4.21± 0.20** 3.62±0.18** 120.02± 1.4** 4.33±0.16** 
Silymarin 25mg/kg 5.18±0.07** 4.46±0.05** 136.13±1.8** 4.62±0.14** 
Values are mean ± S.E.M, n=6; 
ns
p>0.05, *p<0.05, **p<0.01, Vs positive control. 
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CLINICAL ASSESMENT 
Table: 34. IMPROVEMENT IN SIGNS AND SYMPTOMS 
SL. 
NO 
SIGNS AND 
SYMPTOMS 
NO. OF PATIENTS 
BT AT IMP. IMPROVEMENT 
(%) 
1 Anorexia 43 5 38 88 
2 Nausea/ Vomiting 45 4 41 91 
3 Fatigue 35 5 30 86 
4 Insomnia 18 4 14 78 
5 Yellow coloured eyes 47 8 39 83 
6 Yellow coloured urine 45 7 38 84 
7 Pain in abdomen 12 4 8 67 
8 Fever 5 2 3 60 
 
IMPROVEMENT IN SIGNS AND SYMPTOMS 
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INFERENCE: 
Among 50 patients, 
 38 out of 43 patients were relieved from Anorexia. 
 41 out of 45 patients were relieved from Nausea/ Vomiting. 
 30 out of 35 patients were relieved from Fatigue. 
 14 out of 18 patients were relieved from Insomnia. 
 39 out of 47 patients were relieved from Yellow coloured eyes. 
 38 out of 45 patients were relieved from Yellow coloured urine. 
 8 out of 12 patients were relieved from pain in abdomen.  
 3 out of 5 patients were relieved from Fever. 
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GRADATION RESULT 
SL. NO LEVEL OF IMPROVEMENT NO.OF 
PATIENTS 
PERCENTAGE (%) 
1 Good 30 60 
2 Satisfactory 9 18 
3 Moderate 5 10 
4 Poor 6 12 
TOTAL 50 100 
 
GRADATION RESULT 
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STATISTICAL ANALYSIS 
DESCRIPTIVE STATISTICAL FOR IMPROVEMENT 
OF LIVER FUNCTION TEST 
IN KAMALAI 
PAIRED “t” TEST RESULT: 
P value and statistical significance:  
AST in Jaundice Patients: 
The elevated AST (Aspartate transaminase)/ serum glutamic oxaloacetic transaminase 
(SGOT) levels were reduced significantly, when compared to the pre-treatment 
values. The two-tailed P value is less than 0.0001by conventional criteria; this 
difference is considered to be extremely statistically significant.  
Confidence interval: 
The mean of Group One minus Group Two equals 30.084 
 95% confidence interval of this difference: From 23.124 to 38.563  
Intermediate values used in calculations: 
  t = 8.516, df = 15, standard error of difference = 3.622 
Treatment No Patients Mean S.D S.E.M 
Before treatment 16        63.281 14.292 3.573 
After treatment 16 32.438 9.647 2.412 
 
 AST in Alcoholic Liver Disease Patient: 
 The two-tailed P value is less than 0.0008. By conventional criteria, this difference is 
considered to be extremely statistically significant.  
Confidence interval: 
 The mean of Group One minus Group Two equals 84.38 
 95% confidence interval of this difference: From 48.65 to 120.10  
Intermediate values used in calculations: 
  t = 5.58,  df = 7 ,standard error of difference = 15.10 
Treatment No Patients Mean S.D S.E.M 
Before treatment 8 112.88 45.60 16.12 
After treatment 8 28.50 6.28 2.22 
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AST in Fatty Liver disease: 
The two-tailed P value equals 0.0001.  By conventional criteria, this difference is 
considered to be extremely statistically significant.  
Confidence interval: 
 The mean of Group One minus Group Two equals 390.25 
 95% confidence interval of this difference: From 306.97 to 473.53 
Intermediate values used in calculations: 
 t = 9.98, df = 15, standard error of difference = 39.480 
  
Treatment No Patients Mean S.D S.E.M 
Before treatment 16 467.00 190.66 47.67 
After treatment 16 76.75 48.51 12.13 
 
 
 
ALT (Alanine transaminase):  
The elevated ALT (Alanine transaminase) /serum glutamic pyruvic transaminase 
(SGPT) levels were also reduced significantly, when compared to the pre-treatment 
values, The two-tailed P value is less than 0.0001.By conventional criteria, this 
difference is considered to be extremely statistically significant.  
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Confidence interval: 
 The mean of Group One minus Group Two equals 149.00 
 95% confidence interval of this difference: From 88.71 to 209.29 
Intermediate values used in calculations: 
 t = 5.00,df = 38,standard error of difference = 29.78 
 
Treatment No Patients Mean S.D S.E.M 
Before treatment 40 196.50 212.14 33.54 
After treatment 40       45.28 36.41 5.83 
 
ALP: Alkaline Phosphatase: 
The elevated alkaline phosphatase levels were also reduced significantly, when 
compared to the pre-treatment values, the two-tailed P value is less than 0.0001. By 
conventional criteria, this difference is considered to be extremely statistically 
significant.  
Confidence interval: 
 The mean of Group One minus Group Two equals 12.155 
 95% confidence interval of this difference: From 7.522 to 16.788  
Intermediate values used in calculations: 
 t = 5.3071, df = 39,standard error of difference = 2.290  
 
Treatment No Patients Mean S.D S.E.M 
Before treatment 40 105.265 25.825 4.083 
After treatment 40 93.110 15.685 2.480 
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Bilirubin: 
  The mean serum bilirubin values were elevated at the time of the enrolment, in 
all patients in these studies. Cumulative data analysis showed a significant reduction 
in the mean serum bilirubin level,The two-tailed P value is less than 0.0001By 
conventional criteria, this difference is considered to be extremely statistically 
significant.  
Confidence interval: 
 The mean of Group One minus Group Two equals 0.832 
 95% confidence interval of this difference: From 0.589 to 1.076 
Intermediate values used in calculations: 
  t = 6.003,df = 39, standard error of difference = 0.121 
 
Treatment No Patients Mean S.D S.E.M 
Before treatment 40 2.220 0.887 0.140 
After treatment 40 1.387 0.940 0.149 
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STATISTICAL ANALYSIS 
DESCRIPTIVE STATISTICAL FOR IMPROVEMENT OF SIGNS & 
SYMPTOMS IN “KAMALAI” 
PAIRED “t” TEST RESULT: 
“p” value & statistical significance: 
Group N Mean SD SEM 
Group I 8 31.25 16.96 6.00 
Group II 8 26.38 15.56 5.50 
P value and statistical significance:  
  The two-tailed P value equals 0.0002 
  By conventional criteria, this difference is considered to be extremely statistically    
significant.  
Confidence interval: 
  The mean of Group One minus Group Two equals 4.88 
  95% confidence interval of this difference: From 3.30 to 6.45  
Intermediate values used in calculations: 
  t = 7.3145 
  df = 7 
  standard error of difference = 0.666  
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DISCUSSION: 
 Chara parpam was taken for the treatment of Kamali. Various studies have 
been carried out in this trial drug here. The study includes literary collections, 
Biochemical, Physico and Toxicological study Pharmacological study, and Clinical 
study. The drug has been selected for the treatment of Kamalai in reference with 
Pathartha guna vilakam Part II.Literary collections about the drug from various text 
books was done. It indicates the efficacy of the drug in the treatment of Kamalai. 
Chemical aspect deals with the identification, and ethno medicinal importance of the 
mineral. Gunapadam aspect expressed that the drug have protective property of Liver 
Bio-chemical chemical analysis: 
  The analysis shows the precence of Sulphate, chloride, iron, calcium, 
pottasium. These elements are useful in many metabolic functions of our body. 
Toxicological study: 
 Acute and Subaucute toxicological studies reveal that the drug Chara parpam 
does not having any toxic effect and safety of the drug is recorded through the 
histopathological results of animal model. 
 The haematological study results confirmed the safety of the drug. The liver 
and kidney function test of animal model in toxicological studies reveal the normal 
function and the vital organs and also registered the efficacy and safety of the drug.  
Pharmacological study: 
 The results obtained from estimation of biochemical parameters suggesting 
that, Chara Parpam possess significant hepatoprotective property in CCL4 induced 
liver toxicity in rat model.  
Histopathology: 
Histopathological studies of liver in toxicant group cause fatty changes, 
granular degeneration and inflammation. Also showed marked reduction in fatty 
degeneration and necrosis in animals treated with standard drug silymarin and Chara 
Parpam. It is evident that the Chara Parpam caused regeneration of liver parenchyma 
cells and treated hepatic cell damage due to CCL4 toxicity. 
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Clinical study: 
 50 patients of both sexes were selected. 
  Among the 50 patients, 40 patients were treated as out- patients in the Post 
graduate department of Gunapadam, Govt.Siddha medical college hospital and Govt. 
Arignar Anna hospital, Arumbakkam, Chennai- 106.  10 patients were treated as in - 
patients. 
 The patients were observed regularly. 
The clinical study was carried out with 50 patients.  Three groups of cases were 
studied for the effect of Chara parpam. The patients had liver function examination 
before and after the treatment, including contents of serum proteins, total bilirubin 
(TB) and activities of ALT and AST.  
 The cumulative analysis revealed significant reduction in the levels of mean, 
SGOT, SGPT and ALP and Bilirubin. There was renormalization of protein levels. 
The normalcy of the above enzyme levels established the hepatoprotective effect of 
drug Chara parpam that might be able to induce accelerated regeneration of liver cell, 
reducing the leakage of the above mentioned enzymes into the blood. 
 In clinical study there is a marked improvement in signs and symptoms and 
Liver enzymes also. The results revealed that the drug possess 60% good relief, 
18%atisfactory relief, 10% moderate relief mild relief, 12% cases there was no 
improvement 
 It shows the excellent safety and good efficacy of Chara parpam both Pre 
clinical and clinically. It has the potential to become an alternative to conventional 
therapy for Hepato cellular diseases. 
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6. CONCLUSION 
  Chara parpam is a distinctive type medicine, which is made up by a special 
type of preparation method mentioned in Pathartha guna vilakkam written by 
S.Kannusami pillai. 
 Literature survey, Physico chemical anatysis, Chemical analysis, was showed 
the efficacy of charam related to Liver diseases. Juice of  Justicia adathoda  is also 
having the traditional usage in treatement of liver diseases. 
 The finding of the pre clinical study suggests that effective role of Chara 
parpam on liver disease with fatty infiltration of liver with inflammation and hepatic 
necrosis to cirrhosis.  
 Chara parpam had remarkable effect on lipid   with complete reduction in the 
lipid factors in the liver and its related enzymes. The metalloid drug could play 
similar role as extracellular calcium and it could evidence effective hepatoprotective 
drug. 
 Significant efficacy of the drug its human dose prescribed in the siddha 
literature evidences only therapeutic efficacy rather preventive role. It may be 
suggested as a drug to fatty liver which finds negligence cure in modern medicine. 
  This can be a definite alternative drug to modern allopathic drug in liver 
disease. The study reveals the possible mechanism of action on lipid lowering effect 
with potential anti oxidative role. 
 In clinical trials, the drug shows the significant improvement of 60% in 
Hepato cellular diseases.  
 Thus the innovative siddha science based Chara parpam had been proved by 
the modern scientific mechanism as a simple remedy to the complicated metabolic 
disorder in modern period. 
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7.SUMMARY 
The herbo mineral preparation Chara parpam was prepared as per the 
classical way. This drug was subjected to various studies. 
Chara parpam was selected for this study to establish the protection and 
efficacy of its Hepatoprotective activity on Kamalai. 
  I was collected the information about the drug, various text books, Literature 
was referred. From them, the author came to an idea about the drug and its efficacy on 
Kalleral noi a brief description about modern aspect and Siddha aspect of the mineral 
Charam and  Vediyuppu its identifying characters and Physico – chemical data’s were 
given. 
 The Physico – chemical analysis shows the precence of Sulphate, chloride, 
iron, calcium, pottasium. These elements are useful in many metabolic functions of 
our body. 
 Acute and Subacute toxicological studies show strong evidence of the non-
toxic-effect of the Chara parpam. The results showed Chara parpam is safe and 
explained the extensive utilization of the Siddha medicine.  
The pharmacological analysis showed that the drug has got significant 
Hepatoprotective Efficacy. 
 In clinical study, the drug has showed improvement in 60% of cases. 
The patients were responding well from the beginning of the treatment and no 
adverse effects were reported. 
This present study suggests that Chara parpam has remarkable medicinal 
value against the disease Kalleral noi.  
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 I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
 
 
DATE:        SIGNATURE 
         NAME 
 
CONSENT BY THE PATIENT 
 
 I have been informed to my satisfaction by the attending physician the purpose of 
the clinical trial and the nature of the drug treatment and follow up including the lab 
investigations to be performed to monitor and safeguard my body functions. 
 
 I am aware of my right to opt out of the trial at any time during the course of the 
trial without having to give reasons for doing so. 
 
 I ,exercising  my free power of choice , hereby give my consent to be included as 
a subject in the clinical trial of ………………………….for the treatment 
of…………………………………………….. 
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1.     DEPARTMENT OF POST GRATUATE GUNAPADAM BRANCH,  
GOVERNMENT SIDDHA MEDICAL COLLEGE,  
CHENNAI - 106. 
ARIGNAR ANNA GOVERNMENT HOSPITAL FOR 
INDIAN MEDICINE AND HOMEOPATHY, ARUMBAKKAM, 
CHENNAI - 106. 
OPEN CLINICAL TRAIL PHASE II B 
HAEMATINIC ACTIVITY ON PULI ILAI CHOORANAM, 
FORM II 
1. Centre :  
2. Code no  :      Level of study: OPD/IPD 
3. Name of the patient  :  
4. Address  : 
     
    
5. Age :   :   sex: Male  Female   
6. Educational Status  :  
7. Occupation  :  
8. Income  :  
9. Religion  : H M CH  S 
10. Marital Status  : 
     11. Date of Admission   : 
     12. Date of Discharge   : 
     13Diagnosis   : 
 
PERSONAL HISTORY: 
11. Food habits  : Veg Non Veg Veg/Egg 
12. Addiction  : None Smoking Snuff 
    Ganja Alcohol Opium 
13. Sleep  : Good Distributed Insomnia 
14. Presence of anxiety  : Yes No 
15. Naadi  : Vatham  Pitham Kapam        Thontham 
FAMILY HISTORY: 
1. Hypertension  : Yes  NO  
2. Diabetes mellitus  : Yes  NO 
3. Tuberculosis  : Yes  NO 
4. IHD/MI/MS/AS  : Yes  NO 
5. If any other disease specify  : Yes   NO 
 
PRESENTING SYMPTOMS: 
       Yes    No  Duration (WEEKS) 
1. Pain : 
2. Vomiting : 
3. Indigestion : 
4. Sore tongue : 
5. Diarrhoea : 
6. Constipation : 
7. Haematemesis : 
8. Loss of appetite : 
9. Thirst : 
10. Dysphasia : 
11. Flatulence : 
12. Heart-burn : 
13. If any other disease :  
 
 
 
HISTORY OF PRESENT ILLNESS: 
1. Pain  : 
2. Vomiting  : 
3. Indigestion  :  
4. Sore tongue  : 
5. Diarrhoea  : 
6. Constipation  : 
7. Haematemesis  : 
8. Loss of appetite  : 
9. Thirst  : 
10. Dysphasia  : 
11. Flatulence  : 
12. Heart-burn  : 
13. Bloating & abdominal fullness : 
14. Water brash  : 
15. Nausea and copious vomiting: 
16. Weight loss  : 
17. Melena  : 
18. If any other disease   
PAST HISTORY: 
1. Date of diagnosis  : 
2. Duration of disease  :           months/years 
3. Source of any infection  : 
4. Gastrointestinal bleeding   : Yes    No If Yes, when? 
5. Cancer(GI tract)  : Yes    No 
6. Cancer(other organs)  : Yes    No       
7. Sedentary life style  : Yes    No        
8. Achlorhydria  : Yes    No      
9. Tumours in stomach  : Yes    No     
10. Tuberculosis (GI tract)  : Yes    No        
11. Diabetes  : Yes    No   
12. Nephritis  : Yes    No  
13. Syphilis  : Yes    No 
14. AIDS  : Yes    No  
15. Pt.underwent any surgery  : Yes    No 
16. UTI  : Yes    No  
17. Others  : If Yes , Specify    
HISTORY OF PREVIOUS TREATMENT: Yes   No 
If yes, give details as follows: 
PHYSICAL EXAMINATION: 
1. Height (cm)  :  
2. Weight (cm)  : 
3. Pulse  : 
4. Blood pressure  : 
5. Temperature  : 
6. RR  :  /minute 
7. Anaemia  :  Present   Absent 
8. Lymphadenopathy  :  Present    Absent 
9. Pigmentation  :  Present   Absent 
PRESENTING SIGNS:   
1. Bloating and abdominal fullness    :  Present  Absent 
2. Water brash  (Rush of saliva after 
 an episode of Regurgitation to  
Dilute the Acid in oesophagus)     :  Present  Absent 
3. Nausea and copious vomiting      :  Present  Absent 
4. Loss of appetite and weight loss    :  Present  Absent 
5. Haematmesis         :  Present  Absent 
6. Melena(tarry, foul-smelling faces 
 due to oxidized iron from  
Haemoglobin)         :  Present  Absent 
7. Fatigue   :  Present   Absent 
8. Heartburn   :  Present   Absent 
9. Hunger   :  Present   Absent 
CLINICAL EVALUATION: 
1. Cardio vascular system  :  Normal    Abnormal  Details   
2. Respiratory system  :  Normal      Abnormal Details 
3. Central nervous system  :  Normal  Abnormal Details 
4. Urogenital system  :  Normal  Abnormal Details 
SIDDHA PARAMETERS: 
1. Naa  :  Normal  Abnormal Details 
2. Niram  :  Normal   Abnormal Details 
3. Mozhi  :  Normal   Abnormal Details 
4. Vizhi  :  Normal  Abnormal Details 
5. Malam  :  Normal  Abnormal Details 
6. Moothiram  :  Normal  Abnormal Details 
7. Sparisam  :  Normal  Abnormal Details 
8. Naadi  :  Normal  Abnormal Details 
RESULT: 
1. GOOD  : 
2. FAIR  : 
3. POOR  : 
4. NO RESPONSE  : 
SIGNATURE OF MEDICAL OFFICER   SIGNATURE OF INVESTIGATOR 
LABORATORY INVESTIGATION AND CLINICAL PARAMETERS 
1. Centre :  
2. Code no  :      Level of study: OPD/IPD 
3. Name of the patient  :  
4. Age :   :   sex: Male  Female   
5. Date and month of assessment   : 
CLINICAL PARAMETERS: 
 Urine: Albumin, Sugar, Deposits. 
 MOTION; Ova ,Cyst  
HAEMOGRAM :Total WBC Count, RBC, Hb, ESR, Barium meal,Endoscopy,Ultra sound 
 
2.  DEPARTMENT OF POST GRATUATE GUNAPADAM BRANCH,  
GOVERNMENT SIDDHA MEDICAL COLLEGE,  
CHENNAI-106. 
ARIGNAR ANNA GOVERNMENT HOSPITAL FOR 
INDIAN MEDICINE AND HOMEOPATHY, ARUMBAKKAM, 
CHENNAI-106. 
OPEN CLINICAL TRAIL PHASE II B 
HEPATOPROTECTIVE ACTIVITY OF 
“CHARA PARPAM’’ 
FORM II 
16. Centre :  
17. Code no  :      Level of study: OPD/IPD 
18. Name of the patient  :  
19. Address  : 
     
    
20. Age :   :   sex: Male  Female   
21. Educational Status  :  
22. Occupation  :  
23. Income  :  
24. Religion  : H M CH  S 
25. Marital Status  : 
     11. Date of Admission   : 
     12. Date of Discharge   : 
     13. Diagnosis   : 
PERSONAL HISTORY: 
26. Food habits  : Veg Non Veg Veg/Egg 
27. Addiction  : None Smoking Snuff 
    Ganja Alcohol Opium 
28. Sleep  : Good Distributed Insomnia 
29. Presence of anxiety  : Yes No 
30. Naadi  : Vatham  Pitham Kapam        Thontham 
FAMILY HISTORY: 
6. Hypertension  : Yes  NO  
7. Diabetes mellitus  : Yes  NO 
8. Tuberculosis  : Yes  NO 
9. IHD/MI/MS/AS  : Yes  NO 
10. If any other disease specify  : Yes   NO 
PRESENTING SYMPTOMS: 
       Yes    No  Duration (WEEKS) 
14. Anorexia : 
15. Nausea : 
16. Vomiting : 
17. Fatigue : 
18. Insomnia : 
19. Yellow colored eyes : 
20. Yellow colored urine : 
21. Pale coloured motion : 
22. Skin itching : 
23. Pain abdomen : 
24. Fever : 
25. Diarrhoea : 
26. Hematemesis :  
27. If any other disease : 
 
HISTORY OF PRESENT ILLNESS:  
Onset of Jaundice  :      Acute                     Chronic 
 
PAST HISTORY: 
18. Date of diagnosis  : 
19. Duration of disease  :           months/years 
20. Source of HBV infection  : 
21. High risk Group  :  Medical worker         Paramedical worker  
  Sex worker   others  
  Non – High risk group   
22. Alcohol  : Yes    No 
23. Cancer(other organs)  : Yes    No       
24. Sedentary life style  : Yes    No        
25. Achlorhydria  : Yes    No      
26. Tuberculosis  : Yes    No        
27. Diabetes  : Yes    No   
28. Nephritis  : Yes    No  
29. Syphilis  : Yes    No 
30. AIDS  : Yes    No  
31. Pt.underwent any surgery  : Yes    No 
32. UTI  : Yes    No  
33. Others  : If Yes , Specify    
HISTORY OF PREVIOUS TREATMENT: Yes   No 
If yes, give details as follows: 
 
PHYSICAL EXAMINATION: 
10. Height (cm)  :  
11. Weight (cm)  : 
12. Pulse  : 
13. Blood pressure  : 
14. Temperature  : 
15. RR  :  /minute 
16. Anaemia  :  Present  Absent 
17. Lymphadenopathy  :  Present   Absent 
18. Pigmentation  :  Present  Absent 
PRESENTING SIGNS:   
10. Odema feet            :  Present  Absent 
11. Icterus                 : Presen           Absent 
12. Spider      :  Present  Absent 
13. Gynacomastia    :  Present  Absent 
14. Liver    :Palpable  Not palpable 
15. Splenomegaly             :  Present  Absent 
16. Ascites   :  Present   Absent 
17. Encephalopathy   :  Present   Absent 
CLINICAL EVALUATION: 
5. Cardio vascular system  :  Normal  Abnormal  Details   
6. Respiratory system  :  Normal  Abnormal Details 
7. Central nervous system  :  Normal  Abnormal Details 
8. Urogenital system  :  Normal  Abnormal Details 
RESULT: 
5. GOOD  : 
6. FAIR  : 
7. POOR  : 
8. NO RESPONSE  : 
 
SIGNATURE OF MEDICAL OFFICER  SIGNATURE OF INVESTIGATOR 
 
LABORATORY INVESTIGATION AND CLINICAL PARAMETERS 
5. Centre :  
6. Code no  :    
 Level of study                         : OPD/IPD 
7. Name of the patient  :  
8. Age :   :   sex: Male  Female   
5. Date and month of assessment   : 
CLINICAL PARAMETERS: 
 
 Urine: Albumin, Sugar, Deposits,Bile pigments, Bile Salts 
 
Urine: Albumin, Sugar, Deposits. 
 MOTION; Ova ,Cyst  
HAEMOGRAM :Total WBC Count, RBC, Hb, ESR,  
Liver function test: 
AST,ALT,ALP, Bilirubine, total protein, Albumin., Prothrombin time 
 
 
 
 
 
 







